| ID | Title | Body | Facebook Description | Facebook image | Facebook Title | Facebook Video | Twitter Description | Twitter Image | Twitter Title | Meta tags |
|---|---|---|---|---|---|---|---|---|---|---|
| 24899 | NCATS History | The National Center for Advancing Translational Sciences (NCATS) — one of 27 Institutes and Centers at NIH — was established in December 2011 to transform the translational process so that new treatments and cures for disease could be delivered to patients faster. On this page: Founding Leadership Approach Accomplishments Founding Then-NIH Director Francis S. Collins, M.D., Ph.D., published the founding vision of NCATS on July 6, 2011. The Center’s mission is to support the creation of innovative methods and technologies to speed the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Advisory bodies provided guidance and strategic counsel during the development of NCATS: Composed of independent experts, a working group of the Advisory Committee to the NIH Director provided input on how NCATS might partner with the private sector and support the translational research enterprise. Composed of NIH leadership, the NIH CTSA/NCATS Integration Working Group made recommendations to the NIH Director on how the Clinical and Translational Science Awards (CTSA) Program could be integrated into NCATS. Composed of NIH IC Directors (ICD), the ICD-NCATS Working Group made recommendations to the NIH Director about the mission, functions and organization of NCATS. The NIH Scientific Management Review Board recommended that NIH create a new translational medicine and therapeutics center. View the December 2010 Report on Translational Medicine and Therapeutics (PDF - 644KB). Leadership In September 2012, the NIH Director announced the appointment of Christopher P. Austin, M.D., as director of NCATS. When Austin announced his departure in early 2021, Deputy Director Joni L. Rutter, Ph.D., was selected as acting director. In November 2022, Rutter was selected as director of NCATS. Learn more about NCATS’ director and read the Director’s Messages, which highlight NCATS’ priorities. Approach NCATS is unique in that it focuses not on specific diseases, but on what many diseases have in common. Emphasizing the translational science process, NCATS promotes three Ds: Developing new approaches, technologies, resources and models Demonstrating their usefulness Disseminating the data, analysis and methodologies to the community To accomplish the three Ds, the Center relies on the power of data, new technologies and teamwork. In this way, NCATS functions like an adapter, allowing distinct parts of the research system to connect and collaborate more effectively. NCATS’ approach and mission complement the work of other NIH Institutes and Centers, the private sector, and the nonprofit community. Collaborations among government, academia, industry and nonprofit patient groups are crucial for successful translation: No organization can succeed alone. To this end, NCATS leads innovative and collaborative approaches in translational science that are crosscutting and useful for the broader scientific community. Strategic Plan NCATS developed a strategic plan in 2016 to outline the Center’s strategic goals and principles. It is organized into four overarching themes: translational science, collaboration and partnerships, education and training, and stewardship. The themes are captured in the strategic goals and collectively provide an overview of what the Center plans to accomplish to achieve its mission. Accomplishments Annual and biennial reports showcase NCATS’ translational science initiatives that speed medical research progress and shorten the journey from scientific discovery to better health. 2019–2020 web page or PDF (PDF - 3.9MB) 2017–2018 (PDF - 2.2MB) 2016 (PDF - 3.4MB) 2015 (PDF - 3MB) 2014 (PDF - 2MB) 2012–2013 (PDF - 2MB) View the NIH Almanac to see more of NCATS’ program highlights throughout the past decade. Milestone Anniversaries NCATS marked its fifth anniversary in 2016 and its 10th anniversary in 2021. In 2016, the director highlighted several accomplishments, including defining translation and the new field of translational science. At the 10-year anniversary, NCATS hosted an event to highlight how the Center’s innovative and team science approach addresses unmet needs and to usher in the next decade of bold solutions. Read about more examples of NCATS’ achievements in advancing translational science. | NCATS was created to transform the translational process so that new treatments can be delivered to patients faster. | /sites/default/files/NCATS_default_metaimage_tagline_680x383.png | NCATS History | NCATS was created to transform the translational process so that new treatments can be delivered to patients faster. | /sites/default/files/NCATS_default_metaimage_tagline_680x383_0.png | NCATS History | ||
| 24797 | Scientific Publications | Publications May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Publications May 2023 Relations Between the Mcgurk Effect, Social and Communication Skill, and Autistic Features in Children With and Without Autism • Journal of Autism and Developmental Disorders • May 1, 2023 • CTSA Program Socio-Economic and Psychosocial Determinants of Violent Discipline Among Parents in Asia Pacific Countries During COVID-19: Focus on Disadvantaged Populations • Child Abuse & Neglect • May 1, 2023 • CTSA Program April 2023 Plasma Proteomics of SARS-CoV-2 Infection and Severity Reveals Impact on Alzheimer's and Coronary Disease Pathways • iScience • April 21, 2023 • CTSA Program Acute Pain and Analgesic Requirement After Vaginal Childbirth With and Without Neuraxial Labor Analgesia-Retrospective Cohort Study • PLoS One • April 18, 2023 • CTSA Program L-Arginine in Diabetes: Clinical and Preclinical Evidence • Cardiovascular Diabetology • April 18, 2023 • CTSA Program mHealth and COVID-19: A Bibliometric Study • Healthcare • April 18, 2023 • NCATS Myocardial Strain During Surveillance Screening Is Associated With Future Cardiac Dysfunction Among Survivors of Childhood, Adolescent and Young Adult-Onset Cancer • Cancers • April 18, 2023 • CTSA Program StkP- and PhpP-Mediated Posttranslational Modifications Modulate the S. pneumoniae Metabolism, Polysaccharide Capsule, and Virulence • Infection and Immunity • April 18, 2023 • CTSA Program The Role of Telemedicine for Evaluation and Management of Dizzy Patients: A Systematic Review • Otology & Neuerotology • April 17, 2023 • CTSA Program Serum Procalcitonin Level Is Independently Associated With Mechanical Ventilation and Case-Fatality in Hospitalized COVID-19-Positive US Veterans – A Potential Marker for Disease Severity • PLoS One • April 17, 2023 • CTSA Program Exercise Testing in the Risk Assessment of Pulmonary Hypertension • CHEST • April 13, 2023 • CTSA Program Incarceration Status at Buprenorphine Initiation and OUD Treatment Outcomes During Pregnancy • Frontiers in Psychiatry • April 13, 2023 • CTSA Program Human Intravital Microscopy in the Study of Sarcomas: An Early Trial of Feasibility • Frontiers in Oncology • April 12, 2023 • CTSA Program A Multistate Assessment of Population Normalization Factors for Wastewater-Based Epidemiology of COVID-19 • PLoS One • April 12, 2023 • CTSA Program Compassion as a Tool for Allyship and Anti-Racism • Frontiers in Psychology • April 11, 2023 • CTSA Program A Model for Crowdsourcing High-Impact Research Questions for Castleman Disease and Other Rare Diseases • Orphanet Journal of Rare Diseases • April 11, 2023 • Rare Diseases School-Based Diabetes Care: A National Survey of U.S. Pediatric Diabetes Providers • Pediatric Diabetes • April 11, 2023 • CTSA Program Specific Targeting and Labeling of Colonic Polyps in CPC-APC Mice With Mucin 5AC Fluorescent Antibodies: A Model for Detection of Early Colon Cancer • Current Issues in Molecular Biology • April 11, 2023 • New Therapeutic Uses Three-Dimensional Structural Insights Have Revealed the Distinct Binding Interactions of Agonists, Partial Agonists, and Antagonists with the µ Opioid Receptor • International Journal of Molecular Sciences • April 11, 2023 • Division of Preclinical Innovation Use of Physiological Based Pharmacokinetic Modeling for Cross-Species Prediction of Pharmacokinetic and Tissue Distribution Profiles of a Novel Niclosamide Prodrug • Frontiers in Pharmacology • April 11, 2023 • Division of Preclinical Innovation Biomarkers of Cellular Senescence in Idiopathic Pulmonary Fibrosis • Respiratory Research • April 7, 2023 • CTSA Program E-Selectin-Targeting Lipid Nanoparticles Improve Therapeutic Efficacy and Reduce Side Effects of Bortezomib in Multiple Myeloma • Blood Cancer Journal • April 7, 2023 • NCATS Chronic Conditions in Women: The Development of a National Institutes of Health Framework • BMC Women's Health • April 6, 2023 • CTSA Program Familial Hypertrophic Cardiomyopathy: Diagnosis and Management • Vascular Health and Risk Management • April 6, 2023 • CTSA Program Metformin Triggers a Kidney GDF15-Dependent Area Postrema Axis to Regulate Food Intake and Body Weight • Cell Metabolism • April 6, 2023 • RDCRN Pregnancy and STI/HIV Prevention Intervention Preferences of South African Adolescent Girls: Findings From a Cultural Consensus Modelling Qualitative Study • Culture, Health & Sexuality • April 6, 2023 • CTSA Program Gene Expression Signatures in Inflammatory and Sclerotic Morphea Skin and Sera Distinguish Morphea From Systemic Sclerosis • Journal of Investigative Dermatology • April 5, 2023 • CTSA Program Global Discovery and Temporal Changes of Human Albumin Modifications by Pan-Protein Adductomics: Initial Application to Air Pollution Exposure • Journal of the American Society for Mass Spectrometry • April 5, 2023 • CTSA Program Barriers and Facilitators for Under-Represented in Medicine (URiM) Medical Students Interested in Surgical Sub-Specialties • The American Journal of Surgery • April 4, 2023 • CTSA Program Comparing Characteristics and Treatment of Brain Vascular Malformations in Children and Adults With HHT • Journal of Clinical Medicine • April 4, 2023 • RDCRN Limited Efficacy of Empiric Antibiotics for Pediatric Facial Fractures • Journal of Oral and Maxillofacial Surgery • April 4, 2023 • CTSA Program Biomarkers of Stress and Inflammation in Children • Biological Research for Nursing • April 3, 2023 • CTSA Program Home Health Care Workers’ Interactions With Medical Providers, Home Care Agencies, and Family Members for Patients With Heart Failure • Journal of the American Board of Family Medicine • April 3, 2023 • CTSA Program Identification of Potent and Selective Acetylcholinesterase/Butyrylcholinesterase Inhibitors by Virtual Screening • Journal of Chemical Information and Modeling • April 3, 2023 • Division of Preclinical Innovation Post-Burn Psychosocial Outcomes in Pediatric Minority Patients in the United States: An Observational Cohort Burn Model System Study • European Burn Journal • April 3, 2023 • CTSA Program Prenatal Oxidative Stress and Rapid Infant Weight Gain • International Journal of Obesity • April 3, 2023 • CTSA Program Age at Surgery and Outcomes Following Neonatal Cardiac Surgery: An Analysis From the Pediatric Cardiac Critical Care Consortium • The Journal of Thoracic and Cardiovascular Surgery • April 1, 2023 • CTSA Program Biomechanics Models Predict Increasing Smooth Muscle Tone as a Novel Therapeutic Target for Central Arterial Dysfunction in Hypertension • Journal of Hypertension • April 1, 2023 • CTSA Program Brain-Derived Neurotrophic Factor (BDNF) Epigenomic Modifications and Brain-Related Phenotypes in Humans: A Systematic Review • Neuroscience & Biobehavioral Reviews • April 1, 2023 • CTSA Program CRISPR-Induced Exon Skipping of β-Catenin Reveals Tumorigenic Mutants Driving Distinct Subtypes of Liver Cancer • The Journal of Pathology • April 1, 2023 • CTSA Program Does Low-Density Lipoprotein Fully Explain Atherosclerotic Risk in Familial Hypercholesterolemia? • Current Opinion in Lipidology • April 1, 2023 • CTSA Program Early Repeat Resection for Residual Glioblastoma: Decision-Making Among an International Cohort of Neurosurgeons • Journal of Neurosurgery • April 1, 2023 • CTSA Program Effectiveness and Feasibility of Three Types of Parent Reminders to Increase Adolescent Human Papillomavirus (HPV) Vaccination • Preventive Medicine • April 1, 2023 • CTSA Program Fuchs Dystrophy and Cataract: Diagnosis, Evaluation and Treatment • Ophthalmology and Therapy • April 1, 2023 • CTSA Program Impact of Cardiac Implantable Electronic Devices on Cost and Length of Stay in Patients With Surgical Aortic Valve Replacement and Transcutaneous Aortic Valve Implantation • The American Journal of Cardiology • April 1, 2023 • CTSA Program The Impact of Rounds With a Psychiatry Team in the Intensive Care Unit: A Prospective Observational Pilot Study Evaluating the Effects on Delirium Incidence and Outcomes • Journal of Psychiatric Research • April 1, 2023 • CTSA Program Long-Term Opioid Therapy Among Patients With Systemic Lupus Erythematosus in the Community: A Lupus Midwest Network (LUMEN) Study • The Journal of Rheumatology • April 1, 2023 • CTSA Program Mucosal Ulceration in Gastrointestinal Stromal Tumor Is an Independent Predictor of Progression-Free Survival • Journal of Surgical Research • April 1, 2023 • CTSA Program Percutaneous Vertebral Augmentation for Acute Traumatic Vertebral Fractures: A Tqip Database Study • Journal of Clinical Neuroscience • April 1, 2023 • CTSA Program Post-Treatment Outcomes of Ceftriaxone Versus Antistaphylococcal Penicillins or Cefazolin for Definitive Therapy of Methicillin-Susceptible Staphylococcus aureus Bacteremia • European Journal of Clinical Microbiology & Infectious Diseases • April 1, 2023 • CTSA Program Review of Machine Learning and Artificial Intelligence (ML/AI) for the Pediatric Neurologist • Pediatric Neurology • April 1, 2023 • CTSA Program Revision of Total Shoulder Arthroplasty to Hemiarthroplasty: Results at Mean 5-Year Follow-Up • Journal of Shoulder and Elbow Surgery • April 1, 2023 • CTSA Program Social Determinants of Health and Asthma • Current Opinion in Allergy and Clinical Immunology • April 1, 2023 • CTSA Program Understanding Prognosis: Discrepancy in Prognosis Estimates Between Patients With Cirrhosis and their Hepatologists • Clinical Gastroenterology and Hepatology • April 1, 2023 • CTSA Program Variation in Initial and Continued Use of Primary, Mental Health, and Specialty Video Care Among Veterans • Health Services Research • April 1, 2023 • CTSA Program Vascular Contributions to Alzheimer’s Disease • Translational Research • April 1, 2023 • CTSA Program March 2023 A-to-I Edited miR-411-5p Targets MET and Promotes TKI Response in NSCLC-Resistant Cells • Oncogene • March 31, 2023 • CTSA Program Damaged Mitochondria Coincide With Presynaptic Vesicle Loss and Abnormalities in Alzheimer's Disease Brain • Acta Neuropathologica Communications • March 31, 2023 • CTSA Program The Informal Safety Net: Social Network Activation Among Hispanic Immigrants During COVID-19 • SAGE Public Health Emergency Collection • March 31, 2023 • CTSA Program ‘Let the Ladies Know’: Queer Women’s Perceptions of How Gender and Sexual Orientation Shape Their Eating and Weight Concerns • Culture, Health & Sexuality • March 31, 2023 • CTSA Program Organizational Trust, Usability, and Inclusivity Are Key Implementation Facilitators for a Proposed Assets-Based Mobile Health Intervention • Translational Behavioral Medicine • March 31, 2023 • CTSA Program Rapid-Cycle Designs to Adapt Interventions for COVID-19 in Safety-Net Healthcare Systems • Translational Behavioral Medicine • March 31, 2023 • CTSA Program Research Inclusion Across the Lifespan: A Good Start, but There Is More Work to Be Done • Journal of General Internal Medicine • March 31, 2023 • CTSA Program Sparse Clusterability: Testing for Cluster Structure in High Dimensions • BMC Bioinformatics • March 31, 2023 • CTSA Program “Beyond Just the Four Walls of the Clinic”: The Roles of Health Systems Caring for Refugee, Immigrant and Migrant Communities in the United States • Frontiers in Public Health • March 30, 2023 • CTSA Program Global Longitudinal Strain Is Associated With Mortality in Patients With Multiple Myeloma • Journal of Clinical Medicine • March 30, 2023 • CTSA Program Predictors of Mental Health Service Utilization Among Frontline Healthcare Workers During the COVID-19 Pandemic • International Journal of Environmental Research and Public Health • March 30, 2023 • CTSA Program Exploring Preferences and Decision-Making About Long-Acting Injectable HIV Pre-Exposure Prophylaxis (PrEP) Among Young Sexual Minority Men 17-24 Years Old • Scientific Reports • March 29, 2023 • CTSA Program General Perceptions and Knowledge of Antibiotic Resistance and Antibiotic Use Behavior: A Cross-Sectional Survey of US Adults • Antibiotics • March 29, 2023 • CTSA Program Human Milk-Derived Fortifiers Are Linked With Feed Extension Due to Hypoglycemia in Infants <1250 g or <30 Weeks: A Matched Retrospective Chart Review • Journal of Perinatology • March 29, 2023 • CTSA Program Faith-Based Health Screenings for Marshallese Adults Living in the Republic of the Marshall Islands: Study Design and Results • Frontiers in Public Health • March 28, 2023 • CTSA Program Persistent Immune Activation and Altered Gut Integrity Over Time in a Longitudinal Study of Ugandan Youth With Perinatally Acquired HIV • Frontiers in Immunology • March 28, 2023 • CTSA Program Reserpine Maintains Photoreceptor Survival in Retinal Ciliopathy by Resolving Proteostasis Imbalance and Ciliogenesis Defects • eLife • March 28, 2023 • TRND Comparative Effectiveness of Fludrocortisone and Hydrocortisone vs Hydrocortisone Alone Among Patients With Septic Shock • JAMA Internal Medicine • March 27, 2023 • CTSA Program Epidemiology of Intensive Care Admissions for Children in the US From 2001 to 2019 • JAMA Pediatrics • March 27, 2023 • CTSA Program A Systematic Review of Dissemination and Implementation Science Capacity Building Programs Around the Globe • Implementation Science Communications • March 27, 2023 • CTSA Program Immune and Ionic Mechanisms Mediating the Effect of Dexamethasone in Severe COVID-19 • Frontiers in Immunology • March 24, 2023 • CTSA Program Antidepressant Augmentation Versus Switch in Treatment-Resistant Geriatric Depression • The New England Journal of Medicine • March 23, 2023 • CTSA Program Biomonitoring and Precision Health in Deep Space Supported by Artificial Intelligence • Nature Machine Intelligence • March 23, 2023 • Biomedical Data Translator Mindfulness Using a Wearable Brain Sensing Device for Health Care Professionals During a Pandemic: A Pilot Program • Journal of Primary Care & Community Health • March 23, 2023 • CTSA Program Use of a Web-Based Portal to Return Normal Individual Research Results in Early Check: Exploring User Behaviors and Attitudes • Clinical Genetics • March 23, 2023 • CTSA Program Combining Acoustic Bioprinting With AI-Assisted Raman Spectroscopy for High-Throughput Identification of Bacteria in Blood • Nano Letters • March 22, 2023 • CTSA Program Food Insecurity Screening in Primary Care: Patterns During the COVID-19 Pandemic by Encounter Modality • American Journal of Preventive Medicine • March 22, 2023 • CTSA Program MCP Extensors Respond Faster Than Flexors in Individuals With Severe-to-Moderate Stroke-Caused Impairment: Evidence of Uncoupled Neural Pathways • Frontiers in Neurology • March 22, 2023 • CTSA Program Biomimetic Mineralization of Fibrillar Collagen With Strontium-Doped Hydroxyapatite • ACS Macro Letters • March 21, 2023 • CTSA Program Dose Optimization in Surgical Prophylaxis: Sub-Inhibitory Dosing of Vancomycin Increases Rates of Biofilm Formation and the Rates of Surgical Site Infection • Scientific Reports • March 21, 2023 • CTSA Program No Increased Prevalence of Autoantibodies Neutralizing Type I IFNs in Idiopathic Pulmonary Fibrosis Patients • Respiratory Research • March 20, 2023 • CTSA Program Serum Fibroblast Growth Factor 21 Is Markedly Decreased following Exercise Training in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis • Nutrients • March 20, 2023 • CTSA Program The Effects of Exercise and Diet on Oxidative Stress and Telomere Length in Breast Cancer Survivors • Breast Cancer Research and Treatment • March 18, 2023 • CTSA Program Bibliometric and Visual Analysis of Machine Learning-Based Research in Acute Kidney Injury Worldwide • Frontiers in Public Health • March 17, 2023 • NCATS Childhood Adversity Moderates Change in Latent Patterns of Psychological Adjustment During the COVID-19 Pandemic: Results of a Survey of U.S. Adults • Social Sciences • March 17, 2023 • CTSA Program Long-Term Outcomes in ALG13-Congenital Disorder of Glycosylation • The American Journal of Medical Genetics - Part A • March 17, 2023 • RDCRN Preoperative SARS-CoV-2 Infection Increases Risk of Early Postoperative Cardiovascular Complications Following Non-Cardiac Surgery • American Journal of Physiology-Heart and Circulatory Physiology • March 17, 2023 • CTSA Program Clinicoserological Insights Into Patients With Immune Checkpoint Inhibitor-Induced Myasthenia Gravis • Annals of Clinical and Translational Neurology • March 16, 2023 • RDCRN Comparing the Clinical and Cost-Effectiveness of Remote (Telehealth and Online) Cognitive Behavioral Therapy-Based Treatments for High-Impact Chronic Pain Relative to Usual Care: Study Protocol for the RESOLVE Multisite Randomized Control Trial • Trials • March 16, 2023 • CTSA Program miR-4432 Targets FGFBP1 in Human Endothelial Cells • Biology • March 16, 2023 • CTSA Program Uncertainty-Aware Deep Learning Classification of Adamantinomatous Craniopharyngioma From Preoperative MRI • Diagnostics • March 16, 2023 • CTSA Program B-Cell Epitope Discovery: The First Protein Flexibility-Based Algorithm-Zika Virus Conserved Epitope Demonstration • PLoS One • March 15, 2023 • CTSA Program Disease Associations of Excessive Daytime Sleepiness in Multiple Sclerosis: A Prospective Study • Multiple Sclerosis Journal – Experimental, Translational and Clinical • March 15, 2023 • CTSA Program The Structure of Mood and Anxiety Disorder Symptoms in the Perinatal Period • Journal of Affective Disorders • March 15, 2023 • CTSA Program Anti-Biofilm Activity of Human Milk Oligosaccharides in Clinical Strains of Streptococcus Agalactiae With Diverse Capsular and Sequence Types • ChemBioChem • March 14, 2023 • CTSA Program Direct-to-Consumer Recruitment Methods via Traditional and Social Media to Aid in Research Accrual for Clinical Trials for Rare Diseases: Comparative Analysis Study • Journal of Medical Internet Research • March 14, 2023 • RDCRN Do Patients With Metastatic Pancreatic Adenocarcinoma to the Lung Have Improved Survival? • Cancer Medicine • March 14, 2023 • CTSA Program Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women During Malaria Chemoprevention • Antimicrobial Agents and Chemotherapy • March 14, 2023 • CTSA Program Psychological and Physical Function in Allogeneic Hematopoietic Cell Transplant Survivors With Chronic Graft-Versus-Host Disease • Journal of Cancer Survivorship • March 14, 2023 • CTSA Program Racial Disparities in Opioid Prescription and Pain Management Among Breast Cancer Survivors • Cancer Medicine • March 14, 2023 • CTSA Program Assessing the Contributions of Modifiable Risk Factors to Serious Falls and Fragility Fractures Among Older Persons Living With HIV • Journal of the American Geriatrics Society • March 13, 2023 • CTSA Program Association of Life Expectancy With Surveillance Colonoscopy Findings and Follow-Up Recommendations in Older Adults • JAMA Internal Medicine • March 13, 2023 • CTSA Program Cancer, More Than a “COVID-19 Co-Morbidity” • Frontiers in Oncology • March 13, 2023 • CTSA Program Inclusion Complexation of S-Nitrosoglutathione for Sustained Nitric Oxide Release From Catheter Surfaces: A Strategy to Prevent and Treat Device-Associated Infections • ACS Biomaterials Science & Engineering • March 13, 2023 • CTSA Program Multidisciplinary Perspectives on the Implementation of a Comprehensive Sexual Assault Telehealth Program in Rural Communities: A Qualitative Study • Violence Against Women • March 13, 2023 • CTSA Program The New Crisis of Increasing All-Cause Mortality in US Children and Adolescents • Journal of the American Medical Association • March 13, 2023 • CTSA Program A Sequential, Multiple Assignment Randomized Trial Comparing Web-Based Education to Mobile Video Interpreter Access for Improving Provider Interpreter Use in Primary Care Clinics: The mVOCAL Hybrid Type 3 Study Protocol • Implementation Science • March 13, 2023 • CTSA Program SULT1A1-Dependent Sulfonation of Alkylators Is a Lineage-Dependent Vulnerability of Liver Cancers • Nature Cancer • March 13, 2023 • Division of Preclinical Innovation Hospice Caregivers’ Perception of Family and Non-Family Social Support and Stress over Time: Associations With Reports of General Support • International Journal of Environmental Research and Public Health • March 12, 2023 • CTSA Program Addressing Barriers to Career Development Awards for Early Career Women in Pediatric Psychology • Journal of Pediatric Psychology • March 10, 2023 • CTSA Program Big Data in Stroke: How to Use Big Data to Make the Next Management Decision • Neurotherapeutics • March 10, 2023 • CTSA Program Childhood Asthma Diagnoses Declined During the COVID-19 Pandemic in the United States • Respiratory Research • March 10, 2023 • CTSA Program Ligand-Induced Activation of GPR110 (ADGRF1) to Improve Visual Function Impaired by Optic Nerve Injury • International Journal of Molecular Sciences • March 10, 2023 • Division of Preclinical Innovation Associations Between Multi-Method Latent Factors of Puberty and Brain Structure in Adolescent Girls • Developmental Cognitive Neuroscience • March 9, 2023 • CTSA Program Deep Learning-Enabled Analysis of Medical Images Identifies Cardiac Sphericity as an Early Marker of Cardiomyopathy and Related Outcomes • Med • March 9, 2023 • CTSA Program Strategic Team Science Promotes Collaboration and Practice-Based Research at the Research Centers in Minority Institutions • International Journal of Environmental Research and Public Health • March 9, 2023 • CTSA Program Targeting Nonsense-Mediated RNA Decay Does Not Increase Progranulin Levels in the Grn R493X Mouse Model of Frontotemporal Dementia • PLoS One • March 9, 2023 • CTSA Program Adipose-Targeted SWELL1 Deletion Exacerbates Obesity- and Age-Related Nonalcoholic Fatty Liver Disease • Medical Care • March 8, 2023 • CTSA Program BabyByte: Qualitative Research to Inform the Development of an App to Improve Responsive Feeding Practices in Parents of Infants and Toddlers • International Journal of Environmental Research and Public Health • March 8, 2023 • CTSA Program A Case Study of Dysfunctional Nicotinamide Metabolism in a 20-Year-Old Male • Metabolites • March 8, 2023 • NCATS Effect of Self-Directed Home Therapy Adherence Combined With TheraBracelet on Poststroke Hand Recovery: A Pilot Study • Stroke Research and Treatment • March 8, 2023 • CTSA Program GPMatch: A Bayesian Causal Inference Approach Using Gaussian Process Covariance Function as a Matching Tool • Frontiers in Applied Mathematics and Statistics • March 8, 2023 • CTSA Program Impact of COVID-19 on the Research Career Advancement of Health Equity Scholars From Diverse Backgrounds • International Journal of Environmental Research and Public Health • March 8, 2023 • CTSA Program mTOR Inhibition Overcomes RSK3-Mediated Resistance to BET Inhibitors in Small Cell Lung Cancer • JCI Insight • March 8, 2023 • Division of Preclinical Innovation Prenatal Diagnosis of Recurrent Hypoplastic Left Heart Syndrome Associated With MYH6 Variants: A Case Report • BMC Cardiovascular Disorders • March 8, 2023 • GARD Association Between Obstructive Sleep Apnea and 24-h Urine Chemistry Risk Factors for Urinary Stone Disease • Urolithiasis • March 7, 2023 • CTSA Program Association of FDA Mandate Limiting Acetaminophen (Paracetamol) in Prescription Combination Opioid Products and Subsequent Hospitalizations and Acute Liver Failure • Journal of the American Medical Association • March 7, 2023 • CTSA Program Multi-Ancestry Phenome-Wide Association of Complement Component 4 Variation With Psychiatric and Brain Phenotypes in Youth • Genome Biology • March 7, 2023 • CTSA Program Polygenic Risk Score Association with Multiple Sclerosis Susceptibility and Phenotype in Europeans • Brain • March 7, 2023 • CTSA Program Association Between the Epigenetic Lifespan Predictor Grimage and History of Suicide Attempt in Bipolar Disorder • Neuropsychopharmacology • March 6, 2023 • CTSA Program Biomechanical Impact of Pathogenic Mybpc3 Truncation Variant Revealed By Dynamically Tuning In Vitro Afterload • Journal of Cardiovascular Translational Research • March 6, 2023 • CTSA Program Circulating Ketone Bodies and Cardiovascular Outcomes: The MESA Study • European Heart Journal • March 6, 2023 • CTSA Program ctDNA and Residual Cancer Burden Are Prognostic in Triple-Negative Breast Cancer Patients With Residual Disease • NPJ Breast Cancer • March 6, 2023 • CTSA Program Performance of Automated Oral Cancer Screening Algorithm in Tobacco Users vs. Non-Tobacco Users • Applied Sciences • March 6, 2023 • CTSA Program Evaluation of Right Ventricular Strain in Two Separate Cohorts With Precapillary Pulmonary Hypertension • Pulmonary Circulation • March 5, 2023 • CTSA Program Small Molecule Inhibitors of Intestinal Epithelial Anion Exchanger SLC26A3 (DRA) With a Luminal, Extracellular Site of Action • European Journal of Medicinal Chemistry • March 5, 2023 • CTSA Program Urolithin A Analog Inhibits Castration-Resistant Prostate Cancer by Targeting the Androgen Receptor And Its Variant, Androgen Receptor-Variant 7 • Frontiers in Pharmacology • March 3, 2023 • CTSA Program ATP/ADP Biosensor Organoids for Drug Nephrotoxicity Assessment • Frontiers in Cell and Developmental Biology • March 2, 2023 • Tissue Chip Cluster Analysis of Plasma Cytokines Identifies Two Unique Endotypes of Children With Asthma in the Pediatric Intensive Care Unit • Scientific Reports • March 2, 2023 • CTSA Program The Effect of Supervision on Community Health Workers’ Effectiveness With Households in Rural South Africa: A Cluster Randomized Controlled Trial • PLoS Medicine • March 2, 2023 • CTSA Program Functional Annotation of the Animal Genomes: An Integrated Annotation Resource for the Horse • PLOS Genetics • March 2, 2023 • Extramural Loan Repayment Program for Pediatric Research Principal Investigators’ Priorities and Perceived Barriers and Facilitators When Making Decisions About Conducting Essential Research in the COVID-19 Pandemic • Science and Engineering Ethics • March 2, 2023 • CTSA Program Racial/Ethnic and Geographic Disparities in Comorbid Traumatic Brain Injury-Renal Failure in US Veterans and Associated Veterans Affairs Resource Costs, 2000-2020 • Journal of Racial and Ethnic Health Disparities • March 2, 2023 • CTSA Program Ambivalence Is Associated With Decreased Physical Activity and Cardiorespiratory Fitness Among Adolescents With Critical Congenital Heart Disease • Heart & Lung • March 1, 2023 • CTSA Program The Association Between Hypophosphatemia and Lactic Acidosis After Cardiac Surgery With Cardiopulmonary Bypass: a Retrospective Cohort Study • Journal of Cardiothoracic and Vascular Anesthesia • March 1, 2023 • CTSA Program Association Between Preoperative Hematologic Markers and Aggressive Behavior in Meningiomas • Clinical Neurology and Neurosurgery • March 1, 2023 • CTSA Program Associations of Cephalad Drainage in Neonatal Veno-Venous ECMO - A Mixed-Effects, Propensity Score Adjusted Retrospective Analysis of 20 Years of ELSO Data • Journal of Pediatric Surgery • March 1, 2023 • CTSA Program Associations of Early Life Phthalate Exposures With Adolescent Lipid Levels and Insulin Resistance: The HOME Study • International Journal of Hygiene and Environmental Health • March 1, 2023 • CTSA Program Associations of Urinary Isoprostanes With Measures of Subclinical Atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA) • Atherosclerosis Plus • March 1, 2023 • CTSA Program Blood Pressure Changes in Gestational Hypertension, Preeclampsia, and Chronic Hypertension From Preconception to 42-Day Postpartum • Pregnancy Hypertension • March 1, 2023 • CTSA Program Circulating Polyunsaturated Fatty Acids and Pain Intensity in Five Chronic Pain Conditions • The Journal of Pain • March 1, 2023 • CTSA Program Clinical Outcomes of Liposomal Bupivacaine Erector Spinae Block in Minimally Invasive Transforaminal Lumbar Interbody Fusion Surgery • Neurosurgery • March 1, 2023 • CTSA Program Clinical Trial Site Perspectives and Practices on Study Participant Diversity and Inclusion • Clinical Pharmacology & Therapeutics • March 1, 2023 • CTSA Program Clinician and Caregiver Determinations of Acuity for Children Transported by Emergency Medical Services: A Prospective Observational Study • Annals of Emergency Medicine • March 1, 2023 • CTSA Program Deprescribing Medications Among Older Adults From End of Hospitalization Through Postacute Care: A Shed-MEDS Randomized Clinical Trial • JAMA Internal Medicine • March 1, 2023 • CTSA Program Effects of a Responsive Parenting Intervention Among Black Families on Infant Sleep: A Secondary Analysis of the Sleep SAAF Randomized Clinical Trial • JAMA Network Open • March 1, 2023 • CTSA Program Efficacy Randomized Controlled Trials • American Journal of Nursing • March 1, 2023 • CTSA Program Factors Associated With Provision of Nonbeneficial Surgery: A National Survey of Surgeons • Annals of Surgery • March 1, 2023 • CTSA Program Healthcare System Engagement and Algorithm-Identified Cancer Incidence Following Initiation of a New Medication • Pharmacoepidemiology and Drug Safety • March 1, 2023 • CTSA Program Household Transmission and Clinical Features of SARS-CoV-2 Infections • Pediatric • March 1, 2023 • CTSA Program Impact of Ocular Conditions and Improvements After Refractive Surgery in Quality of Life for Children With Neurodevelopmental Disorders • American Journal of Ophthalmology • March 1, 2023 • CTSA Program Increased Stroke Severity and Mortality in Patients With SARS-CoV-2 Infection: An Analysis From the N3C Database • Journal of Stroke and Cerebrovascular Diseases • March 1, 2023 • CTSA Program Intensive Care Unit-Acquired Weakness in Patients With Acute Kidney Injury: A Contemporary Review • American Journal of Kidney Diseases • March 1, 2023 • CTSA Program Long COVID: Major Findings, Mechanisms and Recommendations • Nature Reviews Microbiology • March 1, 2023 • CTSA Program Long-Term Outcomes of a 1-Year Hypertension Quality Improvement Initiative in a Large Health System • JCI Insight • March 1, 2023 • CTSA Program Meta-Analysis: Chemoprevention of Hepatocellular Carcinoma With Statin Aspirin and Metformin • Alimentary Pharmacology & Therapeutics • March 1, 2023 • CTSA Program Metabolic Outcomes in Adults With Type 2 Diabetes and Sleep Disorders • Sleep and Breathing • March 1, 2023 • CTSA Program Methods of Arterial Stiffness Calculation and Cardiovascular Disease Events: The Multiethnic Study of Atherosclerosis • Journal of Hypertension • March 1, 2023 • CTSA Program MicroRNA-Based Engineering of Mesenchymal Stem Cell Extracellular Vesicles for Treatment of Retinal Ischemic Disorders: Engineered Extracellular Vesiclesand Retinal Ischemia • Acta Biomaterialia • March 1, 2023 • CTSA Program Mucosal Microbiota Associated With Eosinophilic Esophagitis and Eosinophilic Gastritis • Journal of Pediatric Gastroenterology and Nutrition • March 1, 2023 • RDCRN Multiomic Analyses Implicate a Neurodevelopmental Program in the Pathogenesis of Cerebral Arachnoid Cysts • Nature Medicine • March 1, 2023 • CTSA Program Outcomes and Risk Factors for Failure After Debridement, Antibiotics, and Implant Retention for Elbow Periprosthetic Joint Infection • Journal of Shoulder and Elbow Surgery • March 1, 2023 • CTSA Program Palatability and Acceptability of Flaxseed-Supplemented Foods in Children With Sickle Cell Disease • Nutrients • March 1, 2023 • CTSA Program Parieto-Occipital Injury on Diffusion MRI Correlates With Poor Neurologic Outcome Following Cardiac Arrest • American Journal of Neuroradiology • March 1, 2023 • CTSA Program Patient and Operative Factors Predict Risk of Discretionary Prolonged Postoperative Mechanical Ventilation in a Broad Surgical Cohort • Anesthesia & Analgesia • March 1, 2023 • CTSA Program Pediatric Hidradenitis Suppurativa: Describing Care Patterns in the Emergency Department • Pediatric Dermatology • March 1, 2023 • CTSA Program Personalized Hypertension Treatment Recommendations by a Data-Driven Model • BMC Medical Informatics and Decision Making • March 1, 2023 • CTSA Program Perspectives on Self-Sampling for Cancer Screening Among Rural and Urban Women: Multilevel Factors Related to Acceptability • The Journal of Rural Health • March 1, 2023 • CTSA Program Phase 1 Study of Belinostat and Adavosertib in Patients With Relapsed or Refractory Myeloid Malignancies • Cancer Chemotherapy and Pharmacology • March 1, 2023 • CTSA Program Placebo-Controlled Effectiveness of Idiopathic Normal Pressure Hydrocephalus Shunting: A Randomized Pilot Trial • Neurosurgery • March 1, 2023 • CTSA Program Principal Component Regression Analysis of Familial Psychiatric Histories and Suicide Risk Factors Among Adults With Opioid Use Disorder • Journal of Psychiatric Research • March 1, 2023 • CTSA Program Racial and Ethnic Disparities in Acute Care Utilization Among Patients With Glomerular Disease • American Journal of Kidney Diseases • March 1, 2023 • CTSA Program The Role of Biologics in Pediatric Food Allergy and Eosinophilic Gastrointestinal Disorders • The Journal of Allergy and Clinical Immunology • March 1, 2023 • Rare Diseases Serious Infections Are Rare in Well-Appearing Neonates With Hypothermia Identified Incidentally at Routine Visits • The American Journal of Emergency Medicine • March 1, 2023 • CTSA Program Sleep Variability and Regularity as Contributors to Obesity and Cardiometabolic Health in Adolescence • Obesity • March 1, 2023 • CTSA Program Structural Causal Model With Expert Augmented Knowledge to Estimate the Effect of Oxygen Therapy on Mortality in the ICU • Artificial Intelligence in Medicine • March 1, 2023 • CTSA Program Temporal and Geographic Patterns of Documentation of Sexual Orientation and Gender Identity Keywords in Clinical Notes • Medical Care • March 1, 2023 • CTSA Program Trajectories of Insomnia Symptoms From Childhood Through Young Adulthood • Pediatrics • March 1, 2023 • CTSA Program February 2023 CAR-T Therapies in Solid Tumors: Opportunities and Challenges • Current Oncology Reports • Feb. 28, 2023 • CTSA Program Development and Design of a Mobile Application for Prescription Opioid Clinical Decision-Making: A Feasibility Study in New York City, USA • BMJ Open • Feb. 28, 2023 • CTSA Program Diagnostic Performance of Contemporary Transesophageal Echocardiography With Modern Imaging for Infective Endocarditis • Cardiovascular Diagnosis and Therapy • Feb. 28, 2023 • CTSA Program Duration of Residence and Hypertension in Black Foreign-Born Residents: NHIS, 2004-2017 • Journal of Racial and Ethnic Health Disparities • Feb. 28, 2023 • CTSA Program An Evaluation of 3D Printable Elastics for Post Stroke Dynamic Hand Bracing: A Pilot Study • Assistive Technology • Feb. 28, 2023 • CTSA Program The IRE1α-XBP1 Signaling Axis Promotes Glycolytic Reprogramming in Response to Inflammatory Stimuli • mBio • Feb. 28, 2023 • CTSA Program Jargon Be Gone - Patient Preference in Doctor Communication • Journal of Patient Experience • Feb. 28, 2023 • CTSA Program Passive Surveillance of Human-Biting Ixodes scapularis Ticks in Massachusetts from 2015–2019 • International Journal of Environmental Research and Public Health • Feb. 28, 2023 • CTSA Program Precision Information Extraction for Rare Disease Epidemiology at Scale • Journal of Translational Medicine • Feb. 28, 2023 • GARD Association Between Proteomic Biomarkers and Myocardial Fibrosis Measured by MRI: The Multi-Ethnic Study of Atherosclerosis • eBioMedicine • Feb. 27, 2023 • CTSA Program Deepening Our Understanding of COVID-19 Vaccine Decision-Making Amongst Healthcare Workers in Southwest Virginia, USA Using Exploratory and Confirmatory Factor Analysis • Vaccines • Feb. 27, 2023 • CTSA Program Real-World Experience of Tixagevimab-Cilgavimab Pre-Exposure Prophylaxis in Orthotopic Heart Transplant Recipients • Transplant Infectious Disease • Feb. 27, 2023 • CTSA Program Returning Home During the Pandemic: A Thematic Analysis Describing Experiences of People With Substance Use Disorders Released Early From New Jersey Prisons During COVID-19 • Health & Justice • Feb. 27, 2023 • CTSA Program Social Determinants, Blood Pressure Control, and Racial Inequities in Childbearing Age Women With Hypertension, 2001 to 2018 • Journal of the American Heart Association • Feb. 27, 2023 • CTSA Program Transcriptomic Analyses of Brains of RBM8A Conditional Knockout Mice at Different Developmental Stages Reveal Conserved Signaling Pathways Contributing to Neurodevelopmental Diseases • International Journal of Molecular Sciences • Feb. 27, 2023 • CTSA Program Cross-Platform Normalization Enables Machine Learning Model Training on Microarray and RNA-seq Data Simultaneously • Communications Biology • Feb. 25, 2023 • RDCRN Sex and Aging: Perspectives of Older Adult Women With Experience of Incarceration • Journal of Women & Aging • Feb. 25, 2023 • CTSA Program Associations Among PTSD, Cognitive Functioning, and Health-Promoting Behavior in Post-9/11 Veterans • Military Medicine • Feb. 24, 2023 • CTSA Program Association of Frailty With the Incidence Risk of Cardiovascular Disease and Type 2 Diabetes Mellitus in Long-Term Cancer Survivors: A Prospective Cohort Study • BMC Medicine • Feb. 24, 2023 • CTSA Program Mining of EHR for Interface Terminology Concepts for Annotating EHRs of COVID Patients • BMC Medical Informatics and Decision Making • Feb. 24, 2023 • CTSA Program Child Adult Relationship Enhancement in Primary Care (PriCARE): Study Design/Protocol for a Randomized Trial of a Primary Care-Based Group Parenting Intervention to Prevent Child Maltreatment • Trials • Feb. 23, 2023 • CTSA Program Developing a Standardized but Extendable Framework to Increase the Findability of Infectious Disease Datasets • Scientific Data • Feb. 23, 2023 • NCATS Do People With Schizophrenia Enjoy Social Activities as Much as Everyone Else? A Meta-Analysis of Consummatory Social Pleasure • Schizophrenia Bulletin • Feb. 23, 2023 • CTSA Program MidCog Study: A Prospective, Observational Cohort Study Investigating Health Literacy, Self-Management Skills and Cognitive Function in Middle-Aged Adults • BMJ Open • Feb. 23, 2023 • CTSA Program Optimal Intensity and Duration of Walking Rehabilitation in Patients With Chronic Stroke: A Randomized Clinical Trial • JAMA Neurology • Feb. 23, 2023 • CTSA Program Preventing Postpartum Hemorrhage With Combined Therapy Rather Than Oxytocin Alone • American Journal of Obstetrics & Gynecology MFM • Feb. 23, 2023 • CTSA Program A Workflow for Viewing Biomedical Computational Fluid Dynamics Results and Corresponding Data Within Virtual and Augmented Reality Environments • Frontiers in Medical Technology • Feb. 23, 2023 • CTSA Program Exercise Modulates Sympathetic and Vascular Function in Chronic Kidney Disease • JCI Insight • Feb. 22, 2023 • CTSA Program Long-Term Neurodevelopmental Follow-Up of Children Exposed to Pravastatin In-Utero • American Journal of Obstetrics & Gynecology • Feb. 22, 2023 • CTSA Program Maternal Hypertensive Disorders and Survival Without Major Morbidities Among Extremely Low Gestation Newborns • Journal of Perinatology • Feb. 22, 2023 • NCATS Obesity Promotes Breast Epithelium DNA Damage in Women Carrying a Germline Mutation in BRCA1 or BRCA2 • Science Translational Medicine • Feb. 22, 2023 • CTSA Program Open-Label Study of the Efficacy, Safety and Durability of Peanut Sublingual Immunotherapy in Peanut-Allergic Children • Journal of Allergy and Clinical Immunology • Feb. 22, 2023 • CTSA Program Oral Mucosal Breaks Trigger Anti-Citrullinated Bacterial and Human Protein Antibody Responses in Rheumatoid Arthritis • Science Translational Medicine • Feb. 22, 2023 • CTSA Program PET Imaging of Hepatocellular Carcinoma Using ZD2-(68Ga-NOTA) • Journal of Hepatocellular Carcinoma • Feb. 22, 2023 • CTSA Program Safety and Patient Experience With At-Home Infusion of Ocrelizumab for Multiple Sclerosis • Annals of Clinical and Translational Neurology • Feb. 22, 2023 • CTSA Program A Tri-Specific Killer Engager Against Mesothelin Targets NK Cells Towards Lung Cancer • Frontiers in Immunology • Feb. 22, 2023 • CTSA Program TrkA Expression Directs the Anti-Neoplastic Activity of MLK3 Inhibitors in Triple-Negative Breast Cancer • Oncogene • Feb. 22, 2023 • CTSA Program Advancing Cancer Research: Insights and Innovations in Pathogenesis and Targeted Therapies • Journal of Personalized Medicine • Feb. 21, 2023 • CTSA Program Dental Patients’ Perceptions of and Desired Content From Patient Health Portals • The Journal of the American Dental Association • Feb. 21, 2023 • CTSA Program Metallomics in Pulmonary Arterial Hypertension Patients • Pulmonary Circulation • Feb. 21, 2023 • CTSA Program Predictors and Outcomes of Acute Pulmonary Embolism in COVID-19; Insights From US National COVID Cohort Collaborative • Respiratory Research • Feb. 21, 2023 • CTSA Program Prevalence of Hearing Loss and Perceptions of Hearing Health and Protection Among Florida Firefighters • International Journal of Environmental Research and Public Health • Feb. 21, 2023 • CTSA Program Quality of Depression Care for Veterans Affairs Primary Care Patients With Experiences of Homelessness • Journal of General Internal Medicine • Feb. 21, 2023 • CTSA Program Sleep Irregularity and Subclinical Markers of Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis • Journal of the American Heart Association • Feb. 21, 2023 • CTSA Program Utility of a Risk Assessment Model in Predicting 30 Day Unplanned Hospital Readmission in Adult Patients Receiving Outpatient Parenteral Antimicrobial Therapy • JAC-Antimicrobial Resistance • Feb. 21, 2023 • CTSA Program Community Paramedic Hospital Reduction and Mitigation Program: Study Protocol for a Randomized Pragmatic Clinical Trial • Trials • Feb. 20, 2023 • CTSA Program The Use of Peer Support Groups for Emergency Physicians During the COVID-19 Pandemic • Journal of the American College of Emergency Physicians Open • Feb. 19, 2023 • CTSA Program Evaluation of the First-Year Data From an HPV Vaccination Van Program in South Carolina, U.S. • Journal of Clinical Medicine • Feb. 18, 2023 • CTSA Program Systemic Effects of Perineural Glucocorticoids on Fasting Serum Glucose, Potassium, and White Blood Cell Count in Total Hip Arthroplasty • Journal of Pain Research • Feb. 18, 2023 • CTSA Program Testing a Biobehavioral Model of Food Insecurity and Chronic Disease in Hispanic Older Adolescents • Nutrients • Feb. 18, 2023 • CTSA Program Data Quality Considerations for Evaluating COVID-19 Treatments Using Real World Data: Learnings From the National COVID Cohort Collaborative (N3C) • BMC Medical Research Methodology • Feb. 17, 2023 • CTSA Program KDM6B Protects T-ALL Cells From NOTCH1-Induced Oncogenic Stress • Leukemia • Feb. 17, 2023 • CTSA Program Potential Problems and Solutions of Opioid-Based Treatment in Neonatal Opioid Withdrawal Syndrome (NOWS): A Scoping Review Protocol • BMJ Open • Feb 17, 2023 • CTSA Program Rasch Validation of the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) in Community-Dwelling Adults • BMC Psychology • Feb. 17, 2023 • CTSA Program Whole-Genome Sequencing Analysis in Families With Recurrent Pregnancy Loss: A Pilot Study • PLoS One • Feb. 17, 2023 • CTSA Program The 2022 n2c2/UW Shared Task on Extracting Social Determinants of Health • Journal of the American Medical Informatics Association • Feb. 16, 2023 • CTSA Program Generation and Characterization of NGLY1 Patient-Derived Midbrain Organoids • BMC Medical Research Methodology • Feb. 16, 2023 • Division of Preclinical Innovation Localized Strain Characterization of Cardiomyopathy in Duchenne Muscular Dystrophy Using Novel 4D Kinematic Analysis of Cine Cardiovascular Magnetic Resonance • Journal of Cardiovascular Magnetic Resonance • Feb 16, 2023 • CTSA Program PARP1 Associates With R-Loops to Promote Their Resolution and Genome Stability • Nucleic Acids Research • Feb. 16, 2023 • CTSA Program Qualitative Similarities and Distinctions Between Participants’ Experiences With a Yoga Intervention and an Attention Control • Supportive Care in Cancer • Feb. 16, 2023 • CTSA Program Cadmium Exposure and Risk of Breast Cancer: A Meta-Analysis • Environmental Research • Feb. 15, 2023 • CTSA Program Cerebral Creatine Deficiency Affects the Timing of Oligodendrocyte Myelination • Journal of Neuroscience • Feb. 15, 2023 • CTSA Program High-Throughput Screening of Toxicants That Modulate Extravillous Trophoblast Migration • Toxicology Letters • Feb. 15, 2023 • CTSA Program Severe Acute Respiratory Syndrome and Particulate Matter Exposure: A Systematic Review • Life • Feb 15, 2023 • CTSA Program Trivalent Mosaic or Consensus HIV Immunogens Prime Humoral and Broader Cellular Immune Responses in Adults • The Journal of Clinical Investigation • Feb. 15, 2023 • CTSA Program Development and Evaluation of an Efficient Training Program to Facilitate the Adoption of a Novel Neurorehabilitation Device • Journal of Rehabilitation and Assistive Technologies Engineering • Feb. 14, 2023 • CTSA Program Effects of Sex and APOE ε4 Genotype on Brain Mitochondrial High-Energy Phosphates in Midlife Individuals at Risk for Alzheimer’s Disease: A 31Phosphorus MR Spectroscopy Study • PLoS One • Feb. 14, 2023 • CTSA Program Feasibility of an Embedded Palliative Care Clinic Model for Patients With an Advanced Thoracic Malignancy • Supportive Care in Cancer • Feb. 14, 2023 • CTSA Program Interstitial Lung Abnormalities in a Large Clinical Lung Cancer Screening Cohort: Association With Mortality and ILD Diagnosis • Respiratory Research • Feb. 14, 2023 • CTSA Program Multimodal CT Imaging of Ischemic Stroke Thrombi Identifies Scale-Invariant Radiomic Features That Reflect Clot Biology • The Journal of NeuroInterventional Surgery • Feb. 14, 2023 • CTSA Program Pain Phenotyping and Investigation of Outcomes in Physical Therapy: An Exploratory Study in Patients With Low Back Pain • PLoS One • Feb. 14, 2023 • CTSA Program A Pilot Study on the Co-Existence of Diabetes and Endometriosis in Reproductive-Age Women: Potential for Endometriosis Progression • Reproductive Sciences • Feb. 14, 2023 • CTSA Program Direct Connection to the ECMO Circuit versus a Hemodialysis Catheter Is Associated with Improved Urea Nitrogen Ultrafiltration during Continuous Renal Replacement Therapy for Patients on Extracorporeal Membrane Oxygenation • Journal of Clinical Medicine • Feb. 13, 2023 • CTSA Program Investigating the Use of SARS-CoV-2 (COVID-19) Odor Expression as a Non-Invasive Diagnostic Tool-Pilot Study • Diagnostics • Feb. 13, 2023 • RADx-RAD, SCENT N-of-1 Trials vs. Usual Care in Children With Hypertension: A Pilot Randomized Clinical Trial • American Journal of Hypertension • Feb. 13, 2023 • CTSA Program Neighborhood and Racial Influences on Triple Negative Breast Cancer: Evidence From Northeast Ohio • Breast Cancer Research and Treatment • Feb. 13, 2023 • CTSA Program Variation in Missed Doses and Reasons for Discontinuation of Anti-Tuberculosis Drugs During Hospital Treatment for Drug-Resistant Tuberculosis in South Africa • PLoS One • Feb. 13, 2023 • CTSA Program Associations Between Influenza Vaccination and Health Care Access Among Adults in the United States • Vaccines • Feb. 11, 2023 • CTSA Program Project BETTER: A Family-Centered, Technology-Delivered Intervention for Pregnant People With Opioid Use Disorder • Children • Feb. 11, 2023 • CTSA Program Associations Between Teamwork and Implementation Outcomes in Multidisciplinary Cross-Sector Teams Implementing a Mental Health Screening and Referral Protocol • Implementation Science Communications • Feb. 10, 2023 • CTSA Program Clinically Significant Scores for Thwarted Belonging and Perceived Burden From the Interpersonal Needs Questionnaire (Inq-15) • Crisis • Feb. 10, 2023 • CTSA Program Ectodomain Shedding of Proteins Important for SARS-CoV-2 Pathogenesis in Plasma of Tobacco Cigarette Smokers Compared to Electronic Cigarette Vapers: A Cross-Sectional Study • Journal of Molecular Medicine • Feb. 10, 2023 • CTSA Program The Effect of Telemental Versus In-Person Mental Health Consults in the Emergency Department on 30-Day Utilization and Processes of Care • Academic Emergency Medicine • Feb. 10, 2023 • CTSA Program Posterior White Matter Integrity and Self-Reported Posterior Cortical Symptoms Using the Colorado Posterior Cortical Questionnaire • Frontiers in Neurology • Feb. 10, 2023 • CTSA Program Technology-Mediated Support Among Siblings of Children With Cancer • Journal of Adolescent and Young Adult Oncology • Feb. 10, 2023 • CTSA Program Temperature Change of Ophthalmic Viscosurgical Devices in a Bi-Chamber Set-Up at a Flow of 0 and 20mL/min • Clinical Ophthalmology • Feb. 10, 2023 • CTSA Program A UVR-Sensor Wearable Device Intervention to Reduce Sun Exposure in Melanoma Survivors: Results From a Randomized Controlled Trial • PLoS One • Feb. 10, 2023 • CTSA Program Considerations for the Design and Implementation of Point-of-Care Technology for Use in Low- and Middle-Income Countries • Nature Reviews Methods Primers • Feb. 9, 2023 • CTSA Program Diagnostic Accuracy of Novel mRNA Blood Biomarkers of Infection to Predict Outcomes in Emergency Department Patients With Undifferentiated Abdominal Pain • Scientific Reports • Feb. 9, 2023 • CTSA Program DOAC Compared With Warfarin for VTE in Patients With Obesity: A Retrospective Cohort Study Conducted Through the VENUS Network • Journal of Thrombosis and Thrombolysis • Feb. 9, 2023 • CTSA Program The Endogenous Repertoire Harbors Self-Reactive CD4+ T Cell Clones That Adopt a Follicular Helper T Cell-Like Phenotype at Steady State • Nature Immunology • Feb. 9, 2023 • CTSA Program The NIH Intramural Research Program: Opportunities for Training and Career Development in Neuroscience and Beyond • Annals of the Child Neurology Society • Feb. 9, 2023 • Division of Preclinical Innovation Race-Based Care and Beliefs Regarding the Etiology of Racial Differences in Health Outcomes • American Journal of Preventive Medicine • Feb. 9, 2023 • CTSA Program Relationships Between Patient Race and Residential Race Context With Missed HIV Care Visits in the United States, 2010-2015 • Clinical Infectious Diseases • Feb. 9, 2023 • CTSA Program Bridging the Communication Gaps: A Prospective Single-Arm Pilot Study Testing the Feasibility of Interdisciplinary Radiotherapy Planning in Locally Advanced Lung Cancer • Academic Radiology • Feb. 8, 2023 • CTSA Program Dysgerminoma Masquerading as Gestational Trophoblastic Neoplasia • Case Reports in Obstetrics and Gynecology • Feb. 8, 2023 • CTSA Program Enhancing Study Recruitment Through Implementation of an Opt-Out, Cold Contact Process With Consideration for Autonomy, Beneficence and Justice • Journal of Clinical and Translational Science • Feb. 8, 2023 • CTSA Program Genomic and Phenotypic Analyses Suggest Moderate Fitness Differences Among Zika Virus Lineages • PLoS Neglected Tropical Diseases • Feb. 8, 2023 • CTSA Program Parsonage-Turner Syndrome Following Monkeypox Infection and Vaccination • Skeletal Radiology • Feb. 8, 2023 • Rare Diseases Phthalates and Incident Diabetes in Midlife Women: The Study of Women's Health Across the Nation (SWAN) • The Journal of Clinical Endocrinology & Metabolism • Feb. 8, 2023 • CTSA Program Pleural Fluid Microbiota as a Biomarker for Malignancy and Prognosis • Scientific Reports • Feb. 8, 2023 • CTSA Program Altered Cytokine Production in Human Intervillous Blood T Cells in Preeclampsia • Reproductive Sciences • Feb. 7, 2023 • CTSA Program Partial Heart Transplantation for Pediatric Heart Valve Dysfunction: A Clinical Trial Protocol • PLoS One • Feb. 7, 2023 • CTSA Program Phenotypes of Overdiagnosed Long QT Syndrome • Journal of the American College of Cardiology • Feb. 7, 2023 • CTSA Program Life-Space Mobility and Post-Hospitalization Outcomes Among Older Mexican American Medicare Beneficiaries • Journal of the American Geriatrics Society • Feb. 6, 2023 • CTSA Program Mediation of the Effect of Incarceration on Selling Sex Among Black Sexual Minority Men and Black Transgender Women in the HPTN 061 Study • AIDS and Behavior • Feb. 6, 2023 • CTSA Program Association of Medical Comorbidities and Cardiovascular Disease With Toxicity and Survival Among Patients Receiving Checkpoint Inhibitor Immunotherapy • Cancer Immunology, Immunotherapy • Feb. 4, 2023 • CTSA Program Geographic Variation and Risk Factor Association of Early Versus Late Onset Colorectal Cancer • Cancers • Feb. 4, 2023 • Rare Diseases Moving Away From One Disease at a Time: Screening, Trial Design, and Regulatory Implications of Novel Platform Technologies • American Journal of Medical Genetics, Seminars in Medical Genetics, Part C • Feb. 4, 2023 • Rare Diseases Intergenerational Transmission of Stress: Multi-Domain Stressors From Maternal Childhood and Pregnancy Predict Children’s Mental Health in a Racially and Socioeconomically Diverse, Multi-Site Cohort • Social Psychiatry and Psychiatric Epidemiology • Feb. 3, 2023 • CTSA Program Mode of Delivery Among Women With Maternal Cardiac Disease • Journal of Perinatology • Feb. 3, 2023 • CTSA Program Care Setting Transitions for People With Dementia: Qualitative Perspectives of Current and Former Care Partners • American Journal of Hospice and Palliative Medicine • Feb. 2, 2023 • CTSA Program Conditional Concordance-Assisted Learning Under Matched Case-Control Design for Combining Biomarkers for Population Screening • Statistics in Medicine • Feb. 2, 2023 • CTSA Program Genomic Analysis of Lean Individuals With NAFLD Identifies Monogenic Disorders in a Prospective Cohort Study • JHEP Reports • Feb. 2, 2023 • CTSA Program The NIH-Led Research Response to COVID-19 • Science • Feb. 2, 2023 • NCATS Presence of Symptoms 6 Weeks After COVID-19 Among Vaccinated and Unvaccinated US Healthcare Personnel: A Prospective Cohort Study • BMJ Open • Feb. 2, 2023 • CTSA Program Ultrasensitive Lateral-Flow Assays via Plasmonically Active Antibody-Conjugated Fluorescent Nanoparticles • Nature Biomedical Engineering • Feb. 2, 2023 • CTSA Program 2021 Update on Pediatric Overuse • Pediatrics • Feb. 1, 2023 • CTSA Program Application of Component Separation and Short-Term Outcomes in Ventral Hernia Repairs • Journal of Surgical Research • Feb. 1, 2023 • CTSA Program Atherosclerotic Cardiovascular Disease Risk and Small Dense Low-Density Lipoprotein Cholesterol in Men, Women, African Americans and Non-African Americans: The Pooling Project • Atherosclerosis • Feb. 1, 2023 • CTSA Program Biomarkers and Their Association With Bacterial Illnesses in Hypothermic Infants • The American Journal of Emergency Medicine • Feb. 1, 2023 • CTSA Program Cognitive Screening Among Older Adults With Diabetes Across Diverse Clinic Settings • Diabetes Research and Clinical Practice • Feb. 1, 2023 • CTSA Program Concomitantly Higher Resting Arterial Blood Pressure and Transduction of Sympathetic Neural Activity In Human Obesity Without Hypertension • Journal of Hypertension • Feb. 1, 2023 • CTSA Program Controlled Air Exchange Rate Method To Evaluate Reduction of Volatile Organic Compounds by Indoor Air Cleaners • Chemosphere • Feb. 1, 2023 • CTSA Program COVID-19 Vaccination and Venous Thromboembolism Risk in Older Veterans • Journal of Clinical and Translational Science • Feb. 1, 2023 • CTSA Program Deceased-Donor Acute Kidney Injury and Acute Rejection in Kidney Transplant Recipients: A Multicenter Cohort • American Journal of Kidney Diseases • Feb. 1, 2023 • CTSA Program Disparities in Detection of Suspected Child Abuse • Journal of Pediatric Surgery • Feb. 1, 2023 • CTSA Program DNA Methylation GrimAge Acceleration in US Military Veterans With PTSD • Neuropsychopharmacology • Feb. 1, 2023 • CTSA Program Does Daily Self-Weighing Contribute to Postpartum Weight Loss? A Secondary Analysis of Daily Postpartum Weights Among Women With Hypertensive Disorders of Pregnancy • American Journal of Perinatology • Feb. 1, 2023 • CTSA Program Effect of Personalized Messages Sent by a Health System’s Patient Portal on Influenza Vaccination Rates: A Randomized Clinical Trial • Journal of General Internal Medicine • Feb. 1, 2023 • CTSA Program The Emergence of the Stem Cell Niche • Trends in Cell Biology • Feb. 1, 2023 • CTSA Program First Experience With Postoperative Transcranial Ultrasound Through Sonolucent Burr Hole Covers in Adult Hydrocephalus Patients • Neurosurgery • Feb. 1, 2023 • CTSA Program First- or Second-Trimester SARS-CoV-2 Infection and Subsequent Pregnancy Outcomes • American Journal of Obstetrics and Gynecology • Feb. 1, 2023 • CTSA Program HIV and Race Are Independently Associated With Endothelial Dysfunction • AIDS • Feb. 1, 2023 • CTSA Program HIV Infection Drives Pro-Inflammatory Immunothrombotic Pathway Activation and Organ Dysfunction Among Adults With Sepsis in Uganda • AIDS • Feb. 1, 2023 • CTSA Program Hmong Microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C): A Phase II Clinical Study Protocol • PLoS One • Feb. 1, 2023 • CTSA Program Human Macrophage Long Intergenic Noncoding RNA, SIMALR, Suppresses Inflammatory Macrophage Apoptosis via NTN1 (Netrin-1) • Arteriosclerosis, Thrombosis, and Vascular Biology • Feb. 1, 2023 • CTSA Program The Impact of Exchanging Cerclage Fixation After Extended Trochanteric Osteotomy in Revision Total Hip Arthroplasty for Periprosthetic Joint Infection • The Journal of Arthroplasty • Feb. 1, 2023 • CTSA Program Impact of Telemedicine on Visit Attendance for Paediatric Patients Receiving Endocrinology Specialty Care • Journal of Telemedicine and Telecare • Feb. 1, 2023 • CTSA Program In-Hospital Outcomes After Carotid Endarterectomy for Stroke Stratified by Modified Rankin Scale Score and Time of Intervention • Journal of Vascular Surgery • Feb. 1, 2023 • CTSA Program Irritability in Early to Middle Childhood: Cross-Sectional and Longitudinal Associations With Resting State Amygdala and Ventral Striatum Connectivity • Developmental Cognitive Neuroscience • Feb. 1, 2023 • CTSA Program Laboratory Parameters and Outcomes in Hospitalized Adults With COVID-19: A Scoping Review • Infection • Feb. 1, 2023 • CTSA Program Maternal Anemia and Childhood Cancer: A Population-Based Case-Control Study in Denmark • Cancer Epidemiology • Feb. 1, 2023 • CTSA Program Medicaid Expansion and Surgery for HPB/GI Cancers: NCDB Difference-in-Difference Analysis • The American Journal of Surgery • Feb. 1, 2023 • CTSA Program Mild Therapeutic Hypothermia Protects Against Inflammatory and Proapoptotic Processes in the Rat Model of Cochlear Implant Trauma • Hearing Research • Feb. 1, 2023 • CTSA Program The Natural History of End-Stage Knee Osteoarthritis: Data From the Osteoarthritis Initiative • Seminars in Arthritis and Rheumatism • Feb. 1, 2023 • CTSA Program Neighborhood Socioeconomic Status and the Effectiveness of Colorectal Cancer Screening Outreach With Mailed Fecal Immunochemical Tests Within a Safety Net Healthcare System in San Francisco, CA: A Subgroup Analysis of a Randomized Controlled Trial • Preventive Medicine • Feb. 1, 2023 • CTSA Program Nonpharmacologic Factors Affecting Milk Production in Pump-Dependent Mothers of Critically Ill Infants: State of the Science • Advances in Neonatal Care • Feb. 1, 2023 • CTSA Program Opioid Use Patterns in a Statewide Adult Medicaid Population Undergoing Elective Lumbar Spine Surgery • Spine • Feb. 1, 2023 • CTSA Program Perceived Effects of Neuropsychiatric Symptoms on Functional Status in Early-stage Huntington Disease • Western Journal of Nursing Research • Feb. 1, 2023 • CTSA Program Pharmacokinetic Interactions of a Licorice Dietary Supplement With Cytochrome P450 Enzymes in Female Participants • Drug Metabolism and Disposition • Feb. 1, 2023 • CTSA Program Pharmacokinetic Parameters Over Time During Sepsis and the Association of Target Attainment and Outcomes in Critically Ill Children and Young • Pharmacotherapy • Feb. 1, 2023 • CTSA Program Postpartum Hemorrhage Protocols and Benchmarks: Improving Care Through Standardization • American Journal of Obstetrics & Gynecology MFM • Feb. 1, 2023 • CTSA Program Predictive Capacity of Population Pharmacokinetic Models for the Tacrolimus Dose Requirements of Pediatric Solid Organ Transplant Recipients • Therapeutic Drug Monitoring • Feb. 1, 2023 • CTSA Program Prescription Habits of Scleral Lenses for the Management of Corneal Irregularity and Ocular Surface Disease Among Scleral Lens Practitioners • Eye & Contact Lens: Science & Clinical Practice • Feb. 1, 2023 • CTSA Program Protecting Breastfeeding During the COVID-19 Pandemic • American Journal of Perinatology • Feb. 1, 2023 • CTSA Program Racial Disparities in Overall Survival After the Introduction of Cyclin-Dependent Kinase 4/6 Inhibitors for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer • Breast Cancer Research and Treatment • Feb. 1, 2023 • CTSA Program Relationship Between Cachexia and the Functional Progress of Patients With Cancer in Inpatient Rehabilitation • American Journal of Physical Medicine & Rehabilitation • Feb. 1, 2023 • CTSA Program Relationship of Vitamin D Levels With Clinical Presentation and Recurrence of BPPV in a Southeastern United States Institution • Auris Nasus Larynx • Feb. 1, 2023 • CTSA Program Restrictive Resuscitation in Patients With Sepsis and Mortality: A Systematic Review and Meta-Analysis With Trial Sequential Analysis • Pharmacotherapy • Feb. 1, 2023 • CTSA Program Risk Factors and Predictors of Intracranial Hemorrhage After Mechanical Thrombectomy in Acute Ischemic Stroke: Insights From the Stroke Thrombectomy and Aneurysm Registry (STAR) • Journal of NeuroInterventional Surgery • Feb. 1, 2023 • CTSA Program Role of Antiplatelet Therapy in Hemodialysis Arteriovenous Graft Secondary Patency Following Successful Percutaneous Thrombectomy • CardioVascular and Interventional Radiology • Feb. 1, 2023 • CTSA Program Self-Reported Experiences of Discrimination and Incident Dementia • Alzheimer’s & Dementia • Feb. 1, 2023 • CTSA Program Self-Reported Physical Function Is Strongly Related to Pain Behavior and Pain Interference and Weakly Related to Physical Capacity in People With Chronic Low Back Pain • Musculoskeletal Science and Practice • Feb. 1, 2023 • CTSA Program Surgical Evaluation in Patients Undergoing Radiation Therapy for Early-Stage Lung Cancer • The Annals of Thoracic Surgery • Feb. 1, 2023 • CTSA Program Transcendental Meditation for Healthcare Workers: Results From a Randomized Clinical Trial • Natural Medicine Journal • Feb. 1, 2023 • CTSA Program Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD • Clinical Gastroenterology and Hepatology • Feb. 1, 2023 • CTSA Program Venglustat, an Orally Administered Glucosylceramide Synthase Inhibitor: Assessment Over 3 Years in Adult Males With Classic Fabry Disease in an Open-Label Phase 2 Study And Its Extension Study • Molecular Genetics and Metabolism • Feb. 1, 2023 • CTSA Program Whole-Slide Cytometric Feature Mapping for Distinguishing Tumor Genomic Subtypes in Head and Neck Squamous Cell Carcinoma Whole-Slide Images • The American Journal of Pathology • Feb. 1, 2023 • CTSA Program WISER Survivor Trial: Combined Effect of Exercise and Weight Loss Interventions on Inflammation in Breast Cancer Survivors • Medicine & Science in Sports & Exercise • Feb. 1, 2023 • CTSA Program January 2023 COVID-19 Causes Ferroptosis and Oxidative Stress in Human Endothelial Cells • Antioxidants • Jan. 31, 2023 • CTSA Program Effects of Welfare Reform on Positive Health and Social Behaviors of Adolescents • Children • Jan. 31, 2023 • CTSA Program Elevated Oxysterol and N-Palmitoyl-O-Phosphocholineserine Levels in Congenital Disorders of Glycosylation • The Journal of Inherited Metabolic Disease • Jan. 31, 2023 • CTSA Program Human Milk Oligosaccharides and Infant Neurodevelopment: A Narrative Review • Nutrients • Jan. 31, 2023 • CTSA Program PRMT5 Is a Therapeutic Target in Choroidal Neovascularization • Scientific Reports • Jan 31, 2023 • CTSA Program Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for COVID- 19: A Randomized Trial • The Journal of Infectious Diseases • Jan. 31, 2023 • CTSA Program Healthcare Provider Reports on Social Determinants of Health in Opioid Treatment • Psych • Jan. 30, 2023 • CTSA Program Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States • Cancers • Jan. 30, 2023 • CTSA Program Molecular Mechanisms of Environmental Exposures and Human Disease • Nature Reviews Genetics • Jan. 30, 2023 • CTSA Program Methamphetamine Induces a Low Dopamine Transporter Expressing State Without Altering the Total Number of Peripheral Immune Cells • Basic & Clinical Pharmacology & Toxicology • Jan. 29, 2023 • CTSA Program Critical Gaps in Knowledge and Implementation of Recommendations by the US Preventive Services Task Force • Preventive Medicine Reports • Jan. 28, 2023 • CTSA Program Locus Coeruleus and Dorsal Cingulate Morphology Contributions to Slowed Processing Speed • Neuropsychologia • Jan 28, 2023 • CTSA Program Monitoring Occupational Noise Exposure in Firefighters Using the Apple Watch • International Journal of Environmental Research and Public Health • Jan. 28, 2023 • CTSA Program VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen • International Journal of Molecular Sciences • Jan. 28, 2023 • CTSA Program Associations of Hiatus Hernia With CT-Based Interstitial Lung Changes: The MESA Lung Study • European Respiratory Journal • Jan. 27, 2023 • CTSA Program A Millimeter-Scale Soft Robot for Tissue Biopsy Procedures • Advanced Intelligent Systems • Jan. 27, 2023 • CTSA Program Opportunities and Barriers to Translating the Hibernation Phenotype for Neurocritical Care • Frontiers in Neurology • Jan. 27, 2023 • CTSA Program Paraventricular Nucleus of the Hypothalamus Oxytocin and Incubation of Heroin Seeking • Neuroendocrinology • Jan. 27, 2023 • CTSA Program Rapid On-Site Microscopy and Mapping of Diagnostic Biopsies for See-and-Treat Guidance of Localized Prostate Cancer Therapy • Cancers • Jan. 27, 2023 • CTSA Program Remote Patient Monitoring for COVID-19: a Retrospective Study on Health Care Utilization • Telemedicine Journal and e-Health • Jan. 27, 2023 • CTSA Program Actigraphy-Based Sleep and Activity Measurements in Intensive Care Unit Patients Randomized to Ramelteon or Placebo for Delirium Prevention • Scientific Reports • Jan. 26, 2023 • CTSA Program Household Transmission of Influenza A Viruses in 2021-2022 • Journal of the American Medical Association • Jan. 26, 2023 • CTSA Program A Longitudinal Epigenome-Wide Association Study of Preeclamptic and Normotensive Pregnancy • Epigenetics Communications • Jan. 26, 2023 • CTSA Program A Multi-Center, Controlled Human Infection Study of Influenza A (H1N1)pdm09 in Healthy Adults • The Journal of Infectious Diseases • Jan. 26, 2023 • CTSA Program The ASH-ASPHO Choosing Wisely Campaign: 5 Hematologic Tests and Treatments to Question • Blood Advances • Jan. 25, 2023 • CTSA Program Mi Puente (My Bridge) Care Transitions Program for Hispanic/Latino Adults With Multimorbidity: Results of a Randomized Controlled Trial • Journal of General Internal Medicine • Jan. 25, 2023 • CTSA Program Binding and Functional Structure-Activity Similarities of 4-Substituted 2,5-Dimethoxyphenyl Isopropylamine Analogues at 5-HT2A and 5-HT2B Serotonin Receptors • Frontiers in Pharmacology • Jan. 24, 2023 • CTSA Program Cholinergic Neurons in the Basal Forebrain Are Involved in Behavioral Abnormalities Associated With Cul3 Deficiency: Role of Prefrontal Cortex Projections in Cognitive Deficits • Translational Psychiatry • Jan. 24, 2023 • CTSA Program Cultural Adaptations to a Telephone Genetic Counseling Protocol and Booklet for Latina Breast Cancer Survivors at Risk for Hereditary Breast and Ovarian Cancer • Translational Behavioral Medicine • Jan. 24, 2023 • CTSA Program Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial • Journal of the American Medical Association • Jan. 24, 2023 • CTSA Program Intensive Mindfulness Meditation Reduces Frequency and Burden of Migraine: An Unblinded Single-Arm Trial • Mindfulness • Jan. 24, 2023 • CTSA Program Association of Cumulative Colorectal Surgery Hospital Costs, Readmissions, and Emergency Department/Observation Stays With Insurance Type • Journal of Gastrointestinal Surgery • Jan. 23, 2023 • CTSA Program An Atlas of Lamina-Associated Chromatin Across Twelve Human Cell Types Reveals an Intermediate Chromatin Subtype • Genome Biology • Jan. 23, 2023 • CTSA Program Redefining Trauma Deserts: Novel Technique to Accurately Map Prehospital Transport Time • Trauma Surgery & Acute Care Open • Jan. 23, 2023 • CTSA Program Scoping Review Protocol of Multicomponent Interventions to Address Cardiometabolic Disease Risk Among Pacific Islander Children • PLoS One • Jan. 23, 2023 • CTSA Program Switching to Cigarette Brand Variants With Different Filter Ventilation Levels: A Descriptive Analysis • Tobacco Control • Jan. 23, 2023 • CTSA Program Walk Before You Run: Feasibility Challenges and Lessons Learned From the PROCLAIM Study, a Multicenter Randomized Controlled Trial of Misoprostol for Prevention of Recurrent C. difficile During COVID-19 • Anaerobe • Jan. 23, 2023 • CTSA Program Analysis of Affinity Purification-Related Proteomic Data for Studying Protein-Protein Interaction Networks in Cells • Briefings in Bioinformatics • Jan. 22, 2023 • CTSA Program CKD Progression Risk and Subsequent Cause of Death: A Population-Based Cohort Study • Kidney Medicine • Jan. 21, 2023 • CTSA Program Oral Intradialytic Amino Acid Supplementation to Vitalize End-Stage Kidney Disease Patients on Hemodialysis (OASIS) • ICH GCP Good Clinical Practice • Jan. 21, 2023 • NCATS Risk of SARS-CoV-2 Infection Among Women With Polycystic Ovary Syndrome • Fertility and Sterility • Jan. 21, 2023 • CTSA Program Analysis of Caregiver Burden Expressed in Social Media Discussions • International Journal of Environmental Research and Public Health • Jan. 20, 2023 • CTSA Program A Qualitative Exploration of the Experiences of Peer Leaders in an Intervention to Improve Diabetes Medication Adherence in African Americans • BMC Public Health • Jan. 20, 2023 • CTSA Program Secondary Bile Acids Improve Risk Prediction for Non-Invasive Identification of Mild Liver Fibrosis in Nonalcoholic Fatty Liver Disease • Alimentary Pharmacology & Therapeutics • Jan. 20, 2023 • CTSA Program Weighing the Risk Profile of Cervical Spine MRI in Evaluating Pediatric Cervical Spine Injuries • Pediatric Neurosurgery • Jan. 20, 2023 • CTSA Program Estimating Random Effects in a Finite Markov Chain With Absorbing States: Application to Cognitive Data • Statistica Neerlandica • Jan. 19, 2023 • CTSA Program Gene Burden Analysis Identifies Genes Associated With Increased Risk and Severity of Adult-Onset Hearing Loss in a Diverse Hospital-Based Cohort • PLOS Genetics • Jan. 19, 2023 • CTSA Program Perceived Barriers and Facilitators to the Adoption of Telemedicine Infectious Diseases Consultations in Southeastern Missouri Hospitals • Journal of Telemedicine and Telecare • Jan. 19, 2023 • CTSA Program Shared Decision-Making in General Surgery: A Prospective Comparison of Telemedicine vs In-Person Visits • Journal of the American College of Surgeons • Jan. 19, 2023 • CTSA Program Urine Cell-Free DNA Multi-Omics to Detect MRD and Predict Survival in Bladder Cancer Patients • npj Precision Oncology • Jan. 19, 2023 • CTSA Program Adverse Effects of Antidepressant Medications and Their Management in Children and Adolescents • Pharmacotherapy • Jan. 18, 2023 • CTSA Program Developing Electronic Health Record Algorithms That Accurately Identify Patients With Juvenile Idiopathic Arthritis • Seminars in Arthritis and Rheumatism • Jan. 18, 2023 • CTSA Program Development of an Improved and Specific Inhibitor of NADPH Oxidase 2 to Treat Traumatic Brain Injury • Redox Biology • Jan. 18, 2023 • Division of Preclinical Innovation Fractionated Plasma N-Glycan Profiling of Novel Cohort of ATP6AP1-CDG Subjects Identifies Phenotypic Association • The Journal of Inherited Metabolic Disease • Jan. 18, 2023 • RDCRN Insights Into the Perinatal Phenotype of Kabuki Syndrome in Infants Identified by Genome-Wide Sequencing • The American Journal of Medical Genetics • Jan 18, 2023 • CTSA Program Mapping the Common Gene Networks That Underlie Related Diseases • Nature Protocols • Jan. 18, 2023 • CTSA Program Validation Testing of Five Home Blood Pressure Monitoring Devices for the Upper Arm According to the ISO 81060-2:2018/AMD 1:2020 Protocol • Journal of Human Hypertension • Jan. 18, 2023 • CTSA Program Health-Related Social Control and Perceived Stress Among High-Risk Latina Mothers With Type 2 Diabetes and Their At-Risk Adult Daughters • International Journal of Behavioral Medicine • Jan. 17, 2023 • CTSA Program Patient Experiences With a Tertiary Care Post-COVID-19 Clinic • Journal of Patient Experience • Jan. 17, 2023 • CTSA Program Acutely Enhancing Affective State and Social Connection Following an Online Dance Intervention During the COVID-19 Social Isolation Crisis • BMC Psychology • Jan. 16, 2023 • CTSA Program Antiviral Approaches Against Influenza Virus • Clinical Microbiology Reviews • Jan 16, 2023 • CTSA Program Attitudes and Beliefs Regarding Race-Targeted Genetic Testing of Black People: A Systematic Review • Vaccine • Jan. 16, 2023 • CTSA Program “There's Not Enough Studies”: Views of Black Breast and Ovarian Cancer Patients on Research Participation • Cancer Medicine • Jan 16, 2023 • CTSA Cardiac Structure and Function Phenogroups and Risk of Incident Heart Failure (From the Multi-Ethnic Study of Atherosclerosis) • The American Journal of Cardiology • Jan. 15, 2023 • CTSA Program Mendelian Randomization Analysis Reveals a Complex Genetic Interplay among Atopic Dermatitis, Asthma, and Gastroesophageal Reflux Disease • American Journal of Respiratory and Critical Care Medicine • Jan. 15, 2023 • CTSA Program Association Between Aphakia and Endophthalmitis After Pediatric Cataract Surgery • Ophthalmology • Jan. 14, 2023 • CTSA Program Feasibility, Acceptability, and Initial Efficacy of a Digital Intervention to Improve Consumption of Foods Received Within a National Nutrition Assistance Program • Nutrients • Jan. 14, 2023 • CTSA Program Impact of Delayed Time to Antibiotics in Medical and Surgical Necrotizing Enterocolitis • Children • Jan. 14, 2023 • CTSA Program Perinatal Mood and Anxiety Disorders: Biomarker Discovery Using Plasma Proteomics • American Journal of Obstetrics & Gynecology • Jan. 14, 2023 • CTSA Program Standard Clinical and Imaging-Based Small Vessel Disease Parameters Associated With Mild Stroke Versus Non-Mild Stroke • Journal of Central Nervous System Disease • Jan. 14, 2023 • CTSA Program Diagnostic and Prognostic Potential of the Microbiome in Ovarian Cancer Treatment Response • Scientific Reports • Jan. 13, 2023 • CTSA Program Dome1–JAK–STAT Signaling Between Parasite and Host Integrates Vector Immunity and Development • Science • Jan. 13, 2023 • Division of Preclinical Innovation Identifying Drivers of Increasing Opioid Overdose Deaths Among Black Individuals: A Qualitative Model Drawing on Experience of Peers and Community Health Workers • Harm Reduction Journal • Jan. 13, 2023 • CTSA Program Addressing Institutional and Community Barriers to Development and Implementation of Community-Engaged Research Through Competency-Based Academic and Community Training • Frontiers in Public Health • Jan. 12, 2023 • CTSA Program The Application of Dental Fluoride Varnish in Children: A Low Cost, High Value Implementation Aided by Passive Clinical Decision Support • Applied Clinical Informatics • Jan. 12, 2023 • CTSA Program Associations Between Caregiver Stress and Language Outcomes in Infants With Autistic and Non-Autistic Siblings: An Exploratory Study • Journal of Speech, Language, and Hearing Research • Jan. 12, 2023 • CTSA Program Cascade of Care for Hepatitis C Virus Infection Among Young Adults Who Inject Drugs in a Rural County in New Mexico • Public Health Reports • Jan. 12, 2023 • CTSA Program Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial • Journal of the American Medical Association • Jan. 12, 2023 • CTSA Program The Effects of Hearing Protection Devices on Spatial Awareness in Complex Listening Environments • PLoS One • Jan. 12, 2023 • CTSA Program Secretory Leukocyte Protease Inhibitor and Risk of Heart Failure in the Multi-Ethnic Study of Atherosclerosis • Scientific Reports • Jan. 12, 2023 • CTSA Program Traditional Risk Factors and Cancer-Related Factors Associated With Cardiovascular Disease Risk in Head and Neck Cancer Patients • Frontiers in Cardiovascular Medicine • Jan. 12, 2023 • CTSA Program Using the Framework for Reporting Adaptations and Modifications-Expanded (FRAME) to Study Adaptations in Lung Cancer Screening Delivery in the Veterans Health Administration: A Cohort Study • Implementation Science Communications • Jan. 12, 2023 • CTSA Program Advance Care Planning (ACP) to Promote Receipt of Value-Concordant Care: Results Vary According to Patient Ppriorities • PLoS One • Jan. 11, 2023 • CTSA Program Association of Psychosocial Factors on COVID-19 Testing Among YWCA Service Recipients • International Journal of Environmental Research and Public Health • Jan. 11, 2023 • CTSA Program Effects of Hypocaloric Low-Fat, Ketogenic and Ketogenic & Ketone Supplement Diets on Aldosterone and Renin • The Journal of Clinical Endocrinology & Metabolism • Jan. 11, 2023 • CTSA Program Guided Bronchoscopy for the Evaluation of Pulmonary Lesions: An Updated Meta-Analysis • CHEST • Jan. 11, 2023 • CTSA Program Musculoskeletal Telemedicine Trends Preceding the COVID-19 Pandemic and Potential Implications of Rapid Telemedicine Expansion • International Journal of Telemedicine and Applications • Jan. 11, 2023 • CTSA Program Novel Approach to Improving Specialist Access in Underserved Populations With Suspicious Oral Lesions • Current Oncology • Jan. 11, 2023 • CTSA Program Novel Nanoparticle-Based Treatment and Imaging Modalities • Pharmaceutics • Jan. 11, 2023 • CTSA Program Social Capital and Sleep Outcomes Across Childhood in US Families • Academic Pediatrics • Jan. 11, 2023 • CTSA Program “They Are Gaining Experience; We Are Gaining Extra Hands”: A Mixed Methods Study to Assess Healthcare Worker Perceptions of a Novel Strategy to Strengthen Human Resources for HIV in South Africa • BMC Health Services Research • Jan. 11, 2023 • CTSA Program Atp7b-Dependent Choroid Plexus Dysfunction Causes Transient Copper Deficit and Metabolic Changes in the Developing Mouse Brain • PLoS Genetics • Jan. 10, 2023 • CTSA Program Borderline Personality Features and Altered Social Feedback Processing in Emerging Adults: An EEG Study • Progress in Neuro-Psychopharmacology and Biological Psychiatry • Jan. 10, 2023 • CTSA Program Enoxaparin May Be Associated With Lower Rates of Mortality Than Unfractionated Heparin In Neurocritical and Surgical Patients • Journal of Thrombosis and Thrombolysis • Jan 10, 2023 • CTSA Program A Plasmodium falciparum Ring Finger E3 Ubiquitin Ligase Modifies the Roles of Pfmdr1 and Pfcrt In Parasite Drug Responses • Antimicrobial Agents and Chemotherapy • Jan. 10, 2023 • Division of Preclinical Innovation Predictors of Re-Engagement After Relapse in a Tobacco Quit Line Intervention: Secondary Analysis From a Randomized Clinical Trial • International Journal of Environmental Research and Public Health • Jan. 10, 2023 • CTSA Program Emerging Perspectives on the Rare Tubulopathy Dent Disease: Is Glomerular Damage a Direct Consequence of ClC-5 Dysfunction? • International Journal of Molecular Sciences • Jan. 9, 2023 • CTSA Program “How Do I Exist in This Body…That's Outside of the Norm?” Trans and Nonbinary Experiences of Conformity, Coping, and Connection in Atypical Anorexia • International Journal of Environmental Research and Public Health • Jan. 9, 2023 • CTSA Program Hypertension Requiring Medication Use: A Silent Predictor of Poor Outcomes After Pancreaticoduodenectomy • Journal of Gastrointestinal Surgery • Jan 9, 2023 • CTSA Real-World Weight-Loss Effectiveness of Glucagon-Like Peptide-1 Agonists Among Patients With Type 2 Diabetes: A Retrospective Cohort Study • Obesity • Jan. 9, 2023 • CTSA Program Single-Cell Transcriptomic Analysis of Endometriosis • Nature Genetics • Jan. 9, 2023 • CTSA Program Trends in Vaccination Schedules and Up-to-Date Status of Children 19-35 Months, United States, 2015-2020 • Vaccine • Jan. 9, 2023 • CTSA Program Assessing Barriers and Facilitators to Transition in Sickle Cell Disease Care Prior to Implementation of a Formalized Program • Pediatric Blood & Cancer • Jan. 8, 2023 • CTSA Program Airway Findings in Patients With Hunter Syndrome Treated With Intravenous Idursulfase • Journal of Clinical Medicine • Jan. 6, 2023 • CTSA Program Association of a State Prescribing Limits Policy With Opioid Prescribing and Long-Term Use: An Interrupted Time Series Analysis • Journal of General Internal Medicine • Jan. 6, 2023 • CTSA Program Civicdb 2022: Evolution of an Open-Access Cancer Variant Interpretation Knowledgebase • Nucleic Acids Research • Jan. 6, 2023 • CTSA Program Death Anxiety in Huntington Disease: Longitudinal Heath-Related Quality-of-Life Outcomes • Journal of Palliative Medicine • Jan. 6, 2023 • CTSA Program Dextrose Administration and Resuscitation Outcomes in Patients With Blood Sugar Less Than 150 mg/dL During Cardiopulmonary Resuscitation: An Observational Data Analysis • Journal of Clinical Medicine • Jan. 6, 2023 • CTSA Program How Epinephrine Administration Interval Impacts the Outcomes of Resuscitation During Adult Cardiac Arrest: A Systematic Review and Meta-Analysis • Journal of Clinical Medicine • Jan. 6, 2023 • CTSA Program Online Racial Discrimination, Critical Consciousness, and Psychosocial Distress Among Black and Latino Adolescents: A Moderated Mediation Model • Journal of Youth and Adolescence • Jan. 6, 2023 • CTSA Program Predictors of Adolescent Resilience During the COVID-19 Pandemic in a Community Sample of Hispanic and Latinx Youth: Expressive Suppression and Social Support • Research on Child and Adolescent Psychopathology • Jan. 6, 2023 • CTSA Program Pregnancy-Associated Extracorporeal Membrane Oxygenation in the United States • American Journal of Perinatology • Jan. 6, 2023 • CTSA Program Remote Implementation of a School-Based Health Promotion and Health Coaching Program in Low-Income Urban and Rural Sites: Program Impact during the COVID-19 Pandemic • International Journal of Environmental Research and Public Health • Jan. 6, 2023 • CTSA Program ADGR: Admixture-Informed Differential Gene Regulation • Genes • Jan. 5, 2023 • CTSA Program Community Risks for SARS-CoV-2 Infection Among Fully Vaccinated US Adults by Rurality: A Retrospective Cohort Study From the National COVID Cohort Collaborative • Journal of Clinical Medicine • Jan. 5, 2023 • CTSA Program The Role of Early Life Adversity and Inflammation in Stress-Induced Change in Reward and Risk Processes Among Adolescents • Brain, Behavior, and Immunity • Jan. 5, 2023 • CTSA Program Acute Respiratory Distress Syndrome After SARS-CoV-2 Infection on Young Adult Population: International Observational Federated Study Based on Electronic Health Records Through the 4CE Consortium • PLoS One • Jan. 4, 2023 • CTSA Program Cyclind2-Mediated Regulation of Neurogenic Output From the Retinal Ciliary Margin Is Perturbed in Albinism • Neuron • Jan. 4, 2023 • CTSA Program Experiences of Peer Navigators Implementing a Bilingual Multilevel Intervention to Address Sexually Transmitted Infection and HIV Disparities and Social Determinants of Health • Health Expectations • Jan. 4, 2023 • CTSA Program The Feasibility and Effectiveness of a Community-Based Intervention to Reduce Sedentary Behavior in Older Adults • Journal of Applied Gerontology • Jan. 4, 2023 • CTSA Program Histologically Interpretable Clot Radiomic Features Predict Treatment Outcomes of Mechanical Thrombectomy for Ischemic Stroke • Neuroradiology • Jan. 4, 2023 • CTSA Program Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma • Journal of Clinical Oncology • Jan. 4, 2023 • CTSA Program Patterns of Use of Recombinant Zoster Vaccine Among Commercially-Insured Immunocompetent and Immunocompromised Adults 50-64 Years Old in the United States • Vaccine • Jan. 4, 2023 • CTSA Program Urinary Supersaturation in a Randomized Trial Among Individuals With Nephrolithiasis Comparing Empiric Versus Selective Therapy (URINE): Design and Rationale of a Clinical Trial • Urolithiasis • Jan. 4, 2023 • CTSA Program Data Sharing to Advance Gene-targeted Therapies in Rare Diseases • American Journal of Medical Genetics, Seminars in Medical Genetics, Part C • Jan. 3, 2023 • Bespoke Gene Therapy Consortium, PaVe-GT Pregnancy Outcomes in Women With Sickle Cell Disease in California • American Journal of Hematology • Jan. 2, 2023 • CTSA Program Adaptation and External Validation of Pathogenic Urine Culture Prediction in Primary Care Using Machine Learning • Annals of Family Medicine • Jan. 1, 2023 • CTSA Program Adult Cleft Patients: An Exploration of Functional Needs and Treatment Barriers • Cancer Epidemiology • Jan. 1, 2023 • CTSA Program An AI Approach for Identifying Patients With Cirrhosis • Journal of Clinical Gastroenterology • Jan. 1, 2023 • CTSA Program Association Between Body-Mass Index, Patient Characteristics, and Obesity-Related Comorbidities Among COVID-19 Patients: A Prospective Cohort Study • Obesity Research & Clinical Practice • Jan. 1, 2023 • CTSA Program Association Between Traumatic Brain Injury and Increased Risk of Stroke: A Systematic Review and Meta-Analysis • Journal of Head Trauma Rehabilitation • Jan. 1, 2023 • CTSA Program Associations Between Pituitary-Ovarian Hormones and Cognition in Recently Menopausal Women Independent of Type of Hormone Therapy • Maturitas • Jan. 1, 2023 • CTSA Program Association of Cardiovascular Disease Risk Factors With Sociodemographic Characteristics and Health Beliefs Among a Community-Based Sample of African American Adults in Minnesota • Mayo Clinic Proceedings • Jan. 1, 2023 • CTSA Program Burning Down the House: Reinventing Drug Discovery in Psychiatry for the Development of Targeted Therapies • Molecular Psychiatry • Jan. 1, 2023 • CTSA Program Challenges in Use of Practice-Based Research Networks for a Medical Device Trial to Detect SARS-CoV-2 • Journal of Primary Care & Community Health • Jan. 1, 2023 • CTSA Program CircRAD54L2 Promotes Triple-Negative Breast Cancer Progression by Regulating the Mir-888 Family/PDK1 Axis • Life Sciences • Jan. 1, 2023 • CTSA Program Clinical Predictors of Endotracheal Intubation in Patients Presenting to the Emergency Department With Angioedema • The American Journal of Emergency Medicine • Jan. 1, 2023 • CTSA Program Comparing Diet Quality Indices for Low-Income 24-Month-Old Toddlers: Exploring Changes Driven by 2020-2025 Dietary Guidelines for Americans • The Journal of Nutrition • Jan. 1, 2023 • CTSA Program Comparing Hospital Length of Stay Risk-Adjustment Models in US Value-Based Physician Payments • Genetics in Medicine • Jan. 1, 2023 • CTSA Program Conversion of External Fixator To Intramedullary Nail In Tibial Fractures • Journal of the American Academy of Orthopaedic Surgeons • Jan. 1, 2023 • CTSA Program COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Xenobiotics) • Journal of Medical Toxicology • Jan. 1, 2023 • Loan Repayment Program Current Psychiatric Treatment for College Students With Depression Only, Anxiety Only, or Comorbid Depression & Anxiety (2013-2019) • Journal of Affective Disorders • Jan. 1, 2023 • CTSA Program Development of a Tool for Quantifying Need-Supportive Coaching in Technology-Mediated Exercise Classes • Psychology of Sport and Exercise • Jan. 1, 2023 • CTSA Program Diagnostic- and Sex-Based Differences in Depression Symptoms in Autistic and Neurotypical Early Adolescents • Autism • Jan. 1, 2023 • CTSA Program Effectiveness and Clinical Usefulness of Electronic Agenda-Setting in Psychiatric Practices: A South Texas Psychiatric PBRN Study • Journal of Psychiatric Practice • Jan. 1, 2023 • CTSA Program Effects of Body Mass Index on Presentation and Outcomes of Covid-19 Among Heart Transplant and Left Ventricular Assist Device Patients: A Multi-Institutional Study • ASAIO Journal • Jan. 1, 2023 • CTSA Program Efficacy of a Brief Tele-Cognitive Behavioral Treatment vs Attention Control for Head and Neck Cancer Survivors With Body Image Distress: A Pilot Randomized Clinical Trial • JAMA Otolaryngology—Head & Neck Surgery • Jan. 1, 2023 • CTSA Program Environmental Exposures in Machine Learning and Data Mining Approaches to Diabetes etiology: A Scoping Review • Artificial Intelligence in Medicine • Jan. 1, 2023 • CTSA Program Equine Peripheral Blood CD14+ Monocyte-Derived Macrophage In-Vitro Characteristics After GM-CSF Pretreatment and LPS+IFN-γ or IL-4+IL-10 Differentiation • Veterinary Immunology and Immunopathology • Jan. 1, 2023 • CTSA Program Examining Psychological Inflexibility As a Mediator of Postpartum Depressive Symptoms: a Longitudinal Observational Study of Perinatal Depression • Journal of Contextual Behavioral Science • Jan. 1, 2023 • CTSA Program “Extremely Slow and Capricious”: A Qualitative Exploration of Genetic Researcher Priorities in Selecting Shared Data Resources • Genetics in Medicine • Jan. 1, 2023 • CTSA Program Fasting Compared With Fed and Oral Intake Before the 1-Hour Oral Glucose Tolerance Test: A Randomized Controlled Trial • Obstetrics & Gynecology • Jan. 1, 2023 • CTSA Program Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat • Clinical Gastroenterology and Hepatology • Jan. 1, 2023 • CTSA Program First-Trimester Surgical Abortion Practice in Canada in 2012 • Canadian Family Physician • Jan. 1, 2023 • CTSA Program Formally Comparing Topic Models and Human-Generated Qualitative Coding of Physician Mothers' Experiences of Workplace Discrimination • Big Data & Society • Jan. 1, 2023 • CTSA Program Impact of a Surgical Wound Infection Prevention Bundle in Pediatric Cardiothoracic Surgery • The Annals of Thoracic Surgery • Jan. 1, 2023 • CTSA Program Impact of Anesthetic Exposures on the Neurocognitive Profiles of Pediatric Brain Tumor Survivors: A New Direction for Research and Multidisciplinary Collaboration • Journal of Neurosurgical Anesthesiology • Jan. 1, 2023 • CTSA Program Impact of Diet on Hydrogen Sulfide Production: Implications for Gut Health • Current Opinion in Clinical Nutrition and Metabolic Care • Jan. 1, 2023 • CTSA Program Improving the Validity of Causal Inferences in Observational Studies • American Journal of Nursing • Jan. 1, 2023 • CTSA Program Inherited Cancer Knowledge Among Black Females With Breast Cancer Before and After Viewing a Web-Based Educational Video • Genetic Testing and Molecular Biomarkers • Jan. 1, 2023 • CTSA Program Intersectionality of Socioecological Factors Associated With Cognitive Function Among Older Women With HIV in the United States: A Structural Equation Model Analysis Using Data From the Women’s Interagency HIV Study • Journal of the Association of Nurses in AIDS Care • Jan. 1, 2023 • CTSA Program How Autistic Adults’ Priorities for Autism Research Differ by Gender Identity: A Mixed-Methods Study • Women’s Health • Jan. 1, 2023 • CTSA Program Hyperkalemia in a Hemolyzed Sample in Pediatric Patients: Repeat or Do Not Repeat? • Pediatric Emergency Care • Jan. 1, 2023 • CTSA Program Keep It in Mind: Assessing the Risk of Dementia in Patients With Rheumatoid Arthritis and Opportunities for Intervention • The Journal of Rheumatology • Jan. 1, 2023 • CTSA Program Lactogenesis and Breastfeeding After Immediate vs. Delayed Birth-Hospitalization Insertion of Etonogestrel Contraceptive Implant: A Noninferiority Trial • American Journal of Obstetrics and Gynecology • Jan 1, 2023 • CTSA Program Managing Multiple Perspectives In the Collaborative Design Process of a Team Health Information Technology • Applied Ergonomics • Jan. 1, 2023 • CTSA Program Metabolomic Profiling of Stool of Two-Year Old Children From the INSIGHT Study Reveals Links Between Butyrate and Child Weight Outcomes • Pediatric Obesity • Jan. 1, 2023 • CTSA Program MetaScore: A Novel Machine-Learning-Based Approach to Improve Traditional Scoring Functions for Scoring Protein-Protein Docking Conformations • Biomolecules • Jan. 1, 2023 • CTSA Program Multiomics in Primary and Metastatic Breast Tumors From the AURORA US Network Finds Microenvironment and Epigenetic Drivers of Metastasis • Nature Cancer • Jan. 1, 2023 • CTSA Program The Next Generation of Evidence-Based Medicine • Nature Medicine • Jan. 1, 2023 • CTSA Program Older Adults Receiving Rehabilitation Services Are More Likely to Get Bathing and Toileting Equipment Installed • American Journal of Occupational Therapy • Jan. 1, 2023 • Mentored Patient-Oriented Research Career Development Award Outcomes Associated With Rural Emergency Department Provider-to-Provider Telehealth for Sepsis Care: A Multicenter Cohort Study • Annals of Emergency Medicine • Jan. 1, 2023 • CTSA Program Perioperative Oxidative Stress Predicts Subsequent Pain-Related Outcomes in the 6 Months After Total Knee Arthroplasty • Pain • Jan. 1, 2023 • CTSA Program Physiology of Chemokines in the Cancer Microenvironment • American Journal of Physiology-Cell Physiology • Jan. 1, 2023 • CTSA Program Predictive Models for Length of Stay and Discharge Disposition in Elective Spine Surgery: Development, Validation, and Comparison to the ACS NSQIP Risk Calculator • Spine • Jan. 1, 2023 • CTSA Program Prenatal Cocaine Exposure and Substance Use Disorder in Emerging Adulthood at Age 21 • Drug and Alcohol Dependence • Jan. 1, 2023 • CTSA Program Primary Care Patients’ and Staff’s Perceptions of Self-Rooming as Alternative to Waiting Rooms • Annals of Family Medicine • Jan. 1, 2023 • CTSA Program A Prospective Cohort Study of Novel Markers of Hepatitis B Virus Replication in Human Immunodeficiency Virus Coinfection • Clinical Gastroenterology and Hepatology • Jan. 1, 2023 • CTSA Program Ramp-db 2.0: A Renovated Knowledgebase for Deriving Biological and Chemical Insight From Metabolites, Proteins, and Genes • Bioinformatics • Jan. 1, 2023 • Division of Preclinical Innovation Simulated Data-Driven Hospital Selection for Surgical Treatment of Well-Differentiated Thyroid Cancer in Older Adults • Surgery • Jan. 1, 2023 • CTSA Program Socioeconomic Correlates of Keratoconus Severity and Progression • Cornea • Jan. 1, 2023 • CTSA Program Substrate Stiffness Enhances Human Regulatory T Cell Induction and Metabolism • Biomaterials • Jan. 1, 2023 • CTSA Program Typology of Eating Episodes in Children and Adolescents With Overweight/Obesity • Eating Behaviors • Jan. 1, 2023 • CTSA Program Virtual Community Engagement for Retention of Black Men in Clinical Research • American Journal of Men’s Health • Jan. 1, 2023 • CTSA Program “You Start Feeling Comfortable, You Just Start Sharing:” A Qualitative Study of Patient Distress Screening in Black and White Patients With Endometrial Cancer • Gynecologic Oncology • Jan. 1, 2023 • CTSA Program December 2022 Development and Validation of an Electronic Health Records-Based Opioid Use Disorder Algorithm by Expert Clinical Adjudication Among Patients With Prescribed Opioids • Pharmacoepidemiology and Drug Safety • Dec. 31, 2022 • CTSA Program Reappraising the Public Health Benefits Conferred by Environmental Policy: Considerations for an Aging Society • Journal of the American Geriatrics Society • Dec. 31, 2022 • CTSA Program Tibial Quantitative Ultrasound Compared to Dual-Energy X-Ray Absorptiometry in Preterm Infants • Journal of Perinatology • Dec. 31, 2022 • CTSA Program Trajectories of Psychological Stress in Youth Across the First Year of Inflammatory Bowel Disease Diagnosis • Journal of Psychosomatic Research • Dec. 31, 2022 • CTSA Program Clinical Outcomes of De Novo Metastatic HER2-Low Breast Cancer: A National Cancer Database Analysis • npj Breast Cancer • Dec. 30, 2022 • CTSA Program Effects of Acute Estradiol and Progesterone on Perimenstrual Exacerbation of Suicidal Ideation and Related Symptoms: A Crossover Randomized Controlled Trial • Translational Psychiatry • Dec. 30, 2022 • CTSA Program Identification and Characterization of ML321: A Novel and Highly Selective D2 Dopamine Receptor Antagonist with Efficacy in Animal Models That Predict Atypical Antipsychotic Activity • ACS Pharmacology & Translational Science • Dec. 30, 2022 • Division of Preclinical Innovation Maternal Plasma Choline During Gestation and Small for Gestational Age Infants • American Journal of Perinatology • Dec. 30, 2022 • CTSA Program Positron Emission Tomography-Computed Tomography Imaging of Selective Lobar Delivery of Stem Cells in Ex Vivo Lung Model of Mechanical Ventilation • Journal of Aerosol Medicine and Pulmonary Drug Delivery • Dec. 30, 2022 • CTSA Program Prospective Observational Study of N-Terminal Pro-Brain Natriuretic Peptide Levels in Obese and Nonobese Women During Pregnancy • American Journal of Perinatology • Dec. 30, 2022 • CTSA Program Time to Treatment and Complexity of Mohs Micrographic Surgery • Archives of Dermatological Research • Dec. 30, 2022 • CTSA Program Underrepresented in Medicine Students’ Perspectives on Impactful Medical Education • BMC Medical Education • Dec. 30, 2022 • CTSA Program Adverse Effects of COVID-19 Pandemic on a Multicenter Randomized Controlled Trial • Journal of Perinatology • Dec. 29, 2022 • CTSA Program Insights Into the Pathogenesis of Hereditary Angioedema Employing Genetic Sequencing and Recombinant Protein Expression Analyses • Journal of Allergy and Clinical Immunology • Dec. 29, 2022 • CTSA Program Longitudinal Assessment of Anxiety and Depression Symptoms in U.S. Adolescents Across Six Months of the Coronavirus Pandemic • BMC Psychology • Dec. 29, 2022 • CTSA Program Sleep Quality Moderates the Association Between Family Bereavement and Heart Rate Variability • Journal of Behavioral Medicine • Dec. 29, 2022 • CTSA Program Cumulative Human Immunodeficiency Virus (HIV)-1 Viremia Is Associated With Increased Risk of Multimorbidity Among US Women With HIV, 1997-2019 • Open Forum Infectious Diseases • Dec. 28, 2022 • CTSA Program Lessons Learned from In-Person Conferences in the Times of COVID-19 • International Journal of Environmental Research and Public Health • Dec. 28, 2022 • CTSA Program Sterile Cerebrospinal Fluid Culture at Cryptococcal Meningitis Diagnosis Is Associated with High Mortality • Journal of Fungi • Dec. 28, 2022 • CTSA Program Understanding Fertility Attitudes and Outcomes Among Survivors of Adolescent and Young Adult Cancers in a Low-Resource Setting: A Registry-Based Computer-Assisted Telephone Interview Survey • Journal of Adolescent and Young Adult Oncology • Dec. 28, 2022 • CTSA Program Caregiver Experiences of Adolescent School Reentry After Adolescent Hospitalization Due to Suicidal Thoughts and Behaviors: Recommendations to Improve Reentry Practices • Journal of School Health • Dec. 27, 2022 • CTSA Program Clinical and Translational Science Award T32/TL1 Training Programs: Program Goals and Mentorship Practices • Journal of Clinical and Translational Science • Dec. 27, 2022 • CTSA Program Environmental Justice and Allergic Disease: A Work Group Report of the AAAAI Environmental Exposure and Respiratory Health Committee and the Diversity, Equity and Inclusion Committee • Journal of Allergy and Clinical Immunology • Dec. 27, 2022 • CTSA Program Heritability of Protein and Metabolite Biomarkers Associated With COVID-19 Severity: A Metabolomics and Proteomics Analysis • Biomolecules • Dec. 27, 2022 • CTSA Program Impact of Early Time-Restricted Eating on Diet Quality, Meal Frequency, Appetite, and Eating Behaviors: A Randomized Trial • Obesity • Dec. 27, 2022 • CTSA Program Reformulation of Top-Selling Processed and Ultra-Processed Foods and Beverages in the Peruvian Food Supply After Front-of-Package Warning Label Policy • International Journal of Environmental Research and Public Health • Dec. 27, 2022 • CTSA Program A Wireless, Regeneratable Cocaine Sensing Scheme Enabled by Allosteric Regulation of pH Sensitive Aptamers • ACS Nano • Dec. 27, 2022 • CTSA Program Dual Impacts of Medicare Payment Reform and the Covid-19 Pandemic on Therapy Staffing in Skilled Nursing Facilities • Journal of the American Geriatrics Society • Dec. 26, 2022 • CTSA Program Financial Impact Associated With Implementation of the Low Back Pain Clinical Practice Guideline in Outpatient Physical Therapist Practice at a Large Academic Medical Center • Physiotherapy Theory and Practice • Dec. 25, 2022 • CTSA Program Insights Into HIV-1 Transmission Dynamics Using Routinely Collected Data in the Mid-Atlantic United States • Viruses • Dec. 25, 2022 • CTSA Program Improved β-Cell Function Leads to Improved Glucose Tolerance in a Transgenic Mouse Expressing Lipoprotein Lipase in Adipocytes • Scientific Reports • Dec. 24, 2022 • CTSA Program Lestaurtinib Induces DNA Damage That Is Related to Estrogen Receptor Activation • Current Research in Toxicology • Dec. 24, 2022 • Division of Preclinical Innovation Nonfulfillment of Desired Postpartum Permanent Contraception and Resultant Maternal and Pregnancy Health Outcomes • AJOG Global Reports • Dec. 24, 2022 • CTSA Program Athletic Disruptions Caused by the COVID-19 Pandemic Negatively Affect High School Student-Athletes Social-Emotional Well-Being • Medicine • Dec. 23, 2022 • CTSA Program Periostin Regulation and Cartilage Degradation Early After Anterior Cruciate Ligament Reconstruction • Inflammation Research • Dec. 23, 2022 • CTSA Program Bridging the Humanities and Health Care With Theatre: Theory and Outcomes of a Theatre-Based Model for Enhancing Psychiatric Care via Stigma Reduction • Psychiatric Rehabilitation Journal • Dec. 22, 2022 • CTSA Program Diet Quality Indices and Changes in Cognition During Chemotherapy • Supportive Care in Cancer • Dec. 22, 2022 • CTSA Program Predictors of Success Following Single-Stage Revision Shoulder Arthroplasty: Results at a Mean of Five Year Follow-Up in One Hundred and Twelve Patients • International Orthopaedics • Dec. 22, 2022 • CTSA Program Staphylococcal Phosphatidylglycerol Antigens Activate Human T Cells via CD1a • Nature Immunology • Dec. 22, 2022 • CTSA Program Pneumocystis Jirovecii Infection in Autologous Hematopoietic Stem Cell Transplant Recipients • Bone Marrow Transplant • Dec. 22, 2022 • CTSA Program Parental Leave During Pediatric Fellowship Training: A National Survey • PloS One • Dec. 22, 2022 • CTSA Program Ancestral Risk Modification for Multiple Sclerosis Susceptibility Detected Across the Major Histocompatibility Complex in a Multi-Ethnic Population • PLoS One • Dec. 22, 2022 • CTSA Program Bioprinted 3D Outer Retina Barrier Uncovers RPE-Dependent Choroidal Phenotype in Advanced Macular Degeneration • Nature Methods • Dec. 22, 2022 • 3-D Modeling, Division of Preclinical Innovation Inflammation and Oxidative Stress in Salt Sensitive Hypertension; The Role of the NLRP3 Inflammasome • Frontiers in Physiology • Dec. 22, 2022 • CTSA Program MiR-451a and let-7i-5p Loaded Extracellular Vesicles Attenuate Heme-Induced Inflammation in hiPSC-Derived Endothelial Cells • Frontiers in Immunology • Dec. 22, 2022 • CTSA Program Plasmodium Infection is Associated With Cross-Reactive Antibodies to Carbohydrate Epitopes on the SARS-CoV-2 Spike Protein • Scientific Reports • Dec. 22, 2022 • CTSA Program Beta Cell Function and Insulin Sensitivity in Youth With Early Type 1 Diabetes From a Two-Hour 7-Sample OGTT • The Journal of Clinical Endocrinology & Metabolism • Dec. 21, 2022 • CTSA Program The Risk of Neonatal Morbidity in Umbilical Artery Hypercarbia and Respiratory Acidosis • American Journal of Perinatology • Dec. 21, 2022 • CTSA Program Sex and Menopause Impact 31P-Magnetic Resonance Spectroscopy Brain Mitochondrial Function in Association With 11C-PiB PET Amyloid-Beta Load • Scientific Reports • Dec. 21, 2022 • CTSA Program Solid Organ Transplantation Is Associated With an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer • Current Oncology • Dec. 21, 2022 • CTSA Program Substance Use Treatment Utilization Among Women With and Without Human Immunodeficiency Virus • Open Forum Infectious Diseases • Dec. 21, 2022 • CTSA Program Caregiver Perceptions of Change in Pediatric Asthma Control During the COVID-19 Pandemic • Journal of Asthma and Allergy • Dec. 20, 2022 • CTSA Program Chronic Demyelination of Rabbit Lesions is Attributable to Failed Oligodendrocyte Progenitor Cell Repopulation • Glia • Dec. 20, 2022 • CTSA Program Disparities in Spatial Access to Neurological Care in Appalachia: A Cross-Sectional Health Services Analysis • The Lancet Regional Health – Americas • Dec. 20, 2022 • CTSA Program Influence of Social and Behavioral Determinants On Health-Related Quality of Life Among Cancer Survivors In the USA • Supportive Care in Cancer • Dec. 20, 2022 • CTSA Program Links Between Early-life Contextual Factors and Later-life Cognition and the Role of Educational Attainment • Journal of the International Neuropsychological Society • Dec. 20, 2022 • CTSA Program Overcoming Barriers and Enhancing Facilitators to COVID-19 Vaccination in the Hispanic Community • BMC Public Health • Dec. 20, 2022 • CTSA Program Chronic Obstructive Pulmonary Disease is Not Associated with In-Hospital Mortality in COVID-19: An Observational Cohort Analysis • International Journal of Chronic Obstructive Pulmonary Disease • Dec. 19, 2022 • CTSA Program Evaluation and Treatment of Vulvodynia: State of the Science • Journal of Midwifery & Women's Health • Dec. 19, 2022 • CTSA Program Isomer-Specific Serum Concentrations of Perfluorooctane Sulfonic Acid Among U.S. Adults: Results From the National Health and Nutrition Examination Survey (NHANES) and the Study of Women's Health Across the Nation Multi-Pollutant Study (SWAN-MPS) • Environmental Science & Technology • Dec. 19, 2022 • CTSA Program Patient Feedback Receiving Care Using a Shared Decision Making Tool for Thyroid Nodule Evaluation—An Observational Study • Endocrine • Dec. 19, 2022 • CTSA Program Posttraumatic Stress Disorder and Depression Residual Symptoms Among Veterans and Service Members Who Completed a 3-Week Cognitive Processing Therapy-Based Intensive Treatment Program • Psychological Trauma: Theory, Research, Practice, and Policy • Dec. 19, 2022 • CTSA Program REPORTing of Antimicrobial Resistance From Blood Cultures (REPORT-ABC), an ARLG Survey Summary: Resistance Marker Reporting Practices From Positive Blood Cultures • Clinical Infectious Diseases • Dec. 19, 2022 • CTSA Program Aromatase-Inhibitor-Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse Model • Pharmaceuticals • Dec. 17, 2022 • CTSA Program Rural and Socioeconomic Differences in the Effectiveness of the HEART Pathway Accelerated Diagnostic Protocol • Academic Emergency Medicine • Dec. 17, 2022 • CTSA Program Knowledge, Attitudes, and Beliefs About Relapse Prevention Research Involving Bupropion Among Current and Former Pregnant Individuals Who Smoke • Journal of Smoking Cessation • Dec. 16, 2022 • CTSA Program Pediatric Considerations for Pharmacogenetic Selective Serotonin Reuptake Inhibitors Clinical Decision Support • Pharmacotherapy • Dec. 16, 2022 • CTSA Program A Prospective Evaluation of Infant Cerebellar-Cerebral Functional Connectivity in Relation to Behavioral Development in Autism Spectrum Disorder • Biological Psychiatry Global Open Science • Dec. 16, 2022 • CTSA Program Retrospective Cohort Study Comparing Surgical Inpatient Charges, Total Costs, and Variable Costs as Hospital Cost Savings Measures • Medicine • Dec. 16, 2022 • CTSA Program Impact of Technology on Social Isolation: Longitudinal Analysis from the National Health Aging Trends Study • Journal of the American Geriatrics Society • Dec. 15, 2022 • CTSA Program Sfrp4 Expression in Thyroxine Treated Calvarial Cells • Life Sciences • Dec. 15, 2022 • CTSA Program TLR7 Agonism Accelerates Disease in a Mouse Model of Primary Sjögren’s Syndrome and Drives Expansion of T-bet+ B Cells • Frontiers in Immunology • Dec. 15, 2022 • CTSA Program Utility of Diffusion Basis Spectrum Imaging in Quantifying Baseline Disease Severity and Prognosis of Cervical Spondylotic Myelopathy • Spine • Dec. 15, 2022 • CTSA Program Chemosensory Deficits Are Best Predictor of Serologic Response Among Individuals Infected With SARS-CoV-2 • PLoS One • Dec. 14, 2022 • CTSA Program Early Time-Restricted Eating Affects Weight, Metabolic Health, Mood, and Sleep in Adherent Completers: A Secondary Analysis • Obesity • Dec. 14, 2022 • CTSA Program Time-Restricted Eating Did Not Alter Insulin Sensitivity or β-Cell Function in Adults With Obesity: A Randomized Pilot Study • Obesity • Dec. 14, 2022 • CTSA Program Two Unique BAP1 Pathogenic Variants Identified in the Same Family by Panel Cascade Testing • Familial Cancer • Dec. 14, 2022 • CTSA Program Abnormal Magnetic Resonance Image Signature in Virologically Stable HIV Individuals • The Journal of Infectious Diseases • Dec. 13, 2022 • CTSA Program Association of Lp(a) (Lipoprotein[a]) and Hypertension in Primary Prevention of Cardiovascular Disease: The MESA • Hypertension • Dec. 13, 2022 • CTSA Program Health Care Personnel's Perspectives on Human Papillomavirus (HPV) Self-Sampling for Cervical Cancer Screening: a Pre-Implementation, Qualitative Study • Implementation Science Communications • Dec. 13, 2022 • CTSA Program Health-Related Quality of Life Is Associated With Fecal Microbial Composition in Breast Cancer Survivors • Supportive Care in Cancer • Dec. 13, 2022 • CTSA Program Impact of the COVID-19 Pandemic on Women’s Health Care Access: A Cross-Sectional Study • Journal of Women’s Health • Dec. 13, 2022 • CTSA Program Motivators and Barriers to COVID-19 Research Participation at the Onset of the COVID-19 Pandemic in Black Communities in the USA: An Exploratory Study • Journal of Racial and Ethnic Health Disparities • Dec. 13, 2022 • CTSA Program Symptom Management Needs of Patients With Irritable Bowel Syndrome and Concurrent Anxiety And/or Depression: A Qualitative Study • Journal of Advanced Nursing • Dec. 13, 2022 • CTSA Program Urinary Metal Profiles in Mother-Offspring Pairs and Their Association With Early Dysglycemia in the International Hyperglycemia and Adverse Pregnancy Outcome Follow Up Study (HAPO-FUS) • Journal of Exposure Science & Environmental Epidemiology • Dec. 13, 2022 • CTSA Program Using Community-Based Participatory Research to Create Animated Videos to Attenuate Disparities in Access to Kidney Transplant Information • Progress in Transplantation • Dec. 13, 2022 • CTSA Program Acceptability and Outcomes of Transdiagnostic Guided Self-Help Bibliotherapy for Internalizing Disorder Symptoms in Adults: A Fully Remote Nationwide Open Trial • Cognitive Therapy and Research • Dec. 12, 2022 • CTSA Program Assessment of In-Hospital Pain Control After Childbirth and Its Correlation With Anxiety in the Postpartum Period: A Cross-Sectional Study at a Single Center in the USA • Reproductive Medicine • Dec. 12, 2022 • CTSA Program Early Adversity Promotes Binge-Like Eating Habits by Remodeling a Leptin-Responsive Lateral Hypothalamus-Brainstem Pathway • Nature Neuroscience • Dec. 12, 2022 • CTSA Program Gabapentin Disrupts Binding of Perlecan to the α2δ1 Voltage Sensitive Calcium Channel Subunit and Impairs Skeletal Mechanosensation • Biomolecules • Dec. 12, 2022 • CTSA Program Patients’ Perspectives of Factors That Influence Pharmacogenetic Testing Uptake: Enhancing Patient Counseling and Results Dissemination • Journal of Personalized Medicine • Dec. 11, 2022 • CTSA Program Assessing the Efficacy of Magnesium Oxide and Riboflavin as Preventative Treatment of Migraines in Pregnancy • Archives of Gynecology and Obstetrics • Dec. 10, 2022 • CTSA Program The Interrelated Multifactorial Actions of Cortisol and Klotho: Potential Implications in the Pathogenesis of Parkinson’s Disease • Brain Sciences • Dec. 10, 2022 • CTSA Program A Photoacoustic Contrast Nanoagent With a Distinct Spectral Signature for Ovarian Cancer Management • Advanced Healthcare Materials • Dec. 10, 2022 • CTSA Program Using Transvaginal Ultrasounds for the Identification of Follicle-Like Structures ≥10 mm in a Multi-Center Randomized Contraceptive Clinical Trial of Three 84-Day Oral Ulipristal Acetate Regimens • Journal of Clinical Ultrasound • Dec. 10, 2022 • CTSA Program Domains for a Comprehensive Geriatric Assessment of Older Adults With Chronic Kidney Disease: Results From the CRIC Study • American Journal of Nephrology • Dec. 9, 2022 • CTSA Program Prostate Volume, Baseline Urinary Function, and Their Association with Treatment Choice and Post-Treatment Urinary Function in Men Treated for Localized Prostate Cancer • Prostate Cancer and Prostatic Diseases • Dec. 8, 2022 • CTSA Program Association Between Tumor Microbiome and Hypoxia Across Anatomic Subsites of Head and Neck Cancers • International Journal of Molecular Sciences • Dec. 8, 2022 • CTSA Program Loss of Alcohol Dehydrogenase 1B in Cancer-Associated Fibroblasts: Contribution to the Increase of Tumor-Promoting IL-6 in Colon Cancer • British Journal of Cancer • Dec. 8, 2022 • CTSA Program Metabolomic Profiling of Red Blood Cells to Identify Molecular Markers of Methotrexate Response in the Collagen Induced Arthritis Mouse Model • Future Pharmacology • Dec. 8, 2022 • CTSA Program Comparison of Oncologist and Model Estimates of Risk for Hospitalization During Systemic Therapy for Advanced Cancer • JCO Oncology Practice • Dec. 7, 2022 • CTSA Program CpG Site-Based Signature Predicts Survival of Colorectal Cancer • Biomedicines • Dec. 7, 2022 • CTSA Program The Demographics of Menière’s Disease: Selection Bias or Differential Susceptibility? • Otology & Neuerotology • Dec. 7, 2022 • CTSA Program Healthspan and Chronic Disease Burden Among Young Adult and Middle-Aged Male Former American-Style Professional Football Players • British Journal of Sports Medicine • Dec. 7, 2022 • CTSA Program Introducing an Adolescent Cognitive Maturity Index • Frontiers in Psychology • Dec. 7, 2022 • CTSA Program Professionals as Change Agents or Instruments of Reproduction? Medical Residents’ Reasoning for Not Sharing the Electronic Health Record Screen with Patients • Future Internet • Dec. 7, 2022 • CTSA Program The RNA-Binding Protein HuR Is Integral to the Function of Nociceptors in Mice and Humans • Journal of Neuroscience • Dec. 7, 2022 • Tissue Chip Bacterial Vaginosis-Associated Bacteria in Cisgender Men Who Have Sex with Women: Prevalence, Association with Non-Gonococcal Urethritis and Natural History • Sexually Transmitted Infections • Dec. 6, 2022 • CTSA Program COVID-19 in Patients With a Primary Refugee-Associated Language in a Kentucky Emergency Department During 2020 • Journal of Immigrant and Minority Health • Dec. 6, 2022 • CTSA Program Machine Learning To Stratify Methicillin-Resistant Staphylococcus aureus Risk among Hospitalized Patients with Community-Acquired Pneumonia • Antimicrobial Agents and Chemotherapy • Dec. 6, 2022 • CTSA Program Preterm Infants at Low Risk for Early-Onset Sepsis Differ in Early Fecal Microbiome Assembly • Gut Microbes • Dec. 6, 2022 • CTSA Program Psychotropic Medication Use in United States Pediatric Emergency Department Visits • Academic Pediatrics • Dec. 6, 2022 • CTSA Program VACtrac: Enhancing Access Immunization Registry Data for Population Outreach Using the Bulk Fast Healthcare Interoperable Resource (FHIR) Protocol • Journal of the American Medical Informatics Association • Dec. 6, 2022 • CTSA Program Association of Longitudinal Urinary Metabolic Biomarkers With ADPKD Severity and Response to Metformin in TAME-PKD Clinical Trial Participants • Kidney International Reports • Dec. 5, 2022 • CTSA Program Cost Analysis of Training Residents in Robotic-Assisted Surgery • Surgical Endoscopy • Dec. 5, 2022 • CTSA Program Effectiveness of Goal-Directed and Outcome-Based Financial Incentives for Weight Loss in Primary Care Patients With Obesity Living in Socioeconomically Disadvantaged Neighborhoods: A Randomized Clinical Trial • JAMA Internal Medicine • Dec. 5, 2022 • CTSA Program Implementation of Group Cognitive Processing Therapy in Correction Centers: Anticipated Determinants from Formative Evaluation • Journal of Traumatic Stress • Dec. 5, 2022 • CTSA Program Increasing Access to Buprenorphine for Opioid Use Disorder in Primary Care: an Assessment of Provider Incentives • Journal of General Internal Medicine • Dec. 5, 2022 • CTSA Program Bayesian Decision Analysis: An Underutilized Tool in Veterinary Medicine • Animals • Dec. 4, 2022 • CTSA Program Clinical Trial Recruitment in Primary Care: Exploratory Factor Analysis of a Questionnaire to Measure Barriers and Facilitators to Primary Care Providers’ Involvement • BMC Primary Care • Dec. 3, 2022 • CTSA Program Mental Health Symptom Changes in Pregnant Individuals Across the COVID-19 Pandemic: A Prospective Longitudinal Study • BMC Pregnancy and Childbirth • Dec. 3, 2022 • CTSA Program A Multi-Cohort Examination of the Independent Contributions of Maternal Childhood Adversity and Pregnancy Stressors to the Prediction of Children’s Anxiety and Depression • Research on Child and Adolescent Psychopathology • Dec. 3, 2022 • CTSA Program Congenital Anomalies Associated with Oil and Gas Development and Resource Extraction: A Population-Based Retrospective Cohort Study in Texas • Journal of Exposure Science & Environmental Epidemiology • Dec. 2, 2022 • CTSA Program Understanding Historical Trauma Among Urban Indigenous Adults at Risk for Diabetes • American Indian and Alaska Native Mental Health Research • Dec. 2, 2022 • CTSA Program Validation of a Highly Accelerated Post-Contrast Wave-Controlled Aliasing in Parallel Imaging (CAIPI) 3D-T1 MPRAGE Compared to Standard 3D-T1 MPRAGE for Detection of Intracranial Enhancing Lesions on 3-T MRI • European Radiology • Dec. 2, 2022 • CTSA Program Acute Responsiveness to Single Leg Cycling in Adults With Obesity • Physiological Reports • Dec. 1, 2022 • CTSA Program Agent-Based Modeling Predicts RAC1 Is Critical for Ovarian Cancer Metastasis • Molecular Biology of the Cell • Dec. 1, 2022 • IDG Application of Consolidated Framework for Implementation Research to Improve Clostridioides Difficile Infection Management in District Hospitals • Research in Social and Administrative Pharmacy • Dec. 1, 2023 • CTSA Program Association of Asymptomatic Hemorrhage After Endovascular Stroke Treatment With Outcomes • The Journal of NeuroInterventional Surgery • Dec. 1, 2022 • CTSA Program Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma • Clinical Genitourinary Cancer • Dec. 1, 2022 • CTSA Program Associations Among Hearing Loss, Multiple Co-Occurring Symptoms, and Quality of Life Outcomes In Cancer Survivors • Journal of Cancer Survivorship • Dec. 1, 2022 • CTSA Program Associations of Neighborhood Opportunity and Social Vulnerability With Trajectories of Childhood Body Mass Index and Obesity Among US Children • JAMA Network Open • Dec. 1, 2022 • CTSA Program Black Families’ Experiences of Developmental Screening: Review of Well-Child Visits to Inform Enhanced Autism Spectrum Disorder Risk Assessment • Journal of Developmental & Behavioral Pediatrics • Dec. 1, 2022 • CTSA Program Blood Pressure Changes Impact Corticospinal Integrity and Downstream Gait and Balance Control • Neurobiology of Aging • Dec. 1, 2022 • CTSA Program Bone Marrow Derived Long-Lived Plasma Cell Phenotypes Are Heterogeneous and Can Change in Culture • Transplant Immunology • Dec. 1, 2022 • CTSA Program Can the Risk Analysis Index for Frailty Predict Morbidity and Mortality in Patients Undergoing High-Risk Surgery? • Annals of Surgery • Dec. 1, 2022 • CTSA Program A Cell-Based Bioluminescence Reporter Assay of Human Sonic Hedgehog Protein Autoprocessing to Identify Inhibitors and Activators • Journal of Biological Chemistry • Dec. 1, 2022 • Division of Preclinical Innovation Characterizing Sleep Phenotypes in Children With Newly Diagnosed Epilepsy • Pediatric Neurology • Dec. 1, 2022 • CTSA Program Comparison of Dose-Response Relationships for Two Isolates of Sars-cov-2 in a Nonhuman Primate Model of Inhalational Covid-19 • Journal of Aerosol Medicine and Pulmonary Drug Delivery • Dec. 1, 2022 • Division of Preclinical Innovation Comparison of Three Approaches to Single-Port Robot-Assisted Radical Prostatectomy: Our Institution’s Initial Experience • Journal of Endourology • Dec. 1, 2022 • CTSA Program Current Approaches to the Management of Pneumatosis Intestinalis: An American Pediatric Surgical Association Membership Survey • Pediatric Surgery International • Dec. 1, 2022 • CTSA Program Describing and Assessing a New Method of Approximating Categorical Individual-Level Income Using Community-Level Income From the Census (Weighting by Income Probabilities) • Health Services Research • Dec. 1, 2022 • CTSA Program Design of the Reducing Diagnostic Error to Improve Patient Safety (REDEfINE) in COPD and Asthma Study: A Cluster Randomized Comparative Effectiveness Trial • Contemporary Clinical Trials • Dec. 1, 2022 • CTSA Program Development and Initial Validation of a Systemic Lupus Erythematosus-Specific Measure of the Extent of and Reasons for Medication Nonadherence • The Journal of Rheumatology • Dec. 1, 2022 • CTSA Program A Dried Blood Spot Test for Diagnosis of Autoimmune Pulmonary Alveolar Proteinosis • Journal of Immunological Methods • Dec. 1, 2022 • RDCRN Effectiveness of a Community-Based Structured Physical Activity Program for Adults With Type 2 Diabetes: A Randomized Clinical Trial • Journal of the American Medical Association • Dec. 1, 2022 • CTSA Program Epidemiology of Eustachian Tube Dysfunction and Related Otologic Diagnoses Among Children with Achondroplasia • International Journal of Pediatric Otorhinolaryngology • Dec. 1, 2022 • CTSA Program Everyday Discrimination Is a Stronger Predictor of Eating Competence Than Food Insecurity or Perceived Stress in College Students Amidst COVID-19 • Appetite • Dec. 1, 2022 • CTSA Program Examining Patient Perspectives on Sarcoma Surveillance: The Sarcoma Surveillance Survey • Surgical Oncology • Dec. 1, 2022 • CTSA Program Examining the Relationship Between Clinician Communication and Patient Participatory Behaviors In Cardiology Encounters • Patient Education and Counseling • Dec. 1, 2022 • CTSA Program Experiential Learning Methods for Biostatistics Students: A Model for Embedding Student Interns in Academic Health Centres • Stat • Dec. 1, 2022 • CTSA Program Exploring Emergent Barriers to Hospital-Based Violence Intervention Programming During the COVID-19 Pandemic • Preventive Medicine • Dec. 1, 2022 • CTSA Program Exploring the Intersection of Structural Racism and Ageism in Healthcare • Journal of the American Geriatrics Society • Dec. 1, 2022 • NCATS Extent of Extranodal Extension in Oral Cavity Squamous Cell Carcinoma Is Not Independently Associated With Overall or Disease-Free Survival at a 2.0-mm Threshold • Journal of Oral and Maxillofacial Surgery • Dec. 1, 2022 • CTSA Program Factor H Related Proteins Modulate Complement Activation on Kidney Cells • Kidney International • Dec. 1, 2022 • CTSA Program Factors Associated with the Accurate Self-Report of Cancer Screening Behaviors Among Women Living in the Rural Midwest Region of the United States • Preventive Medicine Reports • Dec. 1, 2022 • CTSA Program Factors Associated with Gastrostomy Tube Complications in Infants with Congenital Heart Disease • Journal of Surgical Research • Dec. 1, 2022 • CTSA Program Federal and Statewide Coverage for Opioid-Sparing Chronic Pain Treatments • Pain Physician • Dec. 1, 2022 • CTSA Program Glycemic Outcomes of Hospitalized Patients on Ambulatory Humulin-R U-500 Insulin • Endocrine Practice • Dec. 1, 2022 • CTSA Program The Greenlight Plus Trial: Comparative Effectiveness of a Health Information Technology Intervention vs. Health Communication Intervention in Primary Care Offices to Prevent Childhood Obesity • Contemporary Clinical Trials • Dec. 1, 2022 • CTSA Program Gynaecological Care of Women With Chronic Pelvic Pain: Patient Perspectives and Care Preferences • BJOG • Dec. 1, 2022 • CTSA Program Honey Bee Colony Loss Linked to Parasites, Pesticides and Extreme Weather Across the United States • Scientific Reports • Dec. 1, 2022 • CTSA Program Hospitals That Report Severe Sepsis and Septic Shock Bundle Compliance Have More Structured Sepsis Performance Improvement • Journal of Patient Safety • Dec. 1, 2022 • CTSA Program How Compounding Pharmacies Fill Critical Gaps in Pediatric Drug Development Processes: Suggested Regulatory Changes to Meet Future Challenges • Children • Dec. 1, 2022 • CTSA Program Identification of Trajectory-Based Acute Kidney Injury Phenotypes Among Cardiac Surgery Patients • The Annals of Thoracic Surgery • Dec. 1, 2022 • CTSA Program Increasing Utilization of the Twist Score in Workup of Patients With Acute Scrotal Pain: Role in Diagnosis and Risk Stratification • Journal of Pediatric Urology • Dec. 1, 2022 • CTSA Program Innovation in Large-Scale Research Programs: Elevating Research Participants to Governance Roles Through the All of Us Research Program Engagement Core • Academic Medicine • Dec. 1, 2022 • CTSA Program Lessons Learned About Publication of Results of Community Surveys When Regulatory Oversight Has Not Occurred • SSM - Qualitative Research in Health • Dec. 1, 2022 • CTSA Program A Longitudinal Observational Study of Multimorbidity and Partner Support for Physical Activity Among People With Osteoarthritis • International Journal of Behavioral Medicine • Dec. 1, 2022 • CTSA Program Magnetic Resonance Imaging to Assess Body Composition Change in Adolescents With Obesity After Sleeve Gastrectomy • Journal of Pediatric Gastroenterology and Nutrition • Dec. 1, 2022 • CTSA Program Maximizing Clinical Rotation Placements for US Medical Students: Exploring an Optimization Model • Medical Education Online • Dec. 1, 2022 • CTSA Program Mother-Child Synchrony is High Across Child Executive Function Levels for Both Physical and Digital Spatial Play • Trends in Neuroscience and Education • Dec. 1, 2022 • CTSA Program National Trends in Pediatric Metabolic and Bariatric Surgery: 2010-2017 • Pediatrics • Dec. 1, 2022 • CTSA Program Obstetric and Neonatal Outcomes 1 or More Years After a Diagnosis of Breast Cancer • Obstetrics & Gynecology • Dec. 1, 2022 • CTSA Program Perinatal Oxycodone Exposure Causes Long-Term Sex-Dependent Changes in Weight Trajectory and Sensory Processing in Adult Mice • Psychopharmacology • Dec. 1, 2022 • CTSA Program Predicting Need for Intervention in Acute Necrotizing Pancreatitis Following Discharge- A Single Center Experience in 525 Patients • Pancreatology • Dec. 1, 2022 • CTSA Program Progress in Gastroparesis - A Narrative Review of the Work of the Gastroparesis Clinical Research Consortium • Clinical Gastroenterology and Hepatology • Dec. 1, 2022 • CTSA Program Prospective Longitudinal Assessment of Sensorimotor Gating as a Risk/Resiliency Factor for Posttraumatic Stress Disorder • Neuropsychopharmacology • Dec. 1, 2022 • CTSA Program A Qualitative Study of COVID-19 Vaccine Decision Making Among Urban Native Americans • Vaccine: X • Dec. 1, 2022 • CTSA Program Quantifying the Phenome-Wide Disease Burden of Obesity Using Electronic Health Records and Genomics • Obesity • Dec. 1, 2022 • CTSA Program Relationship of Low-Density Lipoprotein-Cholesterol and Lipoprotein(A) to Cardiovascular Risk: The Multi-Ethnic Study of Atherosclerosis (MESA) • Atherosclerosis • Dec. 1, 2022 • CTSA Program A Sarm1-Mitochondrial Feedback Loop Drives Neuropathogenesis in a Charcot-Marie-Tooth Disease Type 2a Rat Model • The Journal of Clinical Investigation • Dec. 1, 2022 • CTSA Program SARS-CoV-2 mRNA-Based Vaccines in the Aicardi Goutières Syndrome • Molecular Genetics and Metabolism • Dec. 1, 2022 • RDCRN Social Media and Cardiovascular Health: Implications for Women • Current Atherosclerosis Reports • Dec. 1, 2022 • CTSA Program Symptoms and Survivorship Needs Differences Between "good Sleepers" and "bad Sleepers" In Survivors of Breast and Gynecologic Cancers • Sleep Medicine • Dec. 1, 2022 • CTSA Program TCEAL1 Loss-of-Function Results in an X-Linked Dominant Neurodevelopmental Syndrome and Drives the Neurological Disease Trait in Xq22.2 Deletions • American Journal of Human Genetics • Dec. 1, 2022 • CTSA Program Trial of Training to Reduce Driver Inattention in Teens with ADHD • The New England Journal of Medicine • Dec. 1, 2022 • CTSA Program Updates on Sturge-Weber Syndrome • Stroke • Dec. 1, 2022 • NCATS Validation of a Computational Phenotype to Identify Acute Brain Dysfunction in Pediatric Sepsis • Pediatric Critical Care Medicine • Dec. 1, 2022 • CTSA Program Wide Arterial Sparing Encephalo-Duro-Synangiosis for Moyamoya: Surgical Technique and Outcomes • Operative Neurosurgery • Dec. 1, 2022 • CTSA Program November 2022 Clinician Practices, Knowledge, and Attitudes Regarding Primary Human Papillomavirus Testing for Cervical Cancer Screening: A Mixed-Methods Study in Indiana • Preventive Medicine Reports • Nov. 30, 2022 • CTSA Program Genomic Signature of Fanconi Anaemia DNA Repair Pathway Deficiency in Cancer • Nature • Nov. 30, 2022 • CTSA Program Impairments to Executive Function in Emerging Adults With Huntington Disease • Journal of Neurology, Neurosurgery and Psychiatry • Nov. 30, 2022 • CTSA Program The Influence of Posttraumatic Stress Disorder Treatment on Anxiety Sensitivity: Impact of Prolonged Exposure, Sertraline, and Their Combination • Journal of Traumatic Stress • Nov. 30, 2022 • CTSA Program Institution-Specific Perinatal Emergency Checklists: Multicenter Report on Development, Implementation, and Sustainability • American Journal of Perinatology • Nov. 30, 2022 • CTSA Program Ketamine Infusion for Sedation and Analgesia During Mechanical Ventilation in the ICU: A Multicenter Evaluation • Critical Care Research and Practice • Nov. 30, 2022 • CTSA Program Preschool Neurodevelopment in Zika Virus-Exposed Children Without Congenital Zika Syndrome • Pediatric Research • Nov. 30, 2022 • CTSA Program Retailer Marketing Strategies and Customer Purchasing of Sweetened Beverages in Convenience Stores • Journal of the Academy of Nutrition and Dietetics • Nov. 30, 2022 • CTSA Program Use of an Electronic Medical Record to Optimize a Neonatal Sepsis Score for Mortality Prediction • Journal of Perinatology • Nov. 30, 2022 • CTSA Program Beliefs Associated With Cancer Screening Behaviors Among African Americans and Sub-Saharan African Immigrant Adults: A Cross-sectional Study • BMC Public Health • Nov. 29, 2022 • CTSA Program Contextual Pathways Linking Cumulative Experiences of Racial Discrimination to Black American Men’s Covid Vaccine Hesitancy • Journal of Racial and Ethnic Health Disparities • Nov. 29, 2022 • CTSA Program Criterion Validity of a Short Food Frequency Questionnaire for Mexican American Adults • Nutrients • Nov. 29, 2022 • CTSA Program Current Utilization of Interosseous Access in Pediatrics: A Population-Based Analysis Using an EHR Database, TriNetX • International Journal of Emergency Medicine • Nov. 29, 2022 • CTSA Program Depressive Symptoms Exacerbate Disability in Older Adults: A Prospective Cohort Analysis of Participants in the MemAID Trial • PLoS One • Nov. 29, 2022 • CTSA Program Effects of a Grocery Shopping Intervention Designed to Improve Diet Adherence in Diabetes: A Randomized Trial • Obesity • Nov. 29, 2022 • CTSA Program Markers of Ovarian Reserve as Predictors of Future Fertility • Fertility and Sterility • Nov. 29, 2022 • CTSA Program The Penn Medicine BioBank: Towards a Genomics-Enabled Learning Healthcare System to Accelerate Precision Medicine in a Diverse Population • Journal of Personalized Medicine • Nov. 29, 2022 • CTSA Program Vaginal Cleansing Before Unscheduled Cesarean Delivery to Reduce Infection: A Randomized Clinical Trial • American Journal of Obstetrics & Gynecology • Nov. 29, 2022 • CTSA Program COVID-19 Vaccine Hesitancy and Racial Discrimination Among US Adults • Preventive Medicine Reports • Nov. 28, 2022 • CTSA Program The Diagnosis of Severe Combined Immunodeficiency: Implementation of the PIDTC 2022 Definitions • The Journal of Allergy and Clinical Immunology • Nov. 28, 2022 • Rare Diseases Structure-Based Discovery of a Novel Class of Small-Molecule Pure Antagonists of Integrin αVβ3 • Journal of Chemical Information and Modeling • Nov. 28, 2022 • CTSA Program Serum Glycomic Profile as a Predictive Biomarker of Recurrence in Patients with Differentiated Thyroid Cancer • Cancer Medicine • Nov. 27, 2022 • CTSA Program Characterization of SARS-CoV-2 Antibodies in Human Milk from 21 Women with Confirmed COVID-19 Infection • Pediatric Research • Nov. 25, 2022 • CTSA Program Hypermetabolic Lymphadenopathy Following the Administration of COVID-19 Vaccine and Immunotherapy in a Lung Cancer Patient: A Case Report • Journal of Medical Case Reports • Nov. 25, 2022 • CTSA Program Immigration Status, Socioeconomic Status, and Self-Rated Health in Europe • International Journal of Environmental Research and Public Health • Nov. 25, 2022 • CTSA Program Immune Phenotypes That Are Associated With Subsequent COVID-19 Severity Inferred From Post-Recovery Samples • Nature Communications • Nov. 25, 2022 • CTSA Program Application of Temperature-Responsive HIS-Tag Fluorophores to Differential Scanning Fluorimetry Screening of Small Molecule Libraries • Frontiers in Pharmacology • Nov. 24, 2022 • Division of Preclinical Innovation Evaluation of Lung Ultrasound to Detect Volume Overload in Children Undergoing Dialysis • Pediatric Nephrology • Nov. 24, 2022 • CTSA Program Wireless, Closed-Loop, Smart Bandage with Integrated Sensors and Stimulators for Advanced Wound Care and Accelerated Healing • Nature Biotechnology • Nov. 24, 2022 • CTSA Program Longitudinal IgG antibody responses to Plasmodium vivax blood-stage antigens during and after acute vivax malaria in individuals living in the Brazilian Amazon • PLOS Neglected Tropical Diseases • Nov. 23, 2022 • CTSA Program Cross-Sectional Online Survey of Clinicians' Knowledge, Attitudes and Challenges to Screening and Counselling Adolescents and Young Adults for Substance Use • BMJ Open • Nov. 22, 2022 • CTSA Program “I Didn’t Sign Up for This”: Perspectives From Persons Living With Dementia and Care Partners on Challenges, Supports, and Opportunities to Add Geriatric Neuropalliative Care to Dementia Specialty Care • The Journal of Alzheimer’s Disease • Nov. 22, 2022 • CTSA Program Neuropathic Pain as a Trigger for Histone Modifications in Limbic Circuitry • Genes,Brain and Behavior • Nov. 22, 2022 • CTSA Program One-Year Pregnancy and Continuation Rates After Placement of Levonorgestrel or Copper Intrauterine Devices for Emergency Contraception: A Randomized Controlled Trial • American Journal of Obstetrics & Gynecology • Nov. 22, 2022 • CTSA Program Pathogenicity and Impact of HLA Class I Alleles in Aplastic Anemia Patients of Different Ethnicities • JCI Insight • Nov. 22, 2022 • CTSA Program Testing of Drugs Using Human Feto-Maternal Interface Organ-on-Chips Provide Insights into Pharmacokinetics and Efficacy • Lab on a Chip • Nov. 22, 2022 • Tissue Chip You've Got a Friend In Me: How Cognitively Unimpaired Older Adults Select a Study Partner To Participate With Them In Alzheimer's Disease Research • Journal of Alzheimer's Disease • Nov. 22, 2022 • CTSA Program Antitumor Activity of Anti-miR-21 Delivered Through Lipid Nanoparticles • Advanced Healthcare Materials • Nov. 21, 2022 • CTSA Program Effects of Social Complexity and Gender on Social and Non-Social Attention in Male and Female Autistic Children: A Comparison of Four Eye-Tracking Paradigms • Autism Research • Nov. 21, 2022 • CTSA Program Toxicity Index, Patient-Reported Outcomes, and Persistence of Breast Cancer Chemotherapy-Associated Side Effects in NRG Oncology/NSABP B-30 • npj Breast Cancer • Nov. 19, 2022 • CTSA Program Trends in Episode-of-Care Spending for Cancer-Directed Surgery Among US Medicare Beneficiaries from 2011 to 2019 • JAMA Surgery • Nov. 19, 2022 • NCATS Unbiased Identification of Dengue Virus Non-Structural Protein 1 Peptides for Use in Vaccine Design • JOURNAL • Nov. 19, 2022 • CTSA Program Whole-Slide Cytometric Feature Mapping for Distinguishing Tumor Genomic Subtypes in HNSCC Whole Slide Images • The American Journal of Pathology • Nov. 19, 2022 • CTSA Program Agricultural Youth Injuries: An Updated Review of Cases from U.S. News Media Reports, 2016-2021 • Frontiers in Public Health • Nov. 18, 2022 • CTSA Program Association Between Employment Status and Quality of Life for Individuals With Intellectual or Developmental Disability • Journal of Applied Research in Intellectual Disabilities • Nov. 18, 2022 • CTSA Program Barriers and Facilitators to Diabetes Screening and Prevention After a Pregnancy Complicated by Gestational Diabetes • PLoS One • Nov. 18, 2022 • CTSA Program Bortezomib-Induced Neurotoxicity in Human Neurons is the Consequence of Nicotinamide Adenine Dinucleotide Depletion • Disease Models & Mechanisms • Nov. 18, 2022 • Division of Preclinical Innovation, HEAL Therapeutic Potential of Combinative Shrna-Encoded Lentivirus-Mediated Gene Silencing to Accelerate Somatosensory Recovery After Spinal Cord Trauma • Neurotherapeutics • Nov. 18, 2022 • CTSA Program Beyond Income: Material Hardship and the Health and Healthcare of Premature Children • Journal of Perinatology • Nov. 17, 2022 • CTSA Program Diabetes Medications and Associations with Covid-19 Outcomes in the N3C Database: A National Retrospective Cohort Study • PLoS One • Nov. 17, 2022 • CTSA Program Oncology Providers’ and Professionals’ Experiences with Suicide Risk Screening Among Patients with Head and Neck Cancer: A Qualitative Study • JCO Oncology Practice • Nov. 17, 2022 • CTSA Program Organizational and Coalition Strategies for Youth Violence Prevention: A Longitudinal Mixed-Methods Study • American Journal of Criminal Justice • Nov. 17, 2022 • CTSA Program Quality Improvement in a Pediatric Echocardiography Laboratory: A Collaborative Process • Children • Nov. 17, 2022 • CTSA Program The Role of Allogeneic Transplant for Adult Ph+ All in Cr1 With Complete Molecular Remission: A Retrospective Analysis • Blood • Nov. 17, 2022 • CTSA Program Wellness Achieved Through Changing Habits: A Randomized Controlled Trial of an Acceptance-Based Intervention for Adolescent Girls With Overweight or Obesity • Childhood Obesity • Nov. 17, 2022 • CTSA Program Enterococci Enhance Clostridioides difficile Pathogenesis • Nature • Nov. 16, 2022 • CTSA Program Interobserver Agreement of Modified Paris Classification and Histology Prediction of Colorectal Lesions in Patients with Inflammatory Bowel Disease • Gastrointestinal Endoscopy • Nov. 16, 2022 • CTSA Program Clinical Hypnosis Can Reduce Lower Urinary Tract Symptoms in Individuals With Chronic Pain • Neurourology and Urodynamics • Nov. 15, 2022 • CTSA Program Genome-Wide Admixture and Association Analysis Identifies African Ancestry Specific Risk Loci of Eosinophilic Esophagitis in African American • The Journal of Allergy and Clinical Immunology • Nov. 15, 2022 • RDCRN In-Hospital Outcomes Following Carotid Endarterectomy for Stroke Stratified by Modified Rankin Scale and Time of Intervention • Journal of Vascular Surgery • Nov. 15, 2022 • CTSA Program Monocyte/Macrophage Heterogeneity During Skin Wound Healing in Mice • The Journal of Immunology • Nov. 15, 2022 • CTSA Program Ocular Cyclopentolate: A Mini Review Concerning Its Benefits and Risks • Clinical Ophthalmology • Nov. 15, 2022 • Inxight Drugs Brain Aging Among Racially and Ethnically Diverse Middle-Aged and Older Adults • JAMA Neurology • Nov. 14, 2022 • CTSA Program Clinical Impact of ASCO Choosing Wisely Guidelines on Staging Imaging for Early-Stage Breast Cancers: A Time Series Analysis Using SEER-Medicare Data • JCO Oncology Practice • Nov. 14, 2022 • CTSA Program Not All Bone Overuse Injuries Are Stress Fractures: It Is Time for Updated Terminology • British Journal of Sports Medicine • Nov. 14, 2022 • CTSA Program RaMP-DB 2.0: A Renovated Knowledgebase for Deriving Biological and Chemical Insight from Genes, Proteins, and Metabolites • Bioinformatics • Nov. 14, 2022 • RaMP 2.0 Risk of Suicide Attempts and Self-Harm After 1.4 Million General Medical Hospitalizations of Men With Mental Illness • Journal of Psychiatric Research • Nov. 14, 2022 • CTSA Program A Steadier Hand: The First Human Clinical Trial of a Single-Use Robotic-Assisted Surgical Device for Cochlear Implant Electrode Array Insertion • Otology & Neuerotology • Nov. 14, 2022 • CTSA Program Witch Nails (Krt90whnl): A Spontaneous Mouse Mutation Affecting Nail Growth and Development • PLoS One • Nov. 14, 2022 • CTSA Program A Composite Measure of Sleep Health Is Associated With Glycaemic Target Achievement in Young Adults With Type 1 Diabetes • Journal of Sleep Research • Nov. 13, 2022 • CTSA Program The Association Between Preventive Health and Outpatient Spending and Life Expectancy by Income Quartile • International Journal for Equity in Health • Nov. 12, 2022 • CTSA Program High-Throughput 3D Gel-Based Neural Organotypic Model for Cellular Assays Using Fluorescence Biosensors • Communications Biology • Nov. 12, 2022 • HEAL Infertility and Treatments Utilized Have Minimal Effects on First Trimester Placenta DNA Methylation and Gene Expression • Fertility and Sterility • Nov. 12, 2022 • CTSA Program Profiling the Male Germline Genome to Unravel its Reproductive Potential • Fertility and Sterility • Nov. 12, 2022 • CTSA Program Biomarkers of Vitamin D Metabolism and Hip and Vertebral Fracture Risk: The Multi-Ethnic Study of Atherosclerosis • JBMR Plus • Nov. 11, 2022 • CTSA Program Heart and Brain Interactions: Is Small Vessel Disease a Link? • European Heart Journal • Nov. 11, 2022 • CTSA Program The Use of Biological Sensors and Instrumental Analysis to Discriminate COVID-19 Odor Signatures • Biosensors • Nov. 11, 2022 • RADx-RAD, SCENT Clinical and Sociodemographic Factors Associated With Telemedicine Engagement in an Urban Community Health Center Cohort During the COVID-19 Pandemic • Telemedicine and e-Health • Nov. 10, 2022 • CTSA Program Gelatin Coating Enhances Therapeutic Cell Adhesion to the Infarcted Myocardium via ECM Binding • PLoS One • Nov. 10, 2022 • CTSA Program Structural Basis for Inhibition of Mutant EGFR With Lazertinib (YH25448) • ACS Medicinal Chemistry Letters • Nov. 10, 2022 • CTSA Program Anti-Neoplastic Sulfonamides Alter the Metabolic Homeostasis and Disrupt the Suppressor Activity of Regulatory T Cells • Scientific Reports • Nov. 9, 2022 • CTSA Program Disclosing Political Partisanship Polarizes First Impressions of Faces • PLoS One • Nov. 9, 2022 • CTSA Program Parenchymal Border Macrophages Regulate the Flow Dynamics of the Cerebrospinal Fluid • Nature • Nov. 9, 2022 • CTSA Program Proteomic Signatures of the Serological Response to Influenza Vaccination in a Large Human Cohort Study • Viruses • Nov. 9, 2022 • CTSA Program A Transfer Learning Approach to Correct the Temporal Performance Drift of Clinical Prediction Models: Retrospective Cohort Study • JMIR Medical Informatics • Nov. 9, 2022 • CTSA Program Immune-Related Adverse Events in Patients with Pre-Existing Autoimmune Rheumatologic Disease on Immune Checkpoint Inhibitor Therapy • BMC Rheumatology • Nov. 8, 2022 • CTSA Program Ingestible Sensor System for Measuring, Monitoring and Enhancing Adherence to Antiretroviral Therapy: An Open-Label, Usual Care-Controlled, Randomised Trial • eBioMedicine • Nov. 8, 2022 • CTSA Program Using a Learning Health Care System to Advance Nursing and Patient Care • Nurse Leader • Nov. 8, 2022 • CTSA Program Association Between Treatment Failure and Hospitalization After Receipt of Neutralizing Monoclonal Antibody Treatment for COVID-19 Outpatients • BMC Infectious Diseases • Nov. 7, 2022 • CTSA Program A Combined Polygenic Score of 21,293 Rare and 22 Common Variants Improves Diabetes Diagnosis Based On Hemoglobin A1C Levels • Nature Genetics • Nov. 7, 2022 • CTSA Program Copy Number Variants and Fetal Growth in Stillbirths • American Journal of Obstetrics & Gynecology • Nov. 7, 2022 • CTSA Program The Impact of Frailty on Ventral Hernia Repair Outcomes in a Statewide Database • Surgical Endoscopy • Nov. 7, 2022 • CTSA Program Long-Term Kidney Function Recovery and Mortality After COVID-19-Associated Acute Kidney Injury: An International Multi-Centre Observational Cohort Study • eClinicalMedicine • Nov. 7, 2022 • CTSA Program Positive Anxiety or Depression Screen Despite Ongoing Antidepressant Prescription in People with Epilepsy: A Large Cross-Sectional Analysis • Epilepsy & Behavior Reports • Nov. 7, 2022 • CTSA Program Sleep Exerts Lasting Effects on Hematopoietic Stem Cell Function and Diversity • Journal of Experimental Medicine • Nov. 7, 2022 • CTSA Program Methylprednisolone for Heart Surgery in Infants — A Randomized, Controlled Trial • The New England Journal of Medicine • Nov. 6, 2022 • CTSA Program A Computational Study of Aortic Reconstruction In Single Ventricle Patients • Biomechanics and Modeling in Mechanobiology • Nov. 5, 2022 • CTSA Program Epidemiology of Cutaneous Lupus Erythematosus Among Adults over Four Decades (1976-2018): A Lupus Midwest Network (LUMEN) Study • Mayo Clinic Proceedings • Nov. 5, 2022 • CTSA Program Changing Trends of Invasive Pneumococcal Disease in the Era of Conjugate Pneumococcal Vaccination in Olmsted County: A Population-Based Study • Mayo Clinic Proceedings • Nov. 4, 2022 • CTSA Program Discovery of Small Molecule Agonists of the Relaxin Family Peptide Receptor 2 • Communications Biology • Nov. 4, 2022 • Division of Preclinical Innovation (Early Translation Branch) Insights on the Pathogenesis of Type 2 Diabetes as Revealed by Signature Genomic Classifiers in an African American Population in the Washington, DC Area • Diabetes/Metabolism Research and Reviews • Nov. 4, 2022 • CTSA Program Can Non-Directed Living Liver Donation Help Improve Access to Grafts and Correct Socioeconomic Disparities in Pediatric Liver Transplantation? • Pediatric Transplantation • Nov. 3, 2022 • CTSA Program Exome-Wide Association Study to Identify Rare Variants Influencing COVID-19 Outcomes: Results from the Host Genetics Initiative • PLoS Genetics • Nov. 3, 2022 • CTSA Program “Giving the Patients Less Work”: A Thematic Analysis of Telehealth Use and Recommendations to Improve Usability for Autistic Adults • Autism • Nov. 3, 2022 • CTSA Program Interplay of Immunosuppression and Immunotherapy Among Patients with Cancer and COVID-19 • JAMA Oncology • Nov. 3, 2022 • CTSA Program Linking Rivermead Post Concussion Symptoms Questionnaire (RPQ) and Sport Concussion Assessment Tool (SCAT) Scores with Item Response Theory • Journal of the International Neuropsychological Society • Nov. 3, 2022 • CTSA Program Perceptions on Wearable Sensor-Based Interventions for Monitoring of Opioid Therapy: A Qualitative Study • Frontiers in Digital Health • Nov. 3, 2022 • CTSA Program Sleep and Circadian Disturbance in Cardiovascular Risk • Current Cardiology Reports • Nov. 3, 2022 • CTSA Program Socioeconomic Deprivation, Sleep Duration, and Mental Health During the First Year of the COVID-19 Pandemic • International Journal of Environmental Research and Public Health • Nov. 3, 2022 • CTSA Program Temporal Dynamics of Metabolic Acquisition in Grafted Engineered Human Liver Tissue • Advanced Biology • Nov. 3, 2022 • CTSA Program Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness, United States, 2022 • Clinical Infectious Diseases • Nov. 3, 2022 • CTSA Program The Vaccine Hesitancy Continuum Among Hesitant Adopters of the Covid-19 Vaccine • Clinical and Translational Science • Nov. 3, 2022 • CTSA Program Association Between Body Mass Index and Localized Prostate Cancer Management and Disease-Specific Quality of Life • BJUI Compass • Nov. 2, 2022 • CTSA Program Brain Patterns of Pace - But Not Rhythm - Are Associated with Vascular Disease in Older Adults • Cerebral Circulation - Cognition and Behavior • Nov. 2, 2022 • CTSA Program Clinical Characteristics and Outcomes in Patients with Metastatic Breast Cancer and Pseudocirrhosis: A Single Center Retrospective Cohort Study • Breast Cancer Research and Treatment • Nov. 2, 2022 • CTSA Program Feasibility and Safety of Same-Day Discharge Following Single-Port Robotic-Assisted Laparoscopic Prostatectomy • World Journal of Urology • Nov. 2, 2022 • CTSA Program Novel Cardiac Imaging Risk Score for Mortality Prediction in Duchenne Muscular Dystrophy • Pediatric Cardiology • Nov. 2, 2022 • CTSA Program Patient and Health Care Provider Knowledge of Diabetes and Diabetic Microvascular Complications: A Comprehensive Literature Review • Reviews in Endocrine and Metabolic Disorders • Nov. 2, 2022 • CTSA Program Role of Responsive Neurostimulation and Immunotherapy in Refractory Epilepsy Due to Autoimmune Encephalitis: A Case Report • Frontiers in Neurology • Nov. 2, 2022 • CTSA Program Tempo: An Unsupervised Bayesian Algorithm for Circadian Phase Inference in Single-Cell Transcriptomics • Nature Communications • Nov. 2, 2022 • CTSA Program Accuracy in Patient Understanding of Common Medical Phrases • Journal of the American Medical Association • Nov. 1, 2022 • CTSA Program Analysis of Clinical Outcomes of Pregnant Patients Treated With Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection • Journal of the American Medical Association • Nov. 1, 2022 • CTSA Program Are Trauma Surgical Societies Adequately Addressing Mental Health After Injury? • Surgery • Nov. 1, 2022 • CTSA Program Assessing the Impact of Spinal Versus General Anesthesia on Postoperative Urinary Retention in Elective Spinal Surgery Patients • Clinical Neurology and Neurosurgery • Nov. 1, 2022 • CTSA Program Assessment of Dental Health Care Personnel Protocol Deviations and Self-Contamination During Personal Protective Equipment Donning and Doffing • The Journal of the American Dental Association • Nov. 1, 2022 • CTSA Program Association Between Remnant Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Risk of Atherosclerotic Cardiovascular Disease Events in the Multi-Ethnic Study of Atherosclerosis (MESA) • Journal of Clinical Lipidology • Nov. 1, 2022 • CTSA Program Associations Between Saliva and Plasma Cytokines in Cognitively Normal, Older Adults • Aging Clinical and Experimental Research • Nov. 1, 2022 • CTSA Program Association of Incidental Positron Emission Tomography Uptake in the Esophagus to Gastroesophageal Reflux Disease • Clinical Gastroenterology and Hepatology • Nov. 1, 2022 • CTSA Program Attitudes & Practices Surrounding Pregnancy Post Heart Transplant Among Pediatric Providers • The Journal of Heart and Lung Transplantation • Nov. 1, 2022 • CTSA Program Brief Report: Role of Gender-Aaffirming Hormonal Care in HIV Care Continuum Outcomes When Comparing Transgender Women with Cisgender Sexual Minority Men • Journal of Acquired Immune Deficiency Syndromes • Nov. 1, 2022 • CTSA Program Butyrate-Producing Bacteria and Insulin Homeostasis: The Microbiome and Insulin Longitudinal Evaluation Study (MILES) • Diabetes • Nov. 1, 2022 • CTSA Program Centering Health Equity Within Covid-19 Contact Tracing: Connecticut's Community Outreach Specialist Program • Journal of Public Health Management and Practice • Nov. 1, 2022 • CTSA Program Cognitive Outcomes in the Pragmatic Investigation of optimaL Oxygen Targets (CO-PILOT) Trial: Protocol and Statistical Analysis Plan • BMJ Open • Nov. 1, 2021 • CTSA Program Colorectal Neoplasia in Cdh1 Pathogenic Variant Carriers: A Multicenter Analysis • The American Journal of Gastroenterology • Nov. 1, 2022 • CTSA Program Common Human Genetic Variants of APOE Impact Murine Covid-19 Mortality • Nature • Nov. 1, 2022 • CTSA Program Contemporary Management and Outcomes of Peripheral Venous Aneurysms: A Multi-Institutional Study • Journal of Vascular Surgery: Venous and Lymphatic Disorders • Nov. 1, 2022 • CTSA Program Contributions of the NICHD Neonatal Research Network's Generic Database to Documenting and Advancing the Outcomes of Extremely Preterm Infants • Seminars in Perinatology • Nov. 1, 2022 • CTSA Program The Conundrum of Diabetic Neuropathies-Past, Present, and Future • Journal of Diabetes and its Complications • Nov. 1, 2022 • CTSA Program Decreased Levels of Erythrocyte Membrane Arachidonic and Docosahexaenoic Acids Are Associated With Retinopathy of Prematurity • Investigative Ophthalmology & Visual Science • Nov. 1, 2022 • CTSA Program Deep-Learning-Based Hepatic Fat Assessment (DeHFt) on Non-Contrast Chest CT and Its Association With Disease Severity in COVID-19 Infections: A Multi-Site Retrospective Study • eBioMedicine • Nov. 1, 2022 • CTSA Program Disparities in Comorbidities in Lung Cancer: Findings from the Behavioral Risk Factor Surveillance System • Cancer Nursing • Nov. 1, 2022 • CTSA Program Do Interventions Improve Symptoms Among ICU Surrogates Facing End-of-life Decisions? A Prognostically-Enriched Systematic Review and Meta-Analysis • Critical Care Medicine • Nov. 1, 2022 • CTSA Program Does the Levasseur-Merrill Retractor Provide Reliable In Vivo Guidance for the Intraoral Vertical Ramus Osteotomy? • Journal of Oral and Maxillofacial Surgery • Nov. 1, 2022 • CTSA Program The Druggable Transcription Factor Fli-1 Regulates T Cell Immunity and Tolerance in Graft-Versus-Host Disease • The Journal of Clinical Investigation • Nov. 1, 2022 • CTSA Program Economic Analysis of a Single Institutional Review Board Data Exchange Standard In Multisite Clinical Studies • Contemporary Clinical Trials • Nov. 1, 2022 • CTSA Program Efficacy of Ultrasound-Guided Glenohumeral Joint Injections of Leukocyte-Poor Platelet-Rich Plasma Versus Hyaluronic Acid in the Treatment of Glenohumeral Osteoarthritis: A Randomized, Double-Blind Controlled Trial • Clinical Journal of Sport Medicine • Nov. 1, 2022 • CTSA Program Endocrine Surgeons Are Performing More Thyroid Lobectomies for Low-Risk Differentiated Thyroid Cancer Since the 2015 Ata Guidelines • Surgery • Nov. 1, 2022 • CTSA Program Epidemiology of Age-, Sex-, and Race-Specific Hospitalizations for Abdominal Aortic Aneurysms Highlights Gaps in Current Screening Recommendations • Journal of Vascular Surgery • Nov. 1, 2022 • CTSA Program Ethical Issues in the US 1956 National Academy of Sciences BEAR I Genetics Panel Report to the Public • Health Physics • Nov. 1, 2022 • CTSA Program Ethyl EPA and Ethyl DHA Cause Similar and Differential Changes in Plasma Lipid Concentrations and Lipid Metabolism in Subjects With Low-Grade Chronic Inflammation • Journal of Clinical Lipidology • Nov. 1, 2022 • CTSA Program Excess Deaths Will Continue in the United States Until the Root Causes Are Addressed • Health Affairs • Nov. 1, 2022 • CTSA Program Exploring the Interplay Between Mechanisms of Neuroplasticity and Cardiovascular Health in Aging Adults: A Multiple Linear Regression Analysis Study • Autonomic Neuroscience • Nov. 1, 2022 • CTSA Program Factors Associated with Safe Prescription Opioid Disposal After Surgery in Adolescents • Journal of Surgical Research • Nov. 1, 2022 • CTSA Program Impact of Adjunct Testosterone on Cancer-Related Fatigue: An Ancillary Analysis from a Controlled Randomized Trial • Current Oncology • Nov. 1, 2022 • CTSA Program The Impact of Cannabis Packaging Characteristics on Perceptions and Intentions • American Journal of Preventive Medicine • Nov. 1, 2022 • CTSA Program Impact of the FDA Flavour Enforcement Policy on Flavoured Electronic Cigarette Use Behaviour Changes • Tobacco Control • Nov. 1, 2022 • CTSA Program In-Home Covid-19 Testing for Children With Medical Complexity: Feasibility and Association With School Attendance and Safety Perceptions • American Journal of Public Health • Nov. 1, 2022 • CTSA Program Intersectional Stigmas Are Associated with Lower Viral Suppression Rates and Antiretroviral Therapy Adherence Among Women Living with HIV • AIDS • Nov. 1, 2022 • CTSA Program Ivermectin Enhanced Antitumor Activity of Resiquimod in a Co-Loaded Squalene Emulsion • Journal of Pharmaceutical Sciences • Nov. 1, 2022 • CTSA Program “Just Be There”: Desired Partner Behaviors Among Pregnant People Living With Opioid Use Disorder, a Qualitative Study • Journal of Addiction Medicine • Nov. 1, 2022 • CTSA Program Machine Learning Models to Predict 24 Hour Urinary Abnormalities for Kidney Stone Disease • Urology • Nov. 1, 2022 • CTSA Program Models for Zero-Inflated and Overdispersed Correlated Count Data: An Application to Cigarette Use • Nicotine & Tobacco Research • Nov. 1, 2022 • CTSA Program Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled Trial • Chest • Nov. 1, 2022 • CTSA Program ‘Oh, I Don’t Really Want to Bother with That:’ Gay and Bisexual Young Men's Perceptions of Barriers to PrEP Information and Uptake • Culture, Health & Sexuality • Nov. 1, 2021 • CTSA Program Outcomes of Athletes With Genetic Heart Diseases and Implantable Cardioverter-Defibrillators Who Chose to Return to Play • Mayo Clinic Proceedings • Nov. 1, 2022 • CTSA Program Overview of the Cardiovascular Effects of Environmental Metals: New Preclinical and Clinical Insights • Toxicology and Applied Pharmacology • Nov. 1, 2022 • RADx-RAD, SCENT Pathway to Healing and Recovery: Alleviation of Survivor Worries in Sexual Assault Nurse Examiner-Led Sexual Assault Telehealth Examinations • Journal of Emergency Nursing • Nov. 1, 2022 • CTSA Program Perinatal Management: Lessons Learned from the Neonatal Research Network • Seminars in Perinatology • Nov. 1, 2022 • CTSA Program Peripheral CRF-R1/CRF-R2 Antagonist, Astressin C, Induces a Long-Lasting Blockade of Acute Stress-Related Visceral Pain In Male and Female Rats • Peptides • Nov. 1, 2022 • CTSA Program Pharmacological Targeting of Glutamatergic Neurons Within the Brainstem for Weight Reduction • Nature Metabolism • Nov. 1, 2022 • CTSA Program Plasma Protein Alterations During Human Large Vessel Stroke: A Controlled Comparison Study • Toxicology and Applied Pharmacology • Nov. 1, 2022 • CTSA Program Prediction of Drug-Induced Liver Injury and Cardiotoxicity Using Chemical Structure and In Vitro Assay Data • Toxicology and Applied Pharmacology • Nov. 1, 2022 • Tox21 Pre-Hospital Aspirin Use and Patient Outcomes in COVID-19: Results From the International Viral Infection and Respiratory Illness Universal Study (VIRUS) • Archivos de Bronconeumología • Nov. 1, 2022 • CTSA Program Prophylactic Ureteral Stent Placement and Urinary Injury During Hysterectomy for Placenta Accreta Spectrum • Obstetrics & Gynecology • Nov. 1, 2022 • CTSA Program Proteomics, Dietary Intake, and Changes in Cardiometabolic Health Within a Behavioral Weight-Loss Intervention: A Pilot Study • Obesity • Nov. 1, 2022 • CTSA Program Racial and Ethnic Differences in Maternal Social Support and Relationship to Mother-Infant Health Behaviors • Academic Pediatrics • Nov. 1, 2022 • CTSA Program Retinal Toxicity in a Multinational Inception Cohort of Patients with Systemic Lupus on Hydroxychloroquine • Lupus Science & Medicine • Nov. 1, 2022 • CTSA Program Risk of Advanced Fibrosis in First-Degree Relatives of Patients With Nonalcoholic Fatty Liver Disease • The Journal of Clinical Investigation • Nov. 1, 2022 • CTSA Program Robust Method for Screening Sleep Apnea With Single-Lead ECG Using Deep Residual Network: Evaluation With Open Database and Patch-Type Wearable Device Data • IEEE Journal of Biomedical and Health Informatics • Nov. 1, 2022 • CTSA Program School-Age Children’s Wellbeing and School-Related Needs During the COVID-19 Pandemic • Academic Pediatrics • Nov. 1, 2022 • CTSA Program Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem • Transplantation and Cellular Therapy • Nov. 1, 2022 • CTSA Program Sensor-Based Surveillance for Digitising Real-Time COVID-19 Tracking in the USA (DETECT): A Multivariable, Population-Based, Modelling Study • The Lancet Digital Health • Nov. 1, 2022 • CTSA Program Social Withdrawal in Parkinson's Disease: A Scoping Review • Geriatric Nursing • Nov. 1, 2022 • CTSA Program Spoken Language Comprehension in Children and Adults with Angelman Syndrome • Journal of Communication Disorders • Nov. 1, 2022 • CTSA Program Substance Use Disorders and Social Determinants of Health From Electronic Medical Records Obtained During Kentucky’s “Triple Wave” • Pharmacology Biochemistry and Behavior • Nov. 1, 2022 • CTSA Program Supply Chain Disruptions During COVID-19 Pandemic Uncover Differences in Keratinocyte Culture Media • JID Innovations • Nov. 1, 2022 • CTSA Program T Cells Specific for α-Myosin Drive Immunotherapy-Related Myocarditis • Nature • Nov. 1, 2022 • CTSA Program Textbook Outcome in Lung Transplantation: Planned Venoarterial Extracorporeal Membrane Oxygenation Versus Off-Pump Support for Patients Without Pulmonary Hypertension • The Journal of Heart and Lung Transplantation • Nov. 1, 2022 • CTSA Program TLR-Activated Mesenchymal Stromal Cell Therapy and Antibiotics to Treat Multi-Drug Resistant Staphylococcal Septic Arthritis in an Equine Model • Annals of Translational Medicine • Nov. 1, 2022 • CTSA Program Treatment Patterns and Health Care Resource Utilization of Iatrogenic Spinal Cerebrospinal Fluid Leaks in the United States • Clinical Spine Surgery • Nov. 1, 2022 • CTSA Program Unintended Consequences of Covid-19 on Pediatric Falls from Windows: A Multicenter Study • Journal of Surgical Research • Nov 1, 2022 • CTSA Program Utilizing Community Partnerships to Devise a Framework for Cultural Adaptations to Evidence-Based Mental Health Practice in Diverse Communities • Cognitive and Behavioral Practice • Nov. 1, 2022 • CTSA Program Validation and Recalibration of Modified Mayo Delirium Prediction Tool in a Hospitalized Cohort • Journal of the Academy of Consultation-Liaison Psychiatry • Nov. 1, 2022 • CTSA Program A Vascular Quality Initiative Frailty Assessment Predicts Postdischarge Mortality in Patients Undergoing Arterial Reconstruction • Journal of Vascular Surgery • Nov. 1, 2022 • CTSA Program October 2022 Bottlenecks and Solutions During Implementation of the Dreams Program for Adolescent Girls and Young Women in Namibia • Global Health: Science and Practice • Oct. 31, 2022 • CTSA Program A Comprehensive Survey of Collaborative Biostatistics Units in Academic Health Centers • Stat • Oct. 31, 2022 • CTSA Program Development and Calibration Data for the Healthcare Access Item Bank: A New Computer Adaptive Test for Persons with Type 2 Diabetes Mellitus • Quality of Life Research • Oct. 31, 2022 • CTSA Program Inclusion of Non-English-Speaking Participants in Pediatric Health Research: A Review • JAMA Pediatrics • Oct. 31, 2022 • CTSA Program Real World Population Pharmacokinetic Study in Children and Young Adults with Inflammatory Bowel Disease Discovers Novel Blood and Stool Microbial Predictors of Vedolizumab Clearance • Alimentary Pharmacology & Therapeutics • Oct. 31, 2022 • CTSA Program Sleep Apnea and Carotid Atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA): Leveraging State-of-the-Art Vascular Imaging • The International Journal of Cardiovascular Imaging • Oct. 31, 2022 • CTSA Program Third Trimester Fetuses Demonstrate Priming, a Form of Implicit Memory, In Utero • Children • Oct. 31, 2022 • CTSA Program Timing Is Everything: Surgical Outcomes for SARS-CoV-2 Positive Patients • World Journal of Surgery • Oct. 31, 2022 • CTSA Program Development and Calibration Data for the Medication Adherence Item Bank: A New Computer Adaptive Test for Persons with Type 2 Diabetes Mellitus • Quality of Life Research • Oct. 28, 2022 • CTSA Program Hyperkyphosis and Mortality Risk in Older Men: The Osteoporotic Fractures in Men Study • Journal of the American Geriatrics Society • Oct. 28, 2022 • CTSA Program Hypocalcemia After Parathyroidectomy In Patients With a History of Bariatric Surgery • Endocrine • Oct. 28, 2022 • CTSA Program Telemedicine Across the Continuum of Neonatal-Perinatal Care • Seminars in Fetal & Neonatal Medicine • Oct. 28, 2022 • CTSA Program Challenges and Opportunities Associated with the MD Anderson IMPACT2 Randomized Study in Precision Oncology • npj Precision Oncology • Oct. 27, 2022 • CTSA Program Differential Mosquito Attraction to Humans is Associated with Skin-Derived Carboxylic Acid Levels • Cell • Oct. 27, 2021 • CTSA Program Federated Learning for Preserving Data Privacy in Collaborative Healthcare Research • Digital Health • Oct. 27, 2022 • CTSA Program The Instrumented Stand and Walk (ISAW) Test To Predict Falls In Older Men • GeroScience • Oct. 27, 2022 • CTSA Program Neurocognition as a Biomarker in the Rare Autonomic Disorders of CCHS and ROHHAD • Clinical Autonomic Research • Oct. 27, 2022 • CTSA Program Age-Related Skull Fracture Patterns in Infants After Low-Height Falls • Pediatric Research • Oct. 26, 2022 • CTSA Program Cancer Screening and Breast Cancer Family History in Spanish-Speaking Hispanic/Latina Women in California • Frontiers in Oncology • Oct. 26, 2022 • CTSA Program Costs Attributable to Clostridioides difficile Infection Based on the Setting of Onset • Clinical Infectious Diseases • Oct. 26, 2022 • CTSA Program Genetic Variants Associated with Circulating Liver Injury Markers in Mexican Americans, a Population at Risk for Non-Alcoholic Fatty Liver Disease • Frontiers in Genetics • Oct. 26, 2022 • CTSA Program Revealing β-TrCP Activity Dynamics in Live Cells with a Genetically Encoded Biosensor • Nature Communications • Oct. 26, 2022 • Division of Preclinical Innovation Development and Calibration Data for the Illness Burden Item Bank: A New Computer Adaptive Test for Persons with Type 2 Diabetes Mellitus • Quality of Life Research • Oct. 25, 2022 • CTSA Program A GABA-Receptor Agonist Reduces Pneumonitis Severity, Viral Load, and Death Rate in SARS-CoV-2-Infected Mice • Frontiers in Immunology • Oct. 25, 2022 • CTSA Program Multiparameter Analysis of Human B Lymphocytes Identifies Heterogeneous CD19+ CD21lo Subsets • Cytometry Part A • Oct. 25, 2022 • CTSA Program Association Between High-Risk Extracranial Carotid Plaque and Covert Brain Infarctions and Cerebral Microbleeds • Neuroradiology • Oct. 24, 2022 • CTSA Program A Combined Polygenic Score of 21,293 Rare and 22 Common Variants Improves Diabetes Diagnosis Based on Hemoglobin A1C Levels • Nature Genetics • Oct. 24, 2022 • CTSA Program Continuous Glucose Monitor, Insulin Pump, and Automated Insulin Delivery Therapies for Type 1 Diabetes: an Update On Potential for Cardiovascular Benefits • Current Cardiology Reports • Oct. 24, 2022 • CTSA Program Oxygen-Saturation Targets for Critically Ill Adults Receiving Mechanical Ventilation • The New England Journal of Medicine • Oct. 24, 2022 • CTSA Program Sex-Specific Inflammatory and White Matter Effects of Prenatal Opioid Exposure: A Pilot Study • Pediatric Research • Oct. 24, 2022 • CTSA Program Tone in Noise Detection in Children with a History of Temporary Conductive Hearing Loss • Journal of the Association for Research in Otolaryngology • Oct. 24, 2022 • CTSA Program Evaluation of Dundee and Alt-70 Predictive Models for Cellulitis In 56 Patients Who Underwent Tissue Culture • Archives of Dermatological Research • Oct. 23, 2022 • CTSA Program Leveraging Patient Derived Models of FGFR2 Fusion Positive Intrahepatic Cholangiocarcinoma to Identify Synergistic Therapies • npj Precision Oncology • Oct. 23, 2022 • CTSA Program Reversal of Cancer Gene Expression Identifies Repurposed Drugs for Diffuse Intrinsic Pontine Glioma • Acta Neuropathologica Communications • Oct. 23, 2022 • NCATS Matrix Clinical “Red Flags” Differentiating Delayed Puberty From Enduring Hypogonadism • The Journal for Nurse Practitioners • Oct. 22, 2022 • Rare Diseases Identifying Barriers, Facilitators, and Interventions to Support Healthy Eating in Pregnant Women With or at Risk for Hypertensive Disorders of Pregnancy • Cardiovascular Digital Health Journal • Oct. 22, 2022 • CTSA Program Impact of Concomitant Fluconazole on Direct Oral Anticoagulant Bleeding Risk • Pharmacotherapy • Oct. 22, 2022 • CTSA Program Scalp Biomarkers During Dupilumab Treatment Support Th2 Pathway Pathogenicity in Alopecia Areata • Allergy • Oct. 22, 2022 • CTSA Program Use of a Real-Time Risk-Prediction Model to Identify Pediatric Patients at Risk for Thromboembolic Events: Study Protocol for the Children’s Likelihood Of Thrombosis (CLOT) Trial • Trials • Oct. 22, 2022 • CTSA Program Use of Anti-Glycopeptidolipid-Core Antibodies Serology for Diagnosis and Monitoring of Mycobacterium avium Complex Pulmonary Disease in the United States • Open Forum Infectious Diseases • Oct. 22, 2022 • CTSA Program A Comprehensive Update on CIDO: The Community-Based Coronavirus Infectious Disease Ontology • Journal of Biomedical Semantics • Oct. 21, 2022 • CTSA Program Detection of Dynamic Changes in Interaural Delay by Older Adults (L) • The Journal of the Acoustical Society of America • Oct. 21, 2022 • CTSA Program Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial • Journal of the American Medical Association • Oct. 21, 2022 • CTSA Program Impact of COVID-19 on Children’s Attention Deficit Hyperactivity Disorder Symptomology, Daily Life, and Problem Behavior During Virtual Learning • Mind, Brain, and Education • Oct. 21, 2022 • CTSA Program Longitudinal Assessment of Preparation for Care Transition Among Adolescents and Young Adults with Rheumatologic Disease: A Single-Center Pilot Study • Pediatric Rheumatology • Oct. 21, 2022 • CTSA Program Neurodevelopment in Unilateral Coronal Craniosynostosis: A Systematic Review and Meta-Analysis • Journal of Neurosurgery: Pediatrics • Oct. 21, 2022 • CTSA Program Powassan Virus Induces Structural Changes in Human Neuronal Cells In Vitro and Murine Neurons In Vivo • Pathogens • Oct. 21, 2022 • CTSA Program Racial Differences in the Impact of Maternal Smoking on Sudden Unexpected Infant Death • Journal of Perinatology • Oct. 21, 2022 • CTSA Program Reproductive Phenotypes and Genotypes in Men with IHH • The Journal of Clinical Endocrinology & Metabolism e • Oct. 21, 2022 • Rare Diseases Characterization of Errors in Retinopathy of Prematurity Diagnosis by Ophthalmologists-in-Training in the United States and Canada • Journal of Pediatric Ophthalmology & Strabismus • Oct. 20, 2022 • CTSA Program Factors Associated With HPV Vaccine Adherence Among Latino/a Adolescents In a Rural, Texas-mexico Border County • Ethnicity & Disease • Oct. 20, 2022 • CTSA Program Heightened Sensitivity to the Disinhibiting Effect of Alcohol in Women During the Late Follicular Phase of the Menstrual Cycle • Experimental and Clinical Psychopharmacology • Oct. 20, 2022 • CTSA Program Injectable pH Thermo-Responsive Hydrogel Scaffold for Tumoricidal Neural Stem Cell Therapy for Glioblastoma Multiforme • Pharmaceutics • Oct. 20, 2022 • CTSA Program Relationship Between Neighborhood Socioeconomic Disadvantage and Severe Maternal Morbidity and Maternal Mortality • Ethnicity & Disease • Oct. 20, 2022 • CTSA Program Efficient and Safe Single-Cell Cloning of Human Pluripotent Stem Cells Using the CEPT Cocktail • Nature Protocols • Oct. 19, 2022 • Division of Preclinical Innovation (Stem Cell Translation Laboratory) Racial Inequities in Access to Ventricular Assist Device and Transplant Persist After Consideration for Preferences for Care: A Report from the REVIVAL Study • Circulation: Heart Failure • Oct. 19, 2022 • CTSA Program Bayesian Model Averaging to Account for Model Uncertainty in Estimates of a Vaccine’s Effectiveness • Clinical Epidemiology • Oct. 18, 2022 • CTSA Program Contemplative Practices Behavior Is Positively Associated with Well-Being in Three Global Multi-Regional Stanford WELL for Life Cohorts • International Journal of Environmental Research and Public Health • Oct. 18, 2022 • CTSA Program Evaluation of Wear Experience with Soft Daily Disposable Lenses for Astigmatism over 16 Hours of Wear • Clinical Optometry • Oct. 18, 2022 • CTSA Program Invariant Structural and Functional Brain Regions Associated with Tinnitus: A Meta-Analysis • PLoS One • Oct. 18, 2022 • CTSA Program Prevalence and Risk Factors Associated with Readmission with Acute Kidney Injury in Patients Receiving Vancomycin Outpatient Parenteral Antimicrobial Therapy • Journal of Clinical Pharmacy and Therapeutics • Oct. 18, 2022 • CTSA Program Systematic Review of International Studies Evaluating MDRD and CKD-EPI Estimated Glomerular Filtration Rate (eGFR) Equations in Black Adults • PLoS One • Oct. 18, 2022 • CTSA Program Discovery of Small Molecule Inhibitors That Effectively Disrupt IQGAP1-Cdc42 Interaction in Breast Cancer Cells • Scientific Reports • Oct. 17, 2022 • Division of Preclinical Innovation Gender-Affirming Chest Reconstruction Among Transgender and Gender-Diverse Adolescents in the US From 2016 to 2019 • JAMA Pediatrics • Oct. 17, 2022 • CTSA Program The NCATS Assay Guidance Manual Programme: Advancing the Practice and Rigour of Preclinical Translation • Nature Reviews Drug Discovery • Oct. 17, 2022 • Assay Guidance Manual Stimulus- and Person-level Variables Influence Word Production and Response to Anomia Treatment for Individuals with Chronic Poststroke Aphasia • Journal of Speech, Language, and Hearing Research • Oct. 17, 2022 • CTSA Program Neurosarcoidosis in Children: A Systematic Review and Summary of Cases, Imaging and Management • Journal of Neuroimmunology • Oct. 15, 2022 • CTSA Program A Quality Framework to Address Racial and Ethnic Disparities in Emergency Department Care • Annals of Emergency Medicine • Oct. 15, 2022 • CTSA Program Circulating IL-10 Is Associated with Reduced Risk of Prostate Cancer in a Prospective Cohort of Elderly Men: The MrOS Study • Cancer Causes & Control • Oct. 14, 2022 • CTSA Program Development and Initial Testing of Together-ya: an Ehealth-Delivered and Group-Based Psychosocial Intervention for Young Adult Cancer Survivors • Supportive Care in Cancer • Oct. 14, 2022 • CTSA Program Effect of Endoscopic Sleeve Gastroplasty on Gastric Emptying, Motility and Hormones: A Comparative Prospective Study • Gut • Oct. 14, 2022 • CTSA Program Quantitative Epileptiform Burden and Electroencephalography Background Features Predict Post-Traumatic Epilepsy • Journal of Neurology, Neurosurgery and Psychiatry • Oct. 14, 2022 • CTSA Program A Single Nucleotide Polymorphism In Sh2b3/lnk Promotes Hypertension Development and Renal Damage • Circulation Research • Oct. 14, 2022 • CTSA Program Validation of an Intensive Care Unit Data Mart for Research and Quality Improvement • Journal of Medical Systems • Oct. 14, 2022 • CTSA Program Blocking Domain 6 of High Molecular Weight Kininogen to Understand Intrinsic Clotting Mechanisms • Research and Practice in Thrombosis and Haemostasis • Oct. 13, 2022 • CTSA Program Estimating Microbial Population Data from Optical Density • PLoS One • Oct. 13, 2022 • CTSA Program Incidence, Prevalence, and Mortality of Lupus Nephritis: A Population-Based Study Over Four Decades Using the Lupus Midwest Network • Arthritis & Rheumatology • Oct. 13, 2022 • CTSA Program An Open-Label Study Evaluating the Safety, Behavioral, and Electrophysiological Outcomes of Low-Dose Ketamine in Children with ADNP Syndrome Human Genetics and Genomics Advances • Oct. 13, 2022 • Biomedical Data Translator Reflective Functioning in Mothers with Addictions: Differential Relationships Involving Family History of Mental Illness and Substance Use • Frontiers in Psychology • Oct. 13, 2022 • CTSA Program Risk of Venous Thromboembolism in Pediatric Hospitalized Patients Undergoing Noncardiac Surgery: A Report from the Children's Hospital-Acquired Thrombosis Consortium • Research and Practice in Thrombosis and Haemostasis • Oct. 13, 2022 • CTSA Program Suitability of Automated Writing Measures for Clinical Trial Outcome In Writer's Cramp • Movement Disorders • Oct. 13, 2022 • CTSA Program Taking the Good with the Bad?: Social Media and Online Racial Discrimination Influences on Psychological and Academic Functioning in Black and Hispanic Youth • Journal of Youth and Adolescence • Oct. 13, 2022 • CTSA Program Decoding the Transcriptome of Calcified Atherosclerotic Plaque at Single-cell Resolution • Communications Biology • Oct. 12, 2022 • CTSA Program Patient-Reported Outcomes via Electronic Health Record Portal Versus Telephone: A Pragmatic Randomized Pilot Trial of Anxiety or Depression Symptoms in Epilepsy • JAMIA Open • Oct. 12, 2022 • CTSA Program Metformin's Impact on the Microvascular Response to Insulin • Endocrinology • Oct. 11, 2022 • CTSA Program Predictors of Anxiety in Parkinson's Disease: Results from a 3-Year Longitudinal Cohort Study • Neurological Sciences • Oct. 11, 2022 • CTSA Program Testing the Limit: Evaluating Drinking Water Arsenic Regulatory Levels Based on Adverse Pregnancy Outcomes in Bangladesh • Toxics • Oct. 11, 2022 • CTSA Program Artificial Immune Cell, AI-Cell, a New Tool to Predict Interferon Production by Peripheral Blood Monocytes In Response to Nucleic Acid Nanoparticles • Small • Oct. 10, 2022 • Division of Preclinical Innovation A Comprehensive SARS-CoV-2–Human Protein–Protein Interactome Reveals COVID-19 Pathobiology and Potential Host Therapeutic Targets • Nature Biotechnology • Oct. 10, 2022 • COVID-19 OpenData Portal Established Outpatient Care and Follow-Up After Acute Psychiatric Service Use Among Youths and Young Adults • Psychiatric Services • Oct. 10, 2022 • CTSA Program Incidence and Management of Facial Paralysis After Skull Base Trauma, an Administrative Database Study • Otology & Neurotology • Oct. 10, 2022 • CTSA Program Tumor Microbiome Links Cellular Programs and Immunity in Pancreatic Cancer • Cancer Cell • Oct. 10, 2022 • CTSA Program Amygdala-Prefrontal Connectivity in Children with Maladaptive Aggression Is Modulated by Social Impairment • Cerebral Cortex • Oct. 8, 2022 • CTSA Program Barriers to Completion of Cascade Genetic Testing: How Can We Improve the Uptake of Testing for Hereditary Breast and Ovarian Cancer Syndrome? • Familial Cancer • Oct. 8, 2022 • CTSA Program Cardiac Masses (from a 15-Year Experience with 389 Surgical Cases) • The American Journal of Cardiology • Oct. 7, 2022 • CTSA Program The Effect of the COVID-19 Pandemic on Community Violence in Connecticut • The American Journal of Surgery • Oct. 7, 2022 • CTSA Program Heroin Use Is Associated with Vascular Inflammation in HIV • Clinical Infectious Diseases • Oct. 7, 2022 • CTSA Program Human Immunodeficiency Virus Pre-Exposure Prophylaxis Knowledge, Attitudes, and Self-Efficacy Among Family Planning Providers in the Southern United States: Bridging the Gap in Provider Training • Open Forum Infectious Diseases • Oct. 7, 2022 • CTSA Program Lung Mitochondrial DNA Copy Number, Inflammatory Biomarkers, Gene Transcription and Gene Methylation in Vapers and Smokers • eBioMedicine • Oct. 7, 2021 • CTSA Program Relation Between Dietary Protein Intake and Gut Microbiome Composition in Community-Dwelling Older Men: Findings from the Osteoporotic Fractures in Men Study (MrOS) • The Journal of Nutrition • Oct. 7, 2022 • CTSA Program Addressing Drivers of Healthcare Utilization for Neonatal Opioid Withdrawal Syndrome • Journal of Perinatology • Oct. 6, 2021 • CTSA Program Disparities in Head and Neck Cancer Incidence and Trends by Race/Ethnicity and Sex • Head & Neck • Oct. 6, 2022 • CTSA Program Variation in Provider Compliance with Sports Restriction Guidelines in Children with an Isolated Bicuspid Aortic Valve • Cardiology in the Young • Oct. 6, 2022 • CTSA Program Healthcare Utilization for Medicaid-Insured Children with Medical Complexity: Differences by Sociodemographic Characteristics • Maternal and Child Health Journal • Oct. 5, 2022 • CTSA Program Immediate Switching to Reduced Nicotine Cigarettes in a U.S.-Based Sample: The Impact on Cannabis Use and Related Variables at 20 Weeks • Nicotine & Tobacco Research • Oct. 5, 2022 • CTSA Program Outcomes from a Randomized Trial of a Bilingual mHealth Social Media Intervention to Increase Care Engagement Among Young Gay, Bisexual, and Other Men Who Have Sex with Men and Transgender Women with HIV • Health Education & Behavior • Oct. 5, 2022 • CTSA Program Reproductive Healthcare for Adolescent Females Prescribed Mycophenolate at a Children’s Hospital: A 10-year Retrospective Cohort Study • The Journal of Pediatrics • Oct. 5, 2021 • CTSA Program Association of Hurried Communication and Low Patient Self-Efficacy With Persistent Nonadherence to Lupus Medications • Arthritis Care & Research • Oct. 4, 2022 • CTSA Program Accelerated Approvals Hit the Target in Precision Oncology • Nature Medicine • Oct. 3, 2022 • CTSA Program Assessing Patient Barriers to Cochlear Implantation • Otology & Neuerotology • Oct. 3, 2021 • CTSA Program Association of Bariatric Surgery with Cardiovascular Outcomes in Adults with Severe Obesity and Nonalcoholic Fatty Liver Disease • Journal of the American Medical Association • Oct. 3, 2022 • NCATS Energy Intake Estimation Using a Novel Wearable Sensor and Food Images in a Laboratory (Pseudo-Free-Living) Meal Setting: Quantification and Contribution of Sources of Error • International Journal of Obesity • Oct. 3, 2022 • CTSA Program A Genetics-First Approach to Understanding Autism and Schizophrenia Spectrum Disorders: The 22q11.2 Deletion Syndrome • Molecular Psychiatry • Oct. 3, 2022 • CTSA Program HIV and Cardiac End-Organ Damage in Women: Findings from an Echocardiographic Study Across the United States • Clinical Infectious Diseases • Oct. 3, 2022 • CTSA Program Hospital Trajectories and Early Predictors of Clinical Outcomes Differ Between SARS-CoV-2 and Influenza Pneumonia • eBioMedicine • Oct. 3, 2021 • CTSA Program Standardization of Outcome Measures for Intratympanic Steroid Treatment for Idiopathic Sudden Sensorineural Hearing Loss • Otology & Neuerotology • Oct. 3, 2021 • CTSA Program Association of Blood Pressure Variability with Short- and Long-Term Cognitive Outcomes in Patients with Critical Illness • Journal of Critical Care • Oct. 1, 2022 • CTSA Program Association of Volume Status During Veno-Venous Extracorporeal Membrane Oxygenation with Outcome • ASAIO Journal • Oct. 1, 2022 • CTSA Program Community Health Workers and Precision Medicine: A Randomized Controlled Trial • Contemporary Clinical Trials • Oct. 1, 2022 • CTSA Program Comparing Minimally Invasive Sacrocolpopexy With Vaginal Uterosacral Ligament Suspension: A Multicenter Retrospective Cohort Study Through the Fellows’ Pelvic Research Network • Urogynecology • Oct. 1, 2022 • CTSA Program A Comparison of Patient- and Clinician-reported Acute Toxic Effects During Radiation Therapy for Primary Breast Cancer • International Journal of Radiation Oncology - Biology - Physics • Oct. 1, 2022 • CTSA Program Continuous Glucose Monitoring-Guided Insulin Administration in Hospitalized Patients With Diabetes: A Randomized Clinical Trial • Diabetes Care • Oct. 1, 2022 • CTSA Program Culturing Explants for Cutibacterium at Revision Shoulder Arthroplasty: An Analysis of Explant and Tissue Samples at Corresponding Anatomic Sites • Journal of Shoulder and Elbow Surgery • Oct. 1, 2022 • CTSA Program Determinants of Initial Insulin Therapy for Hospitalized Patients with Diabetes Mellitus • Journal of Diabetes and its Complications • Oct. 1, 2022 • CTSA Program Early Life Trauma and Social Processing In HIV: The Role of Neuroendocrine Factors and Inflammation • Psychosomatic Medicine • Oct. 1, 2022 • CTSA Program Effects of Gonadal Steroids on Reward Circuitry Function and Anhedonia in Women With a History of Postpartum Depression • Journal of Affective Disorders • Oct. 1, 2022 • CTSA Program Gadolinium-Based Contrast Agent Exposures and Physical and Cognitive Disability in Multiple Sclerosis • Journal of Neuroimaging • Oct. 1, 2022 • CTSA Program Glucocorticoid Receptor Function and Cognitive Performance in Women With HIV • Psychosomatic Medicine • Oct. 1, 2022 • CTSA Program Health-Related Quality of Life iIn Young Adult Survivors of Hematopoietic Cell Transplantation • Transplantation and Cellular Therapy • Oct. 1, 2022 • CTSA Program Hypertension in Cancer Survivors: A Review of the Literature and Suggested Approach to Diagnosis and Treatment • Journal of Cardiovascular Pharmacology • Oct. 1, 2022 • CTSA Program Impact of Demographics and Clinical Features on Initial Treatment Pathway for Vestibular Schwannoma • Otology & Neurotology • Oct. 1, 2022 • CTSA Program Improving Head CT Scan Decisions for Pediatric Minor Head Trauma in General Emergency Departments: A Pragmatic Implementation Study • Annals of Emergency Medicine • Oct. 1, 2022 • CTSA Program Insulin Resistance, Hyperglycemia, and Risk of Developing Obstructive Sleep Apnea in Men and Women in the United States • Annals of the American Thoracic Society • Oct. 1, 2022 • CTSA Program Interpretive Methodologies in Qualitative Nursing Research • American Journal of Nursing • Oct. 1, 2022 • CTSA Program A Mechanistic Clinical Trial Using (R)- Versus (S)-Propafenone to Test RyR2 (Ryanodine Receptor) Inhibition for the Prevention of Atrial Fibrillation Induction • Circulation: Arrhythmia and Electrophysiology • Oct. 1, 2022 • CTSA Program More-to-Less Home Healthful Foods Ratio Is Associated With Diet Quality in Preadolescents With Elevated Body Mass Index • Journal of Nutrition Education and Behavior • Oct. 1, 2022 • CTSA Program Nasopharyngeal Airway Dual-Transcriptome of Infants with Severe Bronchiolitis and Risk of Childhood Asthma: A Multicenter Prospective Study • Journal of Allergy and Clinical Immunology • Oct. 1, 2022 • CTSA Program Nonsupercharged Retrosternal Roux-en-y Esophagojejunostomy for Distal Esophageal Reconstruction • The Annals of Thoracic Surgery • Oct. 1, 2022 • CTSA Program Outpatient Clinic Attendance and Outcomes Among Patients Hospitalized with Diabetic Foot Ulcers • Journal of Diabetes and its Complications • Oct. 1, 2022 • CTSA Program Pain Is Associated with Depressive Symptoms, Inflammation, and Poorer Physical Function in Older Adults with HIV • Psychosomatic Medicine • Oct. 1, 2022 • CTSA Program Patterns of Use, Outcomes, and Resource Utilization Among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas • Transplantation and Cellular Therapy • Oct. 1, 2022 • CTSA Program Peanuts as a Nighttime Snack Enrich Butyrate-Producing Bacteria Compared to an Isocaloric Lower-Fat Higher-Carbohydrate Snack in Adults with Elevated Fasting Glucose: A Randomized Crossover Trial • Clinical Nutrition • Oct. 1, 2022 • CTSA Program Preclinical Evaluation of a Hypotonic Docetaxel Nanosuspension Formulation for Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer • Drug Delivery and Translational Research • Oct. 1, 2022 • CTSA Program Predictors of Clinical Outcomes of Pharmacomechanical Catheter-Directed Thrombolysis for Acute Iliofemoral Deep Vein Thrombosis: Analysis of a Multicenter Randomized Trial • Implementation Science Communications • Oct. 1, 2022 • CTSA Program Prenatal Choline, Cannabis, and Infection, and Their Association With Offspring Development of Attention and Social Problems Through 4 Years of Age • Psychological Medicine • Oct. 1, 2022 • CTSA Program Preoperative Predictors of Complex Regional Pain Syndrome Outcomes in the 6 Months Following Total Knee Arthroplasty • The Journal of Pain • Oct. 1, 2022 • CTSA Program Primary vs. Salvage Liver Transplantation for Biliary Atresia: A Retrospective Cohort Study • Journal of Pediatric Surgery • Oct. 1, 2022 • CTSA Program Regulation of Placental Efflux Transporters During Pregnancy Complications • Drug Metabolism and Disposition • Oct. 1, 2022 • CTSA Program Rising Hemoglobin A1c in the Nondiabetic Range Predicts Progression of Type 1 Diabetes As Well As Oral Glucose Tolerance Tests • Diabetes Care • Oct. 1, 2022 • CTSA Program Sex-Specific Pathways Lead to Statural Growth Impairment in Children With Crohn's Disease • The Journal of Pediatrics • Oct. 1, 2022 • CTSA Program Smartphone-Guided Self-Prone Positioning vs Usual Care in Nonintubated Hospital Ward Patients With COVID-19: A Pragmatic Randomized Clinical Trial • Chest • Oct. 1, 2022 • CTSA Program Social Risk Factors Influence Pediatric Emergency Department Utilization and Hospitalizations • The Journal of Pediatrics • Oct. 1, 2022 • CTSA Program Spectrum and Prevalence of Side Effects and Complications With Guideline-Directed Therapies for Congenital Long QT Syndrome • Heart Rhythm • Oct. 1, 2022 • CTSA Program Survmaximin: Robust Federated Approach to Transporting Survival Risk Prediction Models • Journal of Biomedical Informatics • Oct. 1, 2022 • CTSA Program T Cells Dominate Peripheral Inflammation in a Cross-Sectional Analysis of Obesity-Associated Diabetes • Obesity • Oct. 1, 2022 • CTSA Program Temporal Order of Clinical and Biomarker Changes in Familial Frontotemporal Dementia • Nature Medicine • Oct. 1, 2022 • RDCRN The Trichloroethylene Metabolite S-(1,2-Dichlorovinyl)-l-Cysteine Inhibits Lipopolysaccharide-Induced Inflammation Transcriptomic Pathways and Cytokine Secretion in a Macrophage Cell Model • Toxicology in Vitro • Oct. 1, 2022 • CTSA Program September 2022 Extracts of the Medicinal Plants Pao Pereira and Rauwolfia vomitoria Inhibit Ovarian Cancer Stem Cells In Vitro • Integrative Cancer Therapies • Sept. 30, 2022 • NCATS Five-Factor Model Personality Traits and the Trajectory of Episodic Memory: Individual-Participant Meta-Analysis of 471,821 Memory Assessments from 120,640 Participants • The Journal of Gerontology, Series B: Psychological Sciences and Social Sciences • Sept. 30, 2022 • CTSA Program Public Attitudes Toward Pharmacogenomic Testing and Establishing a Statewide Pharmacogenomics Database in the State of Minnesota • Journal of Personalized Medicine • Sept. 30, 2022 • CTSA Program Combined Structural Analysis and Molecular Dynamics Reveal Penicillin-Binding Protein Inhibition Mode with β-Lactones • ACS Chemical Biology • Sept. 29, 2022 • CTSA Program Combining Cytotoxic Agents with Continuous Dose Levels in Seamless Phase I-ii Clinical Trials • DeepAI • Sept. 29, 2022 • CTSA Program Depletion of CD4 and CD8 T Cells Reduces Acute Disease and Is Not Associated with Hearing Loss in ML29-Infected STAT1-/- Mice • Biomedicines • Sept. 29, 2022 • CTSA Program Organic Anion Transporters (OAT) and Other SLC22 Transporters in Progression of Renal Cell Carcinoma • Cancers (Basel) • Sept. 29, 2022 • CTSA Program Reducing Uncertainty in Cancer Risk Estimation for Patients with Indeterminate Pulmonary Nodules Using an Integrated Deep Learning Model • Computers in Biology and Medicine • Sept. 29, 2022 • CTSA Program Causal Analysis Identifies Small HDL Particles and Physical Activity as Key Determinants of Longevity of Older Adults • eBioMedicine • Sept. 28, 2021 • CTSA Program Machine Learning in the Management of Lateral Skull Base Tumors: A Systematic Review • Journal of Otorhinolaryngology, Hearing and Balance Medicine • Sept. 28, 2022 • CTSA Program Prenatal Immune Stress Blunts Microglia Reactivity, Impairing Neurocircuitry • Nature • Sept. 28, 2022 • CTSA Program Blood Pressure and Later-Life Cognition in Hispanic and White Adults (BP-COG): A Pooled Cohort Analysis of ARIC, CARDIA, CHS, FOS, MESA, and NOMAS • Journal of Alzheimer's Disease • Sept. 27, 2022 • CTSA Program Genetic Contribution to Cancer Risk in Patients with Tooth Loss: A Genetic Association Study • Scientific Reports • Sept. 27, 2022 • CTSA Program Association of Emergency Department Crowding with Inpatient Outcomes • Health Services Research • Sept. 26, 2022 • CTSA Program Associations of 24-hour Light Exposure and Activity Patterns and Risk of Cognitive Impairment and Decline in Older Men: The MrOS Sleep Study • The Journal of Gerontology, Series A: Biological Sciences and Medical Sciences • Sept. 26, 2022 • CTSA Program Intention to Obtain a COVID-19 Vaccine Among Brazilian Immigrant Women in the U.S. • PLoS One • Sept. 26, 2022 • CTSA Program Tumour, Whole-Blood, Plasma and Tissue Concentrations of Metformin in Lung Cancer Patients • British Journal of Clinical Pharmacology • Sept. 26, 2022 • CTSA Program Medication-Related Osteonecrosis of the Jaw In Cancer Patients: Result From the OneFlorida Clinical Research Consortium • Journal of Bone and Mineral Research • Sept. 24, 2022 • CTSA Program Photodynamic Priming Overcomes Per- and Polyfluoroalkyl Substance (PFAS)-Induced Platinum Resistance in Ovarian Cancer • Photochemistry and Photobiology • Sept. 23, 2022 • CTSA Program Proton Pump Inhibitors in Allergy: Benefits and Risks • The Journal of Allergy and Clinical Immunology: In Practice • Sept. 23, 2022 • CTSA Program Association of QTc Formula with the Clinical Management of Patients with Cancer • JAMA Oncology • Sept. 22, 2022 • CTSA Program Development and Validation of a COVID-19 Vaccine Hesitancy Scale for Adults in the United States • Vaccine • Sept. 22, 2022 • CTSA Program Differential Metabolism of Glycerol Based on Oral Versus Intravenous Administration in Humans • Metabolites • Sept. 22, 2022 • CTSA Program Disaggregation of Race and Ethnicity Group Data: Research-to-Practice Issues in Clinical Environments • Journal of the American Medical Association • Sept. 22, 2022 • CTSA Program Examining Adherence to Oral Anticancer Medications Through a Human Factors Engineering Framework: Protocol for a Scoping Review • PLoS One • Sept. 22, 2022 • CTSA Program Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes • The New England Journal of Medicine • Sept. 22, 2022 • CTSA Program Il-23 Signaling Prevents Ferroptosis-Driven Renal Immunopathology During Candidiasis • Nature Communications • Sept. 22, 2022 • CTSA Program The Impact of Mendelian Sleep and Circadian Genetic Variants in a Population Setting • PLoS Genetics • Sept. 22, 2022 • CTSA Program Multidimensional Analysis and Therapeutic Development Using Patient iPSC–Derived Disease Models of Wolfram Syndrome • JCI Insight • Sept. 22, 2022 • CTSA Program Role of Home Health for Community-Dwelling Older Adults Near the End of Life: A Resource Beyond Hospice? • Journal of Palliative Medicine • Sept. 22, 2022 • CTSA Program Sensor-Based Surveillance for Digitising Real-Time COVID-19 Tracking in the USA (DETECT): A Multivariable, Population-Based, Modelling Study • The Lancet Digital Health • Sept. 22, 2022 • CTSA Program Temporal Order of Clinical and Biomarker Changes in Familial Frontotemporal Dementia • Nature Medicine • Sept. 22, 2022 • RDCRN Assistance Dogs for Military Veterans with PTSD: A Systematic Review, Meta-Analysis, and Meta-Synthesis • PLoS One • Sept. 21, 2022 • CTSA Program Distressing Dreams, Cognitive Decline, and Risk of Dementia: A Prospective Study of Three Population-Based Cohorts • eClinicalMedicine • Sept. 21, 2022 • CTSA Program Patient Understanding of Tumor Genomic Testing: A Quality Improvement Effort • JCO Oncology Practice • Sept. 21, 2022 • CTSA Program Serum Bile Acids as a Prognostic Biomarker in Biliary Atresia Following Kasai Portoenterostomy • Hepatology • Sept. 21, 2022 • CTSA Program An In-Silico Analysis of Experimental Designs to Study Ventricular Function: A Focus on the Right Ventricle • PLoS Computational Biology • Sept. 20, 2022 • CTSA Program Photochemical Targeting of Mitochondria to Overcome Chemoresistance in Ovarian Cancer • Photochemistry and Photobiology • Sept. 19, 2022 • CTSA Program Portopulmonary Hypertension Practice Patterns After Liver Transplantation • Liver Transplantation • Sept. 19, 2022 • CTSA Program Adjuvant Radiotherapy in Surgically Treated HPV-Positive Oropharyngeal Carcinoma with Adverse Pathological Features • Cancers • Sept. 17, 2022 • CTSA Program Oncogenic RAS Commandeers Amino Acid Sensing Machinery to Aberrantly Activate mTORC1 in Multiple Myeloma • Nature Communications • Sept. 17, 2022 • Division of Preclinical Innovation Predicting Risk of Multidrug-Resistant Enterobacterales Infections Among People with HIV • Open Forum Infectious Diseases • Sept. 17, 2022 • CTSA Program Single-Cell Atlas of Human Liver Development Reveals Pathways Directing Hepatic Cell Fates • Nature Cell Biology • Sept. 15, 2022 • BioPlanet Streamlining the QOD Web-Based Calculator for Clinical Integration: Development and Validation of a Reduced Prediction Model for Lumbar Spine Surgery • Spine • Sept. 15, 2022 • CTSA Program Whole-Genome CRISPR Screening Identifies N-Glycosylation as a Genetic and Therapeutic Vulnerability in CALR-Mutant MPNs • Blood • Sept. 15, 2022 • CTSA Program Identification of Patients with Drug-Resistant Epilepsy in Electronic Medical Record Data Using the Observational Medical Outcomes Partnership Common Data Model • Epilepsia • Sept. 14, 2022 • CTSA Program Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction • JACC: Basic to Translational Science • Sept. 14, 2022 • CTSA Program Student Intentions to Pursue Obstetrics and Gynecology Training and Practice in Underserved Areas • American Journal of Obstetrics & Gynecology • Sept. 14, 2022 • CTSA Program Leveraging a New ICD-10 Diagnosis Code to Characterize Hospitalized Patients with Primary Sclerosing Cholangitis • Clinical Gastroenterology and Hepatology • Sept. 13, 2022 • CTSA Program Venlafaxine XR Treatment for Older Patients with Major Depressive Disorder: Decision Trees for When to Change Treatment • Evidence-Based Mental Health • Sept. 13, 2022 • CTSA Program Changes in Sertraline Plasma Concentrations Across Pregnancy and Postpartum • Clinical Pharmacology & Therapeutics • Sept. 12, 2022 • CTSA Program Impact of Antibiotics on the Lung Microbiome and Lung Function in Children with Cystic Fibrosis 1 Year After Hospitalization for an Initial Pulmonary Exacerbation • Open Forum Infectious Diseases • Sept. 12, 2022 • CTSA Program Randomised Feasibility Trial of a Virtual Intervention to Address Infant Car Seat Misuse • Injury Prevention • Sept. 12, 2022 • CTSA Program Younger Age at Cochlear Implant Activation Results in Improved Auditory Skill Development for Children With Congenital Deafness • Journal of Speech, Language, and Hearing Research • Sept. 12, 2022 • CTSA Program Association Between Mild Traumatic Brain Injury, Brain Structure, and Mental Health Outcomes in the Adolescent Brain Cognitive Development Study • NeuroImage • Sept. 11, 2022 • CTSA Program Safety and Dosing Study of a Cholecystokinin Receptor Antagonist In Non-alcoholic Steatohepatitis • Clinical Pharmacology & Therapeutics • Sept. 10, 2022 • CTSA Program Using Machine Learning with Intensive Longitudinal Data To Predict Depression and Suicidal Ideation Among Medical Interns Over Time • Psychological Medicine • Sept. 10, 2022 • CTSA Program A Descriptive Analysis of Redemption Patterns by Vendor Type Among WIC Participants in Massachusetts • Journal of the Academy of Nutrition and Dietetics • Sept. 9, 2022 • CTSA Program Neuronal Activity Reporters as Drug Screening Platforms • Micromachines • Sept. 9, 2022 • CTSA Program Association of Physician Coordination with Interfacility Transfer Acceptance Timeliness • The American Journal of Accountable Care • Sept. 8, 2022 • CTSA Program Evaluating Personalized (N-of-1) Trials in Rare Diseases: How Much Experimentation Is Enough? • Harvard Data Science Review • Sept. 8, 2022 • CTSA Program Personalized Trial Ethics and Institutional Review Board Submissions • Harvard Data Science Review • Sept. 8, 2022 • CTSA Program Weight-Based Compared with Fixed-Dose Enoxaparin Prophylaxis After Cesarean Delivery: A Randomized Controlled Trial • Obstetrics & Gynecology • Sept. 8, 2022 • CTSA Program Costs Associated with Acute Kidney Injury in Critically Ill Neonates with Patent Ductus Arteriosus: Pediatric Health Information System (PHIS) Analysis • Journal of Perinatology • Sept. 7, 2022 • CTSA Program Impact of Tight Glycemic Control and Hypoglycemia After Pediatric Cardiac Surgery on Neurodevelopmental Outcomes at Three Years of Age: Findings from a Randomized Clinical Trial • BMC Pediatrics • Sept. 7, 2022 • CTSA Program Serum Biomarkers Correlated with Liver Stiffness Assessed in a Multicenter Study of Pediatric Cholestatic Liver Disease • Hepatology • Sept. 7, 2022 • CTSA Program COVID-19 Vaccine Uptake Among People Who Inject Drugs in Tijuana Mexico • Frontiers Public Health • Sept. 6, 2022 • CTSA Program Evolution of Functional Antibodies Following Acute Epstein-Barr Virus Infection • PLoS Pathogens • Sept. 6, 2022 • CTSA Program Impact of Hormonal Contraceptives on Sex Differences in Fear Conditioning and Fear Extinction in PTSD • Learning & Memory • Sept. 6, 2022 • CTSA Program Issues with Variability in Electronic Health Record Data About Race and Ethnicity: Descriptive Analysis of the National COVID Cohort Collaborative Data Enclave • JMIR Medical Informatics • Sept. 6, 2022 • CTSA Program Molecular Convergence Between Down Syndrome and Fragile X Syndrome Identified Using Human Pluripotent Stem Cell Models • Cell Reports • Sept. 6, 2022 • CTSA Program Religiosity/Spirituality and Cardiovascular Health: The American Heart Association Life's Simple 7 in African Americans of the Jackson Heart Study • Journal of the American Heart Association • Sept. 6, 2022 • CTSA Program Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function • New England Journal of Medicine • Sept. 4, 2022 • CTSA Program Beyond Coverage: Rural-Urban Disparities in the Timeliness of Childhood Vaccinations in Tanzania • Vaccine • Sept. 2, 2022 • CTSA Program Theater for Vaccine Hesitancy — Setting the Stage for Difficult Conversations • JAMA • Sept. 2, 2022 • CTSA Program Sleep Restriction Impairs Visually and Memory-Guided Force Control • PLoS One • Sept. 2, 2022 • CTSA Program Alliance With an Unguided Smartphone App: Validation of the Digital Working Alliance Inventory • Assessment • Sept. 1, 2022 • CTSA Program Analysis of Vaccine Reactions After COVID-19 Vaccine Booster Doses Among Pregnant and Lactating Individuals • Journal of the American Medical Association • Sept. 1, 2022 • CTSA Program Antinociceptive and Analgesic Effects of (2R,6R)-Hydroxynorketamine • Journal of Pharmacology and Experimental Therapeutics • Sept. 1, 2022 • Division of Preclinical Innovation Arnold Max Meirowsky: Champion of the American Mobile Neurosurgical Unit During the Korean War • Neurosurgical Focus • Sept. 1, 2022 • CTSA Program Association of Age with Survival In Older Patients with Cutaneous Melanoma Treated with Immune Checkpoint Inhibitors • Journal of Geriatric Oncology • Sept. 1, 2022 • CTSA Program Association of Antenatal Steroid Exposure at 21 to 22 Weeks of Gestation with Neonatal Survival and Survival Without Morbidities • Journal of the American Medical Association • Sept. 1, 2022 • NCATS Balanced Crystalloid Versus Saline in Adults With Traumatic Brain Injury: Secondary Analysis of a Clinical Trial • Journal of Neurotrauma • Sept. 1, 2022 • CTSA Program Clock-Drawing Test as a Screening Tool for Cognitive Impairment Associated With Fecal Immunochemical Test Collection Errors • Annals of Family Medicine • Sept. 1, 2022 • CTSA Program Correlation of Fibromyalgia Survey Questionnaire and Quantitative Sensory Testing Among Patients With Active Rheumatoid Arthritis • The Journal of Rheumatology • Sept. 1, 2022 • CTSA Program Cost-Effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-Based Adjuvant Chemotherapy for Colon Cancer • Clinical Colorectal Cancer • Sept. 1, 2022 • CTSA Program Cross-Sectional Characteristics of Pediatric-Onset Discoid Lupus Erythematosus: Results of a Multicenter, Retrospective Cohort Study • Journal of the American Academy of Dermatology • Sept. 1, 2022 • CTSA Program Defining the Patchy Landscape of Esophageal Eosinophilia in Children with Eosinophilic Esophagitis • Clinical Gastroenterology and Hepatology • Sept. 1, 2022 • NCATS The Design of the Dashboard Activated Services and Telehealth for Heart Failure (DASH-HF) Study: A Pragmatic Quality Improvement Randomized Implementation Trial for Patients with Heart Failure with Reduced Ejection Fraction • Contemporary Clinical Trials • Sept. 1, 2022 • CTSA Program Emergency Nurse Consensus on Most Effective and Accessible Support Strategies During Covid-19: A Delphi Study • Journal of Emergency Nursing • Sept. 1, 2022 • CTSA Program Exclusive Breast-Feeding, the Early-Life Microbiome and Immune Response, and Common Childhood Respiratory Illnesses • Journal of Allergy and Clinical Immunology • Sept. 1, 2022 • CTSA Program Human Papillomavirus Vaccinations During the Covid-19 Pandemic in Middle Schools in the Rio Grande Valley of Texas • Quality Management in Health Care • Sept. 1, 2022 • CTSA Program Impact of Bile Acid Diarrhea In Patients with Diarrhea-Predominant Irritable Bowel Syndrome on Symptoms and Quality of Life • Clinical Gastroenterology and Hepatology • Sept. 1, 2022 • CTSA Program Impacts of Medicaid Expansion on Health Insurance and Coverage Transitions Among Women with or at Risk for HIV in the United States • Women's Health Issues • Sept. 1, 2022 • CTSA Program Improving the Solubility and Antileukemia Activity of Wnt/β-Catenin Signaling Inhibitors by Disrupting Molecular Planarity • Bioorganic & Medicinal Chemistry • Sept. 1, 2022 • Division of Preclinical Innovation In-Home Environmental Exposures Predicted from Geospatial Characteristics of the Built Environment and Electronic Health Records of Children with Asthma • Annals of Epidemiology • Sept. 1, 2022 • CTSA Program Insurance and Health Care Outcomes in Regions Where Undocumented Children Are Medicaid-Eligible • Pediatrics • Sept. 1, 2022 • CTSA Program Machine Learning for Acute Kidney Injury Prediction in the Intensive Care Unit • Advances in Chronic Kidney Disease • Sept. 1, 2022 • Tissue Chip for Drug Screening A New Method for Quantifying Abdominal Aortic Wall Shear Stress Using Phase Contrast Magnetic Resonance Imaging and the Womersley Solution • Journal of Biomechanical Engineering • Sept. 1, 2022 • CTSA Program OARD: Open Annotations for Rare Diseases and Their Phenotypes Based on Real-World Data • American Journal of Human Genetics • Sept. 1, 2022 • Biomedical Data Translator A Perspective On the Sickle Cell Disease International COVID-19 Registry • Best Practice & Research Clinical Haematology • Sept. 1, 2022 • CTSA Program Prevalence and Characteristics of Providers’ Care Coordination Communication With Schools • Academic Pediatrics • Sept. 1, 2022 • CTSA Program Psychometric Validation of the AOSL Scale Using Confirmatory Factor Analysis: A Nationally Representative Sample • Journal of the American Pharmacists Association • Sept. 1, 2022 • CTSA Program Rates of In-Hospital Decongestion and Association with Mortality and Cardiovascular Outcomes Among Patients Admitted for Acute Heart Failure • The American Journal of Medicine • Sept. 1, 2022 • CTSA Program Rna Binding by Adar3 Inhibits Adenosine-to-Inosine Editing and Promotes Expression of Immune Response Protein Mavs • Journal of Biological Chemistry • Sept. 1, 2022 • CTSA Program Self-Administered, Remote Assessment of SARS-CoV-2 Seroprevalence in Health Care Workers • The American Journal of the Medical Sciences • Sept. 1, 2022 • CTSA Program The Socioeconomic Gradient of Alcohol Use: An Analysis of Nationally Representative Survey Data from 55 Low-Income and Middle-Income Countries • The Lancet Global Health • Sept. 1, 2022 • CTSA Program Study Protocol for Training Providers in Private Practice in Family-Based Treatment for Adolescents with Anorexia Nervosa: A Randomized Controlled Feasibility Trial • Contemporary Clinical Trials • Sept. 1, 2022 • CTSA Program August 2022 Advancing Translational Science Education • Clinical and Translational Science • Aug. 31, 2022 • NCATS Education Branch Relationships Between Changing Communication Networks and Changing Perceptions of Psychological Safety in a Team Science Setting: Analysis with Actor-Oriented Social Network Models • PLoS One • Aug. 31, 2022 • CTSA Program Human Neural Stem Cells Drug Product: Microsatellite Instability Analysis • PLoS One • Aug. 30, 2022 • Assay Guidance Manual The Imbalance Between Type 17 T-Cells and Regulatory Immune Cell Subsets in Psoriasis Vulgaris • Frontiers in Immunology • Aug 30, 2022 • CTSA Program N1-Methylpseudouridine Found Within Covid-19 mRNA Vaccines Produces Faithful Protein Products • Cell Reports • Aug. 30, 2022 • CTSA Program Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age • Obstetrics & Gynecology • Aug. 29, 2022 • CTSA Program Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys with Duchenne Muscular Dystrophy: A Randomized Clinical Trial • JAMA Neurology • Aug. 29, 2022 • TRND GENE TARGET: A framework for Evaluating Mendelian Neurodevelopmental Disorders for Gene Therapy • Molecular Therapy – Methods & Clinical Development • Aug. 29, 2022 • RDCRN Human Ureteric Bud Organoids Recapitulate Branching Morphogenesis and Differentiate into Functional Collecting Duct Cell Types • Nature Biotechnology • Aug. 29, 2022 • Tissue Chip Lay Beliefs About Doctors’ Knowledge of and Reasons for Recommending COVID-19 Vaccines • Journal of General Internal Medicine • Aug. 29, 2022 • CTSA Program Concordance of SARS-CoV-2 Results in Self-Collected Nasal Swabs vs Swabs Collected by Health Care Workers in Children and Adolescents • Journal of the American Medical Association • Aug. 26, 2022 • CTSA Program Protocol for the MicroRESUS Study: The Impact of Circulatory Shock and Resuscitation on Microcirculatory Function and Mitochondrial Respiration After Cardiovascular Surgery • PLoS One • Aug. 26, 2022 • CTSA Program Quantifying Inequities in COVID-19 Vaccine Distribution over Time by Social Vulnerability, Race and Ethnicity, and Location: A Population-Level Analysis in St. Louis and Kansas City, Missouri • PLoS Medicine • Aug. 26, 2022 • CTSA Program RSDB: A Rare Skin Disease Database to Link Drugs with Potential Drug Targets for Rare Skin Diseases • Scientific Data • Aug. 26, 2022 • GARD Identification of a SGCD x Discrimination Interaction Effect on Systolic Blood Pressure in African American Adults in the Jackson Heart Study • American Journal of Hypertension • Aug. 24, 2022 • CTSA Program Religiosity/Spirituality and Cardiovascular Health: The American Heart Association Life's Simple 7 in African Americans of the Jackson Heart Study • Journal of the American Heart Association • Aug. 24, 2022 • CTSA Program Effects of Sex, APOE4, and Lifestyle Activities on Cognitive Reserve in Older Adults • Neurology • Aug. 23, 2022 • CTSA Program The Cello Trial: Protocol of a Planned Phase 4 Study to Assess the Efficacy of Ocrelizumab in Patients with Radiologically Isolated Syndrome • Multiple Sclerosis and Related Disorders • Aug. 22, 2022 • CTSA Program Strategies to Induce Natural Killer Cell Tolerance in Xenotransplantation • Frontiers in Immunology • Aug. 22, 2022 • CTSA Program Associations of Empirical Dietary Inflammatory Index with Heart Failure in Adults from the United States • European Journal of Clinical Nutrition • Aug. 19, 2022 • CTSA Program Sickle Cell Disease and the Incidence and Etiology of Preterm Birth • American Journal of Obstetrics & Gynecology MFM • Aug. 19, 2022 • CTSA Program The Impact of Infectious Diseases Consultation for Children with Staphylococcus aureus Bacteremia • Pediatric Research • Aug. 18, 2022 • CTSA Program Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19 • The New England Journal of Medicine • Aug. 18, 2022 • CTSA Program Soothe the Savage Beast: Patient Perceptions of the Benefits of Music Therapy in an Inpatient Rehabilitation Facility • PM&R • Aug. 18, 2022 • CTSA Program Heart Failure-Type Symptom Scores in Chronic Kidney Disease: The Importance of Body Mass Index • International Journal of Obesity • Aug. 17, 2022 • CTSA Program Heritable Vaginal Bacteria Influence Immune Tolerance and Relate to Early-Life Markers of Allergic Sensitization in Infancy • Cell Reports Medicine • Aug. 16, 2022 • CTSA Program Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, a Potential Oral Drug Candidate for COVID-19 Treatment • Frontiers in Pharmacology • Aug. 16, 2022 • Division of Preclinical Innovation Activation of Mitochondrial TRAP1 Stimulates Mitochondria-Lysosome Crosstalk and Correction of Lysosomal Dysfunction • iScience • Aug. 14, 2022 • NCATS Mepolizumab for Urban Children with Exacerbation-Prone Eosinophilic Asthma in the USA (MUPPITS-2): A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial • The Lancet • Aug. 13, 2021 • CTSA Program First or Second Trimester SARS-CoV-2 Infection and Subsequent Pregnancy Outcomes • American Journal of Obstetrics & Gynecology • Aug. 12, 2022 • CTSA Program Pediatric Spinal Injury Patterns and Management in All-Terrain Vehicle and Dirt Bike Crashes, 2010-2019 • Journal of Neurosurgery: Pediatrics • Aug. 12, 2022 • CTSA Program Reduced Circumferential Strain in Athletes with Prior COVID-19 • Radiology: Cardiothoracic Imaging • Aug. 11, 2022 • CTSA Program SARS-CoV-2 Reliably Detected in Frozen Saliva Samples Stored up to One Year • PLoS One • Aug. 11, 2022 • CTSA Program A Humanized Nanobody Phage Display Library Yields Potent Binders of SARS CoV-2 Spike • PLoS One • Aug. 10, 2022 • NCATS Reaping What You SOW: Guidelines and Strategies for Writing Scopes of Work for Statistical Consulting • Stat • Aug. 10, 2022 • CTSA Program Human Liver Organoids for Disease Modeling of Fibrolamellar Carcinoma • Stem Cell Reports • Aug. 9, 2022 • CTSA Program Impact Evaluation of a Brief Online Training Module on Physician Use of the Maryland, USA, Prescription Drug Monitoring Program • PLoS One • Aug. 9, 2022 • CTSA Program Inflammation Drives Residual Risk in Chronic Kidney Disease: A CANTOS Substudy • European Heart Journal • Aug. 9, 2022 • NCATS Non-Invasive Cancer Detection in Canine Urine Through Caenorhabditis elegans Chemotaxis • Frontiers in Veterinary Science • Aug. 9, 2022 • CTSA Program Effectiveness of Early Time-Restricted Eating for Weight Loss, Fat Loss, and Cardiometabolic Health in Adults with Obesity: A Randomized Clinical Trial • JAMA Internal Medicine • Aug. 8, 2022 • CTSA Program Inhaled Nitric Oxide Versus Epoprostenol During Acute Respiratory Failure: An Observational Target Trial Emulation • Chest • Aug. 8, 2022 • CTSA Program Integrative Analysis of Drug Response and Clinical Outcome in Acute Myeloid Leukemia • Cancer Cell • Aug. 8, 2022 • CTSA Program The Fish Oil to Reduce Tobacco Use in Expectant Mothers (Fortune) Feasibility Trial • American Journal of Obstetrics & Gynecology MFM • Aug. 7, 2022 • CTSA Program Relation of Sociodemographic Factors with Primary Cause of Hospitalization Among Patients with Left Ventricular Assist Devices (from the National Inpatient Sample 2012 to 2017) • The American Journal of Cardiology • Aug. 6, 2022 • CTSA Program Vaping Flavors and Flavor Representation: A Test of Youth Risk Perceptions, Novelty Perceptions, and Susceptibility • Nicotine & Tobacco Research • Aug. 6, 2022 • CTSA Program Cannabis Consumption Is Associated with Lower COVID-19 Severity Among Hospitalized Patients: A Retrospective Cohort Analysis • Journal of Cannabis Research • Aug. 5, 2022 • CTSA Program Diet Quality and Cardiometabolic Risk Factors in Adolescents with Down Syndrome • Journal of the Academy of Nutrition and Dietetics • Aug. 5, 2022 • CTSA Program Hepatitis E Virus Infection in the United States: Seroprevalence, Risk Factors and the Influence of Immunological Assays • PLoS One • Aug. 5, 2022 • CTSA Program Are Psychosocial Variables, Sleep Characteristics or Central Pain Processing Prognostic Factors for Outcome Following Rotator Cuff Repair? A Protocol for a Prospective Longitudinal Cohort Study • BMJ Open • Aug. 4, 2022 • CTSA Program Case Report: Lack of Response to Givosiran in a Case of ALAD Porphyria • Frontiers in Genetics • Aug. 4, 2022 • RDCRN Impact of COVID-19 on Well-Being and Physical Activity in Ugandan Children with and Without HIV • Journal of Physical Activity and Health • Aug. 4, 2022 • CTSA Program Influence of Literacy, Self-Efficacy, and Social Support on Diabetes-Related Outcomes Following Hospital Discharge • Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy • Aug. 4, 2022 • CTSA Program Missed Opportunities in Medical Therapy for Patients with Heart Failure in an Electronically-Identified Cohort • BMC Cardiovascular Disorders • Aug. 4, 2022 • CTSA Program Natural History of Lower Urinary Tract Symptoms in Treatment-Seeking Women with Pelvic Organ Prolapse; the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) • American Journal of Obstetrics & Gynecology • Aug. 4, 2022 • CTSA Program Parental Resilience and Psychological Distress in the Neonatal Intensive Care Unit • Journal of Perinatology • Aug. 4, 2022 • CTSA Program Speech Recognition Can Help Evaluate Shared Decision Making and Predict Medication Adherence in Primary Care Setting • PLoS One • Aug. 4, 2022 • CTSA Program Associations Between Provider-Assigned Apgar Score and Neonatal Race • American Journal of Obstetrics & Gynecology • Aug. 3, 2022 • CTSA Program Bone, Brain, Heart Study Protocol: A Resilient Nested, Tripartite Prospective Cohort Study of the Role of Estrogen Depletion on HIV Pathology • PLoS One • Aug. 3, 2022 • CTSA Program The Digital Phenotype of Vaccination • Nature Biotechnology • Aug. 3, 2022 • CTSA Program Ten Simple Rules for Maximizing the Recommendations of the NIH Data Management and Sharing Plan • PLoS Computational Biology • Aug. 3, 2022 • CTSA Program Impact of Demographics and Clinical Features on Initial Treatment Pathway for Vestibular Schwannoma • Otology & Neuerotology • Aug. 2, 2022 • CTSA Program Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients with Celiac Disease Exposed to a Gluten Challenge • Gastroenterology • Aug. 2, 2022 • CTSA Program Adolescent Intermittent Ethanol Exposure Induces Sex-Dependent Divergent Changes in Ethanol Drinking and Motor Activity in Adulthood in C57BL/6J Mice • Journal of Neuroscience Research • Aug. 1, 2022 • Division of Preclinical Innovation Association of Genetic Predisposition and Physical Activity with Risk of Gestational Diabetes in Nulliparous Women • Journal of the American Medical Association • Aug. 1, 2022 • CTSA Program Associations Between Implementation of the Collaborative Care Model and Disparities in Perinatal Depression Care • Obstetrics & Gynecology • Aug. 1, 2022 • CTSA Program Astrocyte Ethanol Exposure Reveals Persistent and Defined Calcium Response Subtypes and Associated Gene Signatures • Journal of Biological Chemistry • Aug. 1, 2022 • CTSA Program Awake Prone Positioning in COVID-19: Signal or Noise?—Reply • JAMA Internal Medicine • Aug. 1, 2022 • CTSA Program COVID-19 Vaccine Hesitancy Among Low-Income, Racially and Ethnically Diverse US Parents • Patient Education and Counseling • Aug. 1, 2022 • CTSA Program Development and Validation of a Natural Language Processing Tool to Identify Injuries in Infants Associated With Abuse • Academic Pediatrics • Aug. 1, 2022 • CTSA Program Ectopic Biomolecular Phase Transitions: Fusion Proteins in Cancer Pathologies • Trends in Cell Biology • Aug. 1, 2022 • IDG Electrocardiographic Features and Outcome: Correlations in 124 Hospitalized Patients with Covid-19 and Cardiovascular Events • Journal of Cardiothoracic and Vascular Anesthesia • Aug. 1, 2022 • RADx-RAD, SCENT An Introduction to Qualitative Methods for the Nurse Researcher • American Journal of Nursing • Aug. 1, 2022 • CTSA Program Circular RNA: An Emerging Frontier In RNA Therapeutic Targets, RNA Therapeutics, and mRNA Vaccines • Journal of Controlled Release • Aug. 1, 2022 • CTSA Program Diagnostic and Physical Effects in Parasympathetic Response to Social Evaluation in Youth With and Without Autism Spectrum Disorder • Journal of Autism and Developmental Disorders • Aug. 1, 2022 • CTSA Program Integrating Community Engagement with Implementation Science to Advance the Measurement of Translational Science • Cambridge University Press • Aug. 1, 2022 • CTSA Program Large-Scale Genome-Wide Association Study of Coronary Artery Disease in Genetically Diverse Populations • Nature Medicine • Aug. 1, 2022 • CTSA Program Lessons Learned From a New Reverse-Integration Model to Improve Primary Care Screening in Community Mental Health Settings • Psychiatric Services • Aug. 1, 2022 • CTSA Program North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension • Clinical Gastroenterology and Hepatology • Aug. 1, 2022 • CTSA Program Overwhelmed: A Dementia Caregiver Vital Sign • Journal of General Internal Medicine • Aug. 1, 2022 • CTSA Program Predictive Metabolomic Markers in Early to Mid-Pregnancy for Gestational Diabetes Mellitus: A Prospective Test and Validation Study • Diabetes • Aug. 1, 2022 • CTSA Program Research Shows Hearing Issues Common in Cancer Survivors • The Hearing Review • Aug. 1, 2022 • CTSA Program A Quantitative High-Throughput Screen Identifies Compounds That Lower Expression of the SCA2-and ALS-associated Gene ATXN2 • Journal of Biological Chemistry • Aug. 1, 2022 • Division of Preclinical Innovation Staying in School: Connection, Cohesiveness, and Suspension • Academic Pediatrics • Aug. 1, 2022 • CTSA Program Trends in Out-of-Pocket Cost of Glucagon, 2010-2020 • Journal of the American Medical Association • Aug. 1, 2022 • CTSA Program Umbilical Cord Collection and Drug Testing to Estimate Prenatal Substance Exposure in Utah • Obstetrics & Gynecology • Aug. 1, 2022 • CTSA Program U.S. Nutrition Assistance Program Participation and Childhood Obesity: The Early Childhood Longitudinal Study 2011 • American Journal of Preventive Medicine • Aug. 1, 2022 • CTSA Program Welfare Reform and the Quality of Young Children's Home Environments • National Bureau of Economic Research • Aug. 1, 2022 • CTSA Program What Types of Hospitals Do Adolescents and Young Adults With Complex Chronic Conditions Use? • Academic Pediatrics • Aug. 1, 2022 • CTSA Program Who Doesn't Fit? A Multi-Institutional Study Using Machine Learning to Uncover the Limits of Opioid Prescribing Guidelines • Surgery • Aug. 1, 2022 • CTSA Program July 2022 Effects of Sleep Duration on Neurocognitive Development in Early Adolescents in the USA: A Propensity Score Matched, Longitudinal, Observational Study • The Lancet Child & Adolescent Health • July 29, 2022 • CTSA Program Preliminary Psychometric Properties of a Standard Vocabulary Test Administered Using a Non-Invasive Brain-Computer Interface • Frontiers in Human Neuroscience • July 28, 2022 • CTSA Program Cancer Survivors and Neurotoxic Chemotherapy: Hearing Loss and Tinnitus • BMJ Supportive & Palliative Care • July 27, 2022 • CTSA Program An Automated 13.5 Hour System for Scalable Diagnosis and Acute Management Guidance for Genetic Diseases • Annals of Family Medicine • July 26, 2022 • GARD, Inxight Drugs Body Mass Index and Variability in Meal Duration and Association with Rate of Eating • Frontiers in Nutrition • July 26, 2022 • CTSA Program Characterizing Fatigue Subtypes in Adolescents with Chronic Musculoskeletal Pain and Pain-Free Controls • Journal of Pain Research • July 26, 2022 • CTSA Program Electronic Patient Portal Access, Retention in Care, and Viral Suppression Among People Living with HIV in Southeastern United States: Observational Study • JMIR Medical Informatics • July 25, 2022 • CTSA Program National Institutes of Health Clinical Research Funding and All-Cause In-Hospital Traumatic Brain Injury-Related Mortality • Cureus • July 25, 2022 • NCATS A Simple Approach to the Identification of Guideline-Based Coronary Artery Calcium Score Percentiles (From the Multi-Ethnic Study of Atherosclerosis) • The American Journal of Cardiology • July 25, 2022 • CTSA Program Titration of Ventilator Settings to Target Driving Pressure and Mechanical Power • Respiratory Care • July 22, 2022 • CTSA Program Cultivating an Effective Research Team Through Application of Team Science Principles • Society of Clinical Research Associates • July 21, 2022 • CTSA Program A Microengineered Brain-Chip to Model Neuroinflammation in Humans • iScience • July 21, 2022 • Tissue Chip Inhibition of Casein Kinase 1δ Disrupts Translation Initiation and Exerts Potent Antilymphoma Activity • Blood Advances • July 19, 2022 • CTSA Program Racial and Ethnic Differences in All-Cause and Cardiovascular Disease Mortality: The MESA Study • Circulation • July 19, 2022 • CTSA Program A Systematic Review of Healthcare Provider-Targeted Mobile Applications for Non-Communicable Diseases in Low- and Middle-Income Countries • npj Digital Medicine • July 19, 2022 • CTSA Program The Hunt for Drugs for Mild COVID: Scientists Seek to Treat Those at Lower Risk • Nature • July 18, 2022 • CTSA Program Indirect COVID-19 Health Effects and Potential Mitigating Interventions: Cost-Effectiveness Framework • PLoS One • July 18, 2022 • CTSA Program Prediction of Maternal Hemorrhage Using Machine Learning: Retrospective Cohort Study • Journal of Medical Internet Research • July 18, 2022 • CTSA Program Post-Recovery COVID-19 and Incident Heart Failure in the National COVID Cohort Collaborative (N3C) Study • Nature Communications • July 15, 2022 • CTSA Program Clinical Value of Cell-Based Assays in the Characterisation of Seronegative Myasthenia Gravis • Journal of Neurology, Neurosurgery, and Psychiatry • July 14, 2022 • NCATS HDL Cholesterol Levels and Susceptibility to COVID-19 • eBioMedicine • July 14, 2022 • CTSA Program Use of Tox21 Screening Data to Evaluate the COVID-19 Drug Candidates for Their Potential Toxic Effects and Related Pathways • Frontiers in Pharmacology • July 14, 2022 • Tox21 Cytopathic SARS-CoV-2 Screening on VERO-E6 Cells in a Large-Scale Repurposing Effort • Scientific Data • July 13, 2022 • COVID-19 OpenData Portal Integrated Single Cell and Spatial Transcriptomics Reveal Autoreactive Differentiated B Cells in Joints of Early Rheumatoid Arthritis • Scientific Reports • July 13, 2022 • BioPlanet Nasopharyngeal Metatranscriptome Profiles of Infants with Bronchiolitis and Risk of Childhood Asthma: A Multicentre Prospective Study • European Respiratory Journal • July 13, 2022 • CTSA Program Persisting Uropathogenic Escherichia Coli Lineages Show Signatures of Niche-specific Within-host Adaptation Mediated By Mobile Genetic Elements • Cell Host & Microbe • July 13, 2022 • CTSA Program Exercise-Induced Engagement of the IL-15/IL-15Rα Axis Promotes Anti-Tumor Immunity in Pancreatic Cancer • Cancer Cell • July 11, 2022 • CTSA Program Repetitive Transcranial Magnetic Stimulation for Tobacco Treatment in Cancer Patients: A Preliminary Report of a One-Week Treatment • Journal of Smoking Cessation • July 11, 2022 • CTSA Program Battery-Free, Tuning Circuit–Inspired Wireless Sensor Systems for Detection of Multiple Biomarkers in Bodily Fluids • Science Advances • July 8, 2022 • CTSA Program Enhancing Untargeted Metabolomics Using Metadata-Based Source Annotation • Nature Biotechnology • July 7, 2022 • CTSA Program Wastewater Sequencing Reveals Early Cryptic SARS-CoV-2 Variant Transmission • Nature • July 7, 2022 • CTSA Program Clinical, Biochemical and Genetic Characteristics of MOGS-CDG: A Rare Congenital Disorder of Glycosylation • Journal of Medical Genetics • July 5, 2022 • RDCRN HIF-PHIs for Anemia Management in CKD • Clinical Journal of the American Society of Nephrology • July 5, 2022 • CTSA Program Food Insecurity, Missed Workdays, And Hospitalizations Among Working-Age US Adults with Diabetes • Health Affairs • July 4, 2022 • CTSA Program Concurrent Validity of the Short-Form Family Impact Scale (FIS-8) in 4-year-old US Children • BMC Pediatrics • July 4, 2022 • CTSA Program Family History as a Risk Factor for Peripheral Arterial Disease • The American Journal of Cardiology • July 2, 2022 • CTSA Program Body Mass Index Category and Adverse Events In Hospitalized Children • Academic Pediatrics • July 1, 2022 • CTSA Program Centering Health Equity in Telemedicine • Annals of Family Medicine • July 1, 2022 • CTSA Program Design Considerations for Protective Mask Development: A Remote Mask Usability Evaluation • Applied Ergonomics • July 1, 2022 • CTSA Program Endothelin Receptor Antagonists and Risk of Heart Failure in CKD: Balancing the Cardiorenal Axis • JACC: Heart Failure • July 1, 2022 • CTSA Program A Glomerular Transcriptomic Landscape of Apolipoprotein L1 In Black Patients With Focal Segmental Glomerulosclerosis • Kidney International • July 1, 2022 • RDCRN Growth of Pediatric Refugees After Resettlement to the Southeastern United States • Academic Pediatrics • July 1, 2022 • CTSA Program Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform • Frontiers in Pharmacology • July 1, 2022 • CTSA Program Linguistic Disparities in Child Health and Presence of a Medical Home Among United States Latino Children • Academic Pediatrics • July 1, 2022 • CTSA Program Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications • Mayo Clinic Proceedings • July 1, 2022 • CTSA Program Maternal Predictors of Breast Milk Plasmalogens and Associations with Infant Body Composition and Neurodevelopment • Clinical Therapeutics • July 1, 2022 • CTSA Program A Novel Donor-Derived Cell-Free DNA Assay for the Detection of Acute Rejection In Heart Transplantation • The Journal of Heart and Lung Transplantation • July 1, 2022 • CTSA Program Perspectives From Advancing National Institutes of Health Research to Inform and Improve the Health of Women: A Conference Summary • JACC: Heart Failure • July 1, 2022 • NCATS PTPα Promotes Fibroproliferative Responses After Acute Lung Injury • American Journal of Physiology-Lung Cellular and Molecular Physiology • July 1, 2022 • CTSA Program Relation of Myocardial Perfusion Reserve and Left Ventricular Ejection Fraction in Ischemic and Nonischemic Cardiomyopathy • The American Journal of Cardiology • July 1, 2022 • CTSA Program Remote Delivery in Reproductive Health Care: Operation of Direct-to-Patient Telehealth Medication Abortion Services in Diverse Settings • Annals of Family Medicine • July 1, 2022 • CTSA Program June 2022 Treatment of COVID-19 Patients with Two Units of Convalescent Plasma in a Resource-Constrained State • Laboratory Medicine • June 30, 2022 • CTSA Program Assessing Disparities in COVID-19 Testing Using National COVID Cohort Collaborative • Studies in Health Technology and Informatics • June 29, 2022 • NCATS Excess All-Cause and Cause-Specific Mortality Among People with Diabetes During the COVID-19 Pandemic in Minnesota: Population-Based Study • Obstetrics & Gynecology • June 29, 2022 • NCATS Imipramine and Olanzapine Block apoE4-Catalyzed Polymerization of Aβ and Show Evidence of Improving Alzheimer’s Disease Cognition • Alzheimer's Research & Therapy • June 29, 2022 • CTSA Program Communicating Risk for Obesity in Early Life: Engaging Parents Using Human-Centered Design Methodologies • Frontiers in Pediatrics • June 28, 2022 • CTSA Program Diversity, Equity and Inclusion Actions from the NCATS Clinical and Translational Science Awarded Programs • Nature Medicine • June 28, 2022 • CTSA Program Immediate Impact of Yogic Breathing on Pulsatile Cerebrospinal Fluid Dynamics • Scientific Reports • June 28, 2022 • CTSA Program Loss of Stathmin-2, a Hallmark of Tdp-43-Associated Als, Causes Motor Neuropathy • Cell Reports • June 28, 2022 • CTSA Program Measuring Impact of a Quality Improvement Initiative on Glaucoma Clinic Flow Using an Automated Real-Time Locating System • BMC Ophthalmology • June 28, 2022 • CTSA Program Association of APOE Genotypes and Chronic Traumatic Encephalopathy • JAMA Neurology • June 27, 2022 • CTSA Program Diabetes and the Fragmented State of US Health Care and Policy • Health Affairs • June 27, 2022 • CTSA Program Laundry Detergent Promotes Allergic Skin Inflammation and Esophageal Eosinophilia in Mice • PLoS One • June 27, 2022 • CTSA Program Associations of Dietary Antioxidants with Glycated Hemoglobin and Insulin Sensitivity in Adults with and Without Type 1 Diabetes • Journal of Diabetes Research • June 25, 2022 • CTSA Program Changes in Nicotine Dependence Among Smokers Using Electronic Cigarettes to Reduce Cigarette Smoking in a Randomized Controlled Trial • Nicotine & Tobacco Research • June 25, 2022 • CTSA Program Iatrogenic Femoral Arteriovenous Fistula with Pseudoaneurysm Associated with Worsening Heart Failure Years after Percutaneous Impella Placement • Case Reports in Vascular Medicine • June 24, 2022 • CTSA Program Impact of Blood Lipids on 10-Year Cardiovascular Risk in Individuals Without Dyslipidemia and with Low Risk Factor Burden • Mayo Clinic Proceedings • June 24, 2022 • CTSA Program Lumbar Stenosis Due to Wild-Type Transthyretin Amyloid-Induced Thickening of the Ligamentum Flavum: A Separate Etiology From Degeneration of Intervertebral Discs? • Journal of Neurosurgery • June 24, 2022 • CTSA Program Patient Age at Diagnosis of Peripheral Artery Disease and Its Impact on Cardiovascular and Limb Outcomes • The American Journal of Cardiology • June 24, 2022 • CTSA Program A Cross-Sectional Study of the Neuropsychiatric Phenotype of CACNA1C-Related Disorder • BMJ Yale • June 23, 2022 • CTSA Program The Show Must Go On. Reply to “Distinct Functions of S-Ketamine and R-Ketamine in Mediating Biobehavioral Processes of Drug Dependency: Comments on Bonaventura et al” by Insop Shim • Molecular Psychiatry • June 22, 2022 • Division of Preclinical Innovation Self-Reported Marijuana Use and Cardiac Arrhythmias (from the Multiethnic Study of Atherosclerosis) • The American Journal of Cardiology • June 17, 2022 • CTSA Program Current Therapies and New Developments in NASH • Gut • June 16, 2021 • CTSA Program Neurobehavior in Low-Risk Very Preterm Infants with Low Medical Risk and Full-Term Infants • Journal of Perinatology • June 18, 2022 • CTSA Program What Role Can Decentralized Trial Designs Play to Improve Rare Disease Studies? • Orphanet Journal of Rare Diseases • June 18, 2022 • CTSA Program Impact of the COVID-19 Pandemic on Trends in Cardiothoracic Imaging • Radiology Research and Practice • June 16, 2022 • CTSA Program Association Between Covid-19 Vaccination and Influenza Vaccination Rates • The New England Journal of Medicine • June 15, 2022 • CTSA Program The GA4GH Phenopacket Schema Defines a Computable Representation of Clinical Data • Nature Biotechnology • June 15, 2022 • CTSA Program Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants • The New England Journal of Medicine • June 15, 2022 • CTSA Program A Dose-Finding Safety and Feasibility Study of Oral Activated Charcoal and Its Effects on the Gut Microbiota in Healthy Volunteers Not Receiving Antibiotics • PLoS One • June 14, 2022 • CTSA Program The International Fragile X Premutation Registry: Building a Resource for Research and Clinical Trial Readiness • Journal of Medical Genetics • June 14, 2022 • RaDaR, REDCap Prevalence of Pelvic Floor Disorders in Adult Women Being Seen in a Primary Care Setting and Associated Risk Factors • Scientific Reports • June 14, 2022 • CTSA Program Senna Makki and Other Active Phytochemicals: Myths and Realities Behind Covid19 Therapeutic Interventions • PLoS One • June 14, 2022 • CTSA Program Adaptive Stress Response Genes Associated with Breast Cancer Subtypes and Survival Outcomes Reveal Race-Related Differences • npj Breast Cancer • June 13, 2022 • GARD Associations of Maternal Lipoprotein Particle Distribution in Mid-Pregnancy with Birth Outcomes: A Pilot Study • Lipids in Health and Disease • June 13, 2022 • CTSA Program Computational Simulations and Ca2+ Imaging Reveal That Slow Synaptic Depolarizations (Slow EPSPs) Inhibit Fast EPSP Evoked Action Potentials for Most of Their Time Course in Enteric Neurons • PLoS Computational Biology • June 13, 2022 • SPARC Experimental Rickettsia Typhi Infection in Monodelphis Domestica: Implications for Opossums as an Amplifying Host in the Suburban Cycle of Murine Typhus • American Journal of Tropical Medicine and Hygiene • June 13, 2022 • CTSA Program International Comparisons of Laboratory Values from the 4CE Collaborative to Predict COVID-19 Mortality • npj Digital Medicine • June 13, 2022 • CTSA Program Relation of Right Atrial Strain to Mortality in Infants with Single Right Ventricles • The American Journal of Cardiology • June 13, 2022 • CTSA Program Associations of Plasma Omega-3 and Omega-6 Pufa Levels with Arterial Elasticity: The Multi-Ethnic Study of Atherosclerosis • European Journal of Clinical Nutrition • June 9, 2022 • CTSA Program Diffuse Myocardial Fibrosis at Cardiac MRI in Young Adults Born Prematurely: A Cross-Sectional Cohort Study • Radiology: Cardiothoracic Imaging • June 9, 2022 • CTSA Program A Multimodal Prediction Model for Diagnosing Pulmonary Hypertension in Systemic Sclerosis • Arthritis Care & Research • June 9, 2022 • CTSA Program Factors Associated with Severity of Acute Kidney Injury and Adverse Outcomes in Critically Ill Patients with COVID-19 • Nephron • June 8, 2022 • CTSA Program Host Cells Subdivide Nutrient Niches Into Discrete Biogeographical Microhabitats for Gut Microbes • Cell Host & Microbe • June 8, 2022 • CTSA Program Placental Dysfunction Influences Fetal Monocyte Subpopulation Gene Expression in Preterm Birth • JCI Insight • June 8, 2022 • CTSA Program Evaluation of an Online Case Study-Based Course in Translational Science for a Broad Scientific Audience: Impacts on Students' Knowledge, Attitudes, Planned Scientific Activities, and Career Goals • Journal of Clinical and Translational Science • June 7, 2022 • NCATS Education Branch Academic Medical Center Clinical Research Professional Workforce: Part 2 - Issues in Staff Onboarding and Professional Development • Journal of Clinical and Translational Science • June 3, 2022 • CTSA Program Analysis of Urine Drug Test Results from Substance Use Disorder Treatment Practices and Overdose Mortality Rates, 2013-2020 • Journal of the American Medical Association • June 3, 2022 • CTSA Program Assessment of the Relative Clinical Utility of Shortened Finnegan Neonatal Abstinence Scoring Tools • Journal of Perinatology • June 3, 2022 • CTSA Program CD47 Promotes Autoimmune Valvular Carditis by Impairing Macrophage Efferocytosis and Enhancing Cytokine Production • The Journal of Immunology • June 3, 2022 • CTSA Program Changing Global Epidemiology of Liver Cancer from 2010 to 2019: NASH is the Fastest Growing Cause of Liver Cancer • Cell Metabolism • June 3, 2022 • CTSA Program Hormonal Male Contraception: Getting to Market • Frontiers in Endocrinology • June 3, 2022 • CTSA Program Issues for Recruitment and Retention of Clinical Research Professionals at Academic Medical Centers: Part 1 - Collaborative Conversations Un-Meeting Findings • Journal of Clinical and Translational Science • June 3, 2022 • CTSA Program The Gut Microbiota and Short-Chain Fatty Acids Profile in Postural Orthostatic Tachycardia Syndrome • Frontiers in Physiology • June 2, 2022 • CTSA Program An In Vivo Drug Repurposing Screen and Transcriptional Analyses Reveals the Serotonin Pathway and GSK3 as Major Therapeutic targets for NGLY1 Deficiency • PLoS Genetics • June 2, 2022 • CTSA Program A Multiancestry Genome-Wide Association Study of Unexplained Chronic ALT Elevation as a Proxy for Nonalcoholic Fatty Liver Disease with Histological and Radiological Validation • Nature Genetics • June 2, 2022 • CTSA Program Anesthetic Preconditioning of Traumatic Brain Injury Is Ineffective in a Drosophila Model of Obesity • Journal of Pharmacology and Experimental Therapeutics • June 1, 2022 • CTSA Program Are Outcomes of Temporomandibular Joint Arthroscopy Influenced by Central Sensitization? • Journal of Oral and Maxillofacial Surgery • June 1, 2022 • CTSA Program Assessing and Visualizing Fragility of Clinical Results with Binary Outcomes in R Using the Fragility Package • PLoS One • June 1, 2022 • CTSA Program Diagnostic Studies: Measures of Accuracy in Nursing Research • American Journal of Nursing • June 1, 2022 • CTSA Program Dispatches from Biotech Beginning Beginngs: Rapid Newborn Genome Sequencing to End the Diagnostic and Therapeutic Odyssey • American Journal of Medical Genetics, Seminars in Medical Genetics, Part C • June 1, 2022 • CTSA Program High Neutrophil-Lymphocyte Ratio and Delta Neutrophil-Lymphocyte Ratio Are Associated With Increased Mortality in Patients With Hepatocellular Cancer • Digestive Diseases and Sciences • June 1, 2022 • CTSA Program Nutrition Interventions in Congenital Disorders of Glycosylation • Trends in Molecular Medicine • June 1, 2022 • RDCRN Performance of a Chest Radiograph AI Diagnostic Tool for COVID-19: A Prospective Observational Study • Radiology: Artificial Intelligence • June 1, 2022 • CTSA Program Trends in Prescribing Opioids, Benzodiazepines, and Both among Adults with Alcohol Use Disorder in New York State • Journal of General Internal Medicine • June 1, 2022 • CTSA Program May 2022 The Effects of Betamethasone on the Amplitude Integrated EEG of Infants Born at 34- or 35-Weeks Gestation • Journal of Perinatology • May 26, 2022 • NCATS Associations between Endogenous Sex Hormones and FGF-23 among Women and Men in the Multi-Ethnic Study of Atherosclerosis • PLoS One • May 25, 2022 • CTSA Program Genetics Etiologies and Genotype Phenotype Correlations in a Cohort of Individuals with Central Conducting Lymphatic Anomaly • European Journal of Human Genetics • May 24, 2022 • CTSA Program Prostate Surface Distension and Tumor Texture Descriptors from Pre-Treatment MRI Are Associated with Biochemical Recurrence Following Radical Prostatectomy: Preliminary Findings • Frontiers in Oncology • May 20, 2022 • CTSA Program Using Gamification to Enhance Clinical Trial Start-Up Activities • Journal of Clinical and Translational Science • May 19, 2022 • CTSA Program Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants • The New England Journal of Medicine • May 18, 2022 • CTSA Program Pivoting Novel Exosome-Based Technologies for the Detection of SARS-CoV-2 • Viruses • May 18, 2022 • Division of Preclinical Innovation Effect of a Brain-Penetrant Selective Estrogen Receptor Degrader (SERD) on Binge Drinking in Female Mice • Alcoholism: Clinical and Experimental Research • May 17, 2022 • CTSA Program Identifying Who Has Long COVID in the USA: A Machine Learning Approach Using N3C Data • The Lancet Digital Health • May 16, 2022 • CTSA Program Rising Incidence and Prevalence of Systemic Lupus Erythematosus: A Population-Based Study over Four Decades • Annals of the Rheumatic Diseases • May 16, 2022 • CTSA Program Study Protocol to Test the Efficacy of Self-Administration of Dexmedetomidine Sedative Therapy on Anxiety, Delirium, and Ventilator Days in Critically Ill Mechanically Ventilated Patients: An Open-Label Randomized Clinical Trial • Trials • May 16, 2022 • CTSA Program Frontal Balloon Sinuplasty in Complicated Acute Pediatric Rhinosinusitis (ARS) • Case Reports in Otolaryngology • May 14, 2022 • CTSA Program Uncovering Conditional Vulnerabilities in Human Cancer Cells • The FASEB Journal • May 13, 2022 • Division of Preclinical Innovation E-Consent—A Guide to Maintain Recruitment in Clinical Trials during the COVID-19 Pandemic • Trials • May 12, 2022 • CTSA Program Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients with Multifocal Intrahepatic Cholangiocarcinoma • JAMA Surgery • May 11, 2022 • NCATS PVP1-The People's Ventilator Project: A Fully Open, Low-Cost, Pressure-Controlled Ventilator Research Platform Compatible with Adult and Pediatric Uses • PLoS One • May 11, 2022 • CTSA Program Revival of Light Signalling in the Postmortem Mouse and Human Retina • Nature • May 11, 2022 • CTSA Program Decreased Rate of Presentation, but Worsened Racial-Ethnic Disparity in Acute Gastrointestinal Bleeding During Coronavirus 2019 Shutdown: A Retrospective Cohort Study • Clinical and Experimental Gastroenterology • May 10, 2022 • CTSA Program Close the Pack of Cigarettes - Close the Care Gap: Reflections after World Cancer Day 2022 • Tobacco Induced Diseases • May 9, 2022 • CTSA Program Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case-Control Study Using the PLCO Cancer Screening Trial Data • Cancer Epidemiology, Biomarkers & Prevention • May 9, 2022 • CTSA Program Informative Missingness: What Can We Learn from Patterns in Missing Laboratory Data in the Electronic Health Record? • Harvard University • May 8, 2022 • CTSA Program Recommendations from the IRDiRC Working Group on Methodologies to Assess the Impact of Diagnoses and Therapies on Rare Disease Patients • Orphanet Journal of Rare Diseases • May 7, 2022 • GARD A Community-University Run Conference as a Catalyst for Addressing Health Disparities in an Urban Community • Journal of Clinical and Translational Science • May 6, 2022 • NCATS Longitudinal Assessment of Colonoscopy Adverse Events in the Prospective Cooperative Studies Program No. 380 Colorectal Cancer Screening and Surveillance Cohort • Gastrointestinal Endoscopy • May 6, 2022 • CTSA Program The Potential Epidemiologic, Clinical, and Economic Impact of Requiring Schools to Offer Physical Education (PE) Classes in Mexico City • PLoS One • May 6, 2022 • All of Us Research Program A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors • Molecular Cancer Therapeutics • May 5, 2022 • Division of Preclinical Innovation Leveraging Cardiac Magnetic Resonance Imaging to Assess Skeletal Muscle Progression in Duchenne Muscular Dystrophy • Neuromuscular Disorders • May 3, 2022 • CTSA Program Association of Inappropriate Outpatient Pediatric Antibiotic Prescriptions with Adverse Drug Events and Health Care Expenditures • Journal of the American Medical Association • May 2, 2022 • CTSA Program Demographic and Clinical Characteristics Associated with the Failure of Nonoperative Management of Uncomplicated Appendicitis in Children: Secondary Analysis of a Nonrandomized Clinical Trial • Journal of the American Medical Association • May 2, 2022 • CTSA Program Immunomodulatory Therapy Using a Pediatric Dialysis System Ameliorates Septic Shock in Miniature Pigs • Pediatric Research • May 2, 2022 • SBIR/STIR Comparison of Equine Synovial Sepsis Rate Following Intrasynovial Injection in Ambulatory Versus Hospital Settings • Equine Veterinary Journal • May 1, 2022 • CTSA Program Duration of Effectiveness of Coblation for Recurrent Epistaxis In Hereditary Hemorrhagic Telangiectasia • American Journal of Otolaryngology • May. 1, 2022 • CTSA Program Early Outpatient Treatment for Covid-19 with Convalescent Plasma • The New England Journal of Medicine • May. 1, 2022 • CTSA Program Evaluating Eosinophilic Colitis as a Unique Disease Using Colonic Molecular Profiles: A Multi-Site Study • Gastroenterology • May 1, 2022 • RDCRN Failure to Compensate: Patients with Nerve Injury Use Their Injured Dominant Hand, Even When Their Nondominant Is More Dexterous • Archives of Physical Medicine and Rehabilitation • May 1, 2022 • CTSA Program Feasibility of the Soft Attention-Based Models for Automatic Segmentation of OCT Kidney Images • Optica Publishing Group • May 1, 2022 • CTSA Program Going beyond the Chest X-ray: Investigating Laterality Defects in Primary Ciliary Dyskinesia • Pediatric Pulmonology • May 1, 2022 • RDCRN An Intervention in Congruence for End-of-Life Treatment Preference: A Randomized Trial • Pediatrics • May 1, 2022 • CTSA Program Remote Stewardship for Medically Underserved Nurseries: A Stepped-Wedge, Cluster Randomized Study • Pediatrics • May 1, 2022 • CTSA Program | Scientific Publications | Scientific Publications | ||||||
| 24683 | Immune Modulator Drugs Improved Survival for People Hospitalized with COVID-19 | UPDATE: The ACTIV-1 trial is complete. The resulting data has been deposited in the NIAID Clinical Trials Repository. Investigators interested in using ACTIV-1 data for research projects may file a data access request. ACTIV-1 biospecimens are also available. Illustration of a cytokine storm response to infection with the coronavirus SARS-CoV-2. A cytokine storm is a severe immune reaction that results in greatly elevated levels of inflammatory immune proteins (cytokines, purple) in the body. (Fernando Da Cunha/Science Photo Library)June 2, 2022A large randomized, placebo-controlled clinical trial led by the National Institutes of Health shows that treating adults hospitalized with COVID-19 with infliximab or abatacept — drugs widely used to treat certain autoimmune diseases — did not significantly shorten time to recovery but did substantially improve clinical status and reduce deaths.Some COVID-19 patients experience an immune response in which the immune system unleashes excessive amounts of proteins that trigger inflammation that can lead to acute respiratory distress syndrome, multiple organ failure and other life-threatening complications. As part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private initiative, NIH launched the ACTIV-1 Immune Modulators clinical trial to determine if certain drugs that help minimize the effects of an overactive immune response could speed recovery and reduce deaths in adults hospitalized with moderate to severe COVID-19. The ACTIV-1 master protocol included three sub-studies; each one tested an immune modulator drug as compared to a placebo. This approach allowed for coordinated and efficient evaluation of multiple investigational agents simultaneously.NCATS coordinated and oversaw the trial with funding from the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response.“These promising ACTIV-1 results demonstrate the collaborative power of public-private partnerships to accelerate therapeutic answers during this unprecedented global health crisis,” said Acting NIH Director Lawrence A. Tabak, D.D.S., Ph.D. “Working together, NIH and our ACTIV partners have brought to bear the best tools and clinical trial designs in our research arsenals. The innovative ACTIV model is bringing greater clarity to the search for effective, evidence-based COVID-19 treatments.”ACTIV-1 participants were randomly assigned to one of the immune modulator drugs or placebo in addition to the standard of care, which may include remdesivir (Veklury) supplied by Gilead Sciences, Inc. About 90% received remdesivir, and about 85% received dexamethasone.Investigators monitored participants and recorded their clinical status daily while hospitalized according to an eight-point scale ranging from not hospitalized with no limitations on activities to death. The full report on these data in a peer-reviewed scientific journal is expected in fall of 2022, and a preprint will be available sooner.The topline results showed:Compared to placebo, participants receiving infliximab (Remicade) displayed a strong but not statistically significant improvement in the primary endpoint of time to recovery as measured by day of discharge from hospital. Substantial improvements for both key secondary endpoints of mortality and clinical status at 28 days were observed. The 518 participants receiving infliximab had a death rate of 10.0%, compared to 14.5% for the 519 participants receiving placebo, resulting in 40.5% lower adjusted odds of dying. The relative improvement in mortality was similar in both moderately and severely ill participants. People in the infliximab group had 43.8% better odds of clinical improvement than those in the placebo group. Infliximab, which was given as a single dose, was developed and is marketed by Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.Compared to placebo, participants receiving abatacept (Orencia) displayed a strong but not statistically significant improvement in the primary endpoint of time to recovery as measured by day of discharge from hospital. Substantial improvements for both key secondary endpoints of mortality and clinical status at 28 days were observed. The 509 participants receiving abatacept had a death rate of 11.0%, compared to 15.0% for the 513 participants receiving placebo, resulting in 37.4% lower adjusted odds of dying. The relative improvement in mortality was similar in both moderately and severely ill participants. People in the abatacept group had 34.2% better odds of clinical improvement than those in the placebo group. Abatacept, which was given as a single dose, was developed and is marketed by Bristol Myers Squibb.Enrollment into the third sub-study evaluating the investigational medicine cenicriviroc was stopped in September 2021 after an independent data and safety monitoring board (DSMB) recommended closing it due to lack of efficacy. Cenicriviroc was provided by AbbVie.The results will be made available to treatment guideline groups and regulatory bodies.“When given in addition to standard of care treatments, like remdesivir and dexamethasone, infliximab and abatacept each offered a substantial reduction in mortality,” said the trial’s protocol chair, William G. Powderly, M.D., director of the Institute for Clinical and Translational Sciences and co-director of the Division of Infectious Diseases at Washington University School of Medicine in St. Louis. “These drugs could potentially add to the therapeutic options available for the treatment of patients hospitalized with COVID-19 .”From October 2020 through December 2021, the ACTIV-1 Immune Modulators clinical trial enrolled 1,971 participants at 46 medical facilities in the United States and 23 medical facilities in Latin America. The study was reviewed periodically by an independent DSMB, and no safety concerns were noted during the conduct of the trial.NCATS’ Clinical and Translational Science Awards (CTSA) Program and the Trial Innovation Network played a key role in enrolling participants in the United States. “More than half of the CTSA Program sites contributed their infrastructure and expertise to speed completion of this trial,” said Joni L. Rutter, Ph.D., acting director of NCATS. “This collaborative and efficient multinational platform trial design streamlined our ability to urgently and robustly test promising therapies for treating people hospitalized with COVID-19.”For more information about the trial, please visit clinicaltrials.gov and search identifier NCT04593940.Media Contact: NCATS Information Officer, ncatsinfo@mail.nih.gov.About HHS, ASPR, and BARDA: HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA invests in the innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures — vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats. To date, BARDA-supported products have achieved 62 FDA approvals, licensures or clearances. For more on BARDA’s development portfolios and on partnering with BARDA, visit medicalcountermeasures.gov.About the National Center for Advancing Translational Sciences (NCATS): NCATS conducts and supports research on the science and operation of translation — the process by which interventions to improve health are developed and implemented — to allow more treatments to get to more patients more quickly. For more information about how NCATS helps shorten the journey from scientific observation to clinical intervention, visit https://ncats.nih.gov.About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov.NIH…Turning Discovery Into Health® | Two immune modulator drugs were shown to substantially improve clinical status and reduce deaths for adults hospitalized with COVID-19. | /sites/default/files/C0492806-Covid-19_cytokine_storm_illustration_BLUE_900x600_0.jpeg | Immune Modulator Drugs Improved Survival for People with COVID-19 | Two immune modulator drugs were shown to substantially improve clinical status and reduce deaths for adults hospitalized with COVID-19. | /sites/default/files/C0492806-Covid-19_cytokine_storm_illustration_BLUE_900x600_1.jpeg | Immune Modulator Drugs Improved Survival for People with COVID-19 | ||
| 24521 | Scientists Identify Characteristics to Better Define Long COVID | Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility in Fort Detrick, Maryland. (NIAID)May 17, 2022Using machine learning, researchers find patterns in electronic health record data to better identify those likely to have the conditionA research team supported by the National Institutes of Health has identified characteristics of people with long COVID and those likely to have it. Scientists, using machine learning techniques, analyzed an unprecedented collection of electronic health records (EHRs) available for COVID-19 research to better identify who has long COVID. Exploring de-identified EHR data in the National COVID Cohort Collaborative (N3C), a national, centralized public database led by NCATS, the team used the data to find more than 100,000 likely long COVID cases as of October 2021 (as of May 2022, the count is more than 200,000). The findings appeared May 16 in The Lancet Digital Health.Long COVID is marked by wide-ranging symptoms, including shortness of breath, fatigue, fever, headaches, “brain fog” and other neurological problems. Such symptoms can last for many months or longer after an initial COVID-19 diagnosis. One reason long COVID is difficult to identify is that many of its symptoms are similar to those of other diseases and conditions. A better characterization of long COVID could lead to improved diagnoses and new therapeutic approaches.“It made sense to take advantage of modern data analysis tools and a unique big data resource like N3C, where many features of long COVID can be represented,” said co-author Emily Pfaff, Ph.D., a clinical informaticist at the University of North Carolina at Chapel Hill.The N3C Data Enclave currently includes information representing more than 13 million people nationwide, including nearly 5 million COVID-19-positive cases. The resource enables rapid research on emerging questions about COVID-19 vaccines, therapies, risk factors and health outcomes.The new research is part of a related, larger trans-NIH initiative, Researching COVID to Enhance Recovery (RECOVER), which aims to improve the understanding of the long-term effects of COVID-19, called post-acute sequelae of SARS-CoV-2 infection (PASC). RECOVER will accurately identify people with PASC and develop approaches for its prevention and treatment. The program also will answer critical research questions about the long-term effects of COVID through clinical trials, longitudinal observational studies, and more.In the Lancet study, Pfaff, Melissa Haendel, Ph.D., at the University of Colorado Anschutz Medical Campus, and their colleagues examined patient demographics, health care use, diagnoses and medications in the health records of 97,995 adult COVID-19 patients in the N3C. They used this information, along with data on nearly 600 long COVID patients from three long COVID clinics, to create three machine learning models to identify long COVID patients.In machine learning, scientists “train” computational methods to rapidly sift through large amounts of data to reveal new insights — in this case, about long COVID. The models looked for patterns in the data that could help researchers both understand patient characteristics and better identify individuals with the condition.The models focused on identifying potential long COVID patients among three groups in the N3C database: All COVID-19 patients, patients hospitalized with COVID-19, and patients who had COVID-19 but were not hospitalized. The models proved to be accurate, as people identified as at risk for long COVID were similar to patients seen at long COVID clinics. The machine learning systems classified approximately 100,000 patients in the N3C database whose profiles were close matches to those with long COVID.“Once you’re able to determine who has long COVID in a large database of people, you can begin to ask questions about those people,” said Josh Fessel, M.D., Ph.D., senior clinical advisor at NCATS and a scientific program lead in RECOVER. “Was there something different about those people before they developed long COVID? Did they have certain risk factors? Was there something about how they were treated during acute COVID that might have increased or decreased their risk for long COVID?”The models searched for common features, including new medications, doctor visits and new symptoms, in patients with a positive COVID diagnosis who were at least 90 days out from their acute infection. The models identified patients as having long COVID if they went to a long COVID clinic or demonstrated long COVID symptoms and likely had the condition but hadn’t been diagnosed.“We want to incorporate the new patterns we’re seeing with the diagnosis code for COVID and include it in our models to try to improve their performance,” said the University of Colorado’s Haendel. “The models can learn from a greater variety of patients and become more accurate. We hope we can use our long COVID patient classifier for clinical trial recruitment.”This study was funded by NCATS, which contributed to the design, maintenance and security of the N3C Enclave, and the NIH RECOVER Initiative, supported by NIH OT2HL161847. RECOVER is coordinating, among others, the participant recruitment protocol to which this work contributes. The analyses were conducted with data and tools accessed through the NCATS N3C Data Enclave and supported by NCATS U24TR002306.Media Contact: NCATS Information Officer, ncatsinfo@mail.nih.gov.About the National Center for Advancing Translational Sciences (NCATS): NCATS conducts and supports research on the science and operation of translation — the process by which interventions to improve health are developed and implemented — to allow more treatments to get to more patients more quickly. For more information about how NCATS helps shorten the journey from scientific observation to clinical intervention, visit https://ncats.nih.gov.About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov.NIH…Turning Discovery Into Health® | NIH-supported researchers used N3C data and machine learning to better identify common features of long COVID. | /sites/default/files/NIAID_COVID%20Image_900x600_0.jpg | Scientists Identify Characteristics to Better Define Long COVID | NIH-supported researchers used N3C data and machine learning to better identify common features of long COVID. | /sites/default/files/NIAID_COVID%20Image_900x600_1.jpg | Scientists Identify Characteristics to Better Define Long COVID | ||
| 24416 | Job Opportunities | NCATS is looking for innovative partners to join its dynamic team. Learn more about current job opportunities at NCATS or across NIH and the U.S. Department of Health and Human Services (HHS). NIH and HHS are Equal Opportunity Employers. All information provided by candidates will remain confidential and will not be released outside NCATS' search process without a signed release from candidates. NIH encourages the application and nomination of qualified women, minorities and individuals with disabilities. DHHS and NIH are Equal Opportunity Employers. NIH is dedicated to building a diverse community in its training and employment programs. Current Vacancies Supervisory Administrative Officer (Chief), Administrative Services Branch Trial Innovation Network Section Chief, Division of Clinical Innovation, Clinical Affairs Branch Senior Medicinal Chemist (Staff Scientist), Division of Preclinical Innovation, Therapeutics Development Branch, Medicinal Chemistry Group Director, Office of Program Evaluation, Analysis and Reporting (OPEAR), Division of Clinical Innovation Program Officer (Program Director), CTSA Program Branch, Education and Training Section, Division of Clinical Innovation Staff Scientist (Informatics Algorithms Engineer), Division of Preclinical Innovation, Informatics Core Research Associate (Biology), Division of Preclinical Innovation, Chemical Technologies Group Research Scientist (Virology) Position, Division of Preclinical Innovation, 3-D Tissue Bioprinting Laboratory Bioinformatician, Division of Preclinical Innovation, Chemical Genomics Branch, Stem Cell Translation Laboratory Postdoctoral Positions in the Division of Preclinical Innovation Postdoctoral Fellow (Synthetic Chemist), Division of Preclinical Innovation, Therapeutic Development Branch, Medicinal Chemistry Group Systems Toxicology Postdoctoral Fellow, Division of Preclinical Innovation, Toxicology in the 21st Century (Tox21) Program Biology Postdoctoral Position, Division of Preclinical Innovation, Early Translation Branch Biology Postdoctoral Position, Division of Preclinical Innovation, Early Translation Branch Bioanalytical Chemistry Postdoctoral Fellow, Division of Preclinical Innovation, Drug Metabolism and Pharmacokinetics Computational Toxicology/Informatics Postdoctoral Fellow Position, Division of Preclinical Innovation, Computational Toxicology Laboratory Neuroscientist Postdoctoral Fellow Positions, Division of Preclinical Innovation, 3-D Tissue Bioprinting Laboratory Postdoctoral Bioinformatics Position, Division of Preclinical Innovation, Informatics Core Postdoctoral Biomedical Engineer Position, Division of Preclinical Innovation, 3-D Tissue Bioprinting Laboratory Postdoctoral Antibody Discovery and Characterization Position, Division of Preclinical Innovation, Early Translation Branch Postdoctoral Medicinal Chemistry Position, Division of Preclinical Innovation, Therapeutic Development Branch Postdoctoral Genomic Toxicology Position, Division of Preclinical Innovation, Genomic Toxicology Laboratory Postdoctoral Mass Spectrometry Position, Division of Preclinical Innovation, Analytical Chemistry Core Facility Postdoctoral Bioengineering Positions, Division of Preclinical Innovation 3-D Tissue Bioprinting Laboratory Postdoctoral Computational Biologist/Bioinformatician, Division of Preclinical Innovation, Therapeutic Development Branch Postdoctoral Informatics Scientist, Division of Preclinical Innovation, NCATS Chemical Genomics Center (NCGC), Adenine Informatics Group Postdoctoral Informatics Scientist Position, Division of Preclinical Innovation, Informatics Group Stem Cell Scientist and Postdoctoral Positions, Division of Preclinical Innovation, Chemical Genomics Branch, Stem Cell Translation Laboratory Supervisory Administrative Officer (Chief), Administrative Services Branch National Institutes of Health National Center for Advancing Translational Sciences Office of Administrative Management Administrative Services Branch Bethesda, Maryland Description NCATS, a major research component of NIH, seeks applications from qualified candidates to fill a supervisory administrative officer position, serving as chief of the Administrative Services Branch (ASB) within the center’s Office of Administrative Management (OAM). NCATS’ OAM directs the administrative and financial operations management of the center. Specifically, it develops, administers and oversees the center’s internal control processes, policies, and procedures for administration, program management, and information technology. It also oversees personnel management and workforce planning. The mission of OAM is to empower NCATS to accelerate translational sciences through administrative and technological excellence. Core Responsibilities As a supervisory administrative officer, the selected candidate will serve as the chief of ASB and provide management, direction and oversight for the branch in carrying out a broad range of administrative programs and functions for NCATS. The ASB chief will serve as an advisor for all human resource management activities, perform a full range of supervisory functions, oversee all administrative management matters associated with the center’s programs and operations, oversee monitoring of the budget process, and participate in and oversee planning sessions related to a range of administrative areas. Qualifications Candidates must demonstrate at least one year of qualifying experience equivalent to at least the GS-14 level in the federal service obtained in either the private or public sector. The successful candidate must have extensive experience in (1) managing or directing major components of programs that perform professional, technical or administrative work; (2) providing strategic and business advice to senior-level officials on a wide range of complex policy or program matters involving significant or controversial issues; (3) developing and implementing administrative policies, procedures or initiatives to meet organizational needs and accomplish program objectives; (4) providing leadership, guidance and advice on matters related to a variety of administrative management functions; (5) analyzing budget formulation; (6) overseeing staffing and personnel; (7) allocating and tracking resources and managing and evaluating their use. Salary/Benefits Salary is commensurate with experience and accomplishments; a full civil service package of benefits — including retirement; health, life and long-term care insurance; and Thrift Savings Plan (401[k] equivalent) participation — is available. How to Apply This vacancy, open to current employees of the U.S. Department of Health and Human Services serving on a permanent appointment in the competitive service, is advertised under merit promotion (MP) procedures on USAjobs.gov under announcement NIH-NCATS-MP-23- 11915345. This vacancy is open from April 24 to May 3, 2023. This announcement includes additional information regarding qualification requirements, evaluation criteria and application instructions. Please direct questions about applying to Sindy Barnette at 301-827-1296 or sindy.barnette@nih.gov. Review of applicants will begin on May 4, 2023. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Trial Innovation Network Section Chief, Division of Clinical Innovation, Clinical Affairs Branch National Institutes of Health National Center for Advancing Translational Sciences Division of Clinical Innovation Clinical Affairs Branch Bethesda, Maryland Description NCATS, a major research component of NIH, seeks applications from exceptional candidates for a Trial Innovation Network section chief position in the center’s Division of Clinical Innovation (DCI). Candidates should have recognized leadership and demonstrated expertise in improving clinical trial efficiency through tool development, clinical trial training and education. The selected candidate also will be expected to broaden the scope of clinical trial questions and the clinical trial enterprise so that trials address the health concerns of people in a broad variety of situations and locations, including those living in rural and remote locations, individuals of diverse cultures and beliefs, and minority populations. The section chief will be responsible for developing a strategy to test, disseminate and incorporate the tools developed by this section and from other parts of the NCATS Trial Innovation Network, ensuring the dissemination and sustainability of these tools within NCATS-funded programs, NIH and the extramural research community. Dissemination should include a variety of organization types and geographic locations. To facilitate this, the Trial Innovation Network section chief will work with clinical trial networks and training programs through NIH and non-NIH programs to ensure that the tools are accessible and used appropriately. This process will be iterative and bilateral, such that suggestions and requests from collaborators will be provided back to the Trial Innovation Network to make sure the needs of participants, families, communities, providers and researchers are optimized. To this end, community engagement will be important to enhance the tool development process, increase uptake and dissemination, and ensure that the necessary types of tools are developed. Clinical trials are balanced by understanding efficacy/effectiveness and outcome measures, but safety is paramount. Therefore, the section chief will be responsible for tool development that highlights, flags or streamlines safety issues and will lead clinical safety protocol activities within DCI. The position will be within the Clinical Affairs Branch of DCI, which supports the NCATS Trial Innovation Network and The Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®. Core Responsibilities The Trial Innovation Network section chief will be responsible for providing authoritative, technical and scientific leadership and guidance for the clinical trial activities within DCI and when needed by NCATS and NIH. The section chief will direct the activities of the section, including providing a national resource for rapid response to public health emergencies via the Trial Innovation Network and promoting the identification, development and dissemination of innovative clinical trial designs and recruitment strategies. The section chief will develop and provide resources for the planning, implementation and conduct of NIH-supported clinical trials. The section’s products and resources aim to improve clinical trial efficiency, maximize safety and enhance the types of information within clinical trials. Examples of the activities within the section will include the implementation of techniques/tools to enhance trial design, site selection efficiency, Institutional Review Board efficiency, startup and expansion efficiency, realistic cost, and time calculations for both NIH and investigator expectations, personnel, and site turnover issues. The section chief will serve as a senior leader, representing DCI and NCATS in clinical, research and clinical trial training/career development programs across NIH, other government agencies, industry, academia and patient-support organizations. The section chief will provide advice to the clinical affairs branch chief and the DCI director on trial-, safety- and clinical-related matters. The section chief will also work to diversify the clinical trial landscape by working in coordination with the various components of DCI, including the Education and Training Section of the Clinical and Translational Science Awards (CTSA) Program Branch. The CTSA Program Branch supports the CTSA Program, an innovative national network of more than 60 medical research centers that aims to improve human health by transforming the research and training environment to enhance the efficiency and quality of clinical and translational research. Qualifications The successful candidate will have a Medical Doctorate (M.D.), an active state medical license, and real-world experience in academia or industry in clinical trial development and conduct. The successful candidate will have experience in trial bottlenecks/barriers, optimization strategies and potential efficiencies. An important aspect of the position will be safety; therefore, the successful candidate will have extensive experience with clinical safety issues. The successful candidate also will have strong and demonstratable experience in conceiving, developing and testing tools to support clinical trials in novel groups and settings. The successful candidate will also have a strong history of working with diverse federal and nonfederal organizations and partners. The successful candidate must have extensive experience in (1) leading a diverse, highly complex research program and employing strategies for implementing and disseminating research tools and products; (2) providing expert advice to senior leaders on scientific and clinically relevant policies and programs; (3) developing innovative training programs for advancing clinical tool development, dissemination and usage by trainees; and (4) leading teams. The successful candidate must appreciate new trends in the clinical trial enterprise, such as the novel use of informatics, big data and site-selection strategies to improve the conduct of trials. The successful candidate will have the ability to communicate and collaborate well with others. Candidates should demonstrate (1) a clear pattern of success in setting, planning, implementing and analyzing research projects, program objectives and priorities; (2) the ability to communicate and collaborate effectively with diverse scientific and lay audiences; and (3) the ability to form collaborations with national and international organizations, as well as with individuals who represent wide-ranging disciplines and competing priorities. Salary/Benefits Salary is commensurate with qualifications, experience and accomplishments; a full civil service package of benefits — including retirement; health, life and long-term care insurance; and Thrift Savings Plan (401[k] equivalent) participation — is available. How to Apply Interested individuals should apply from April 11 to May 10, 2023 (submission deadline may be extended if needed) by submitting (via email) a cover letter describing their interest in the position and a curriculum vitae with a complete bibliography, and the names of and contact information for at least three references to NCATSSBRBPASPosition@nih.gov. Include your name and name of the position in the subject line. Please submit questions about this position to Salina Waddy, M.D., via salina.waddy@nih.gov. Review of applications will begin May 11, 2023, and will continue until the position is filled. Do not include your birthdate or social security number on application materials. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Senior Medicinal Chemist (Staff Scientist), Division of Preclinical Innovation, Therapeutics Development Branch, Medicinal Chemistry Group National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Therapeutics Development Branch Medicinal Chemistry Group Rockville, Maryland Description NCATS, a major research component of the NIH, seeks applications from exceptional candidates to fill a senior medicinal chemist (staff scientist) position in the Therapeutic Development Branch (TDB) within its Division of Preclinical Innovation (DPI) in Rockville, Maryland. The selected applicant will manage Investigational New Drug–enabling drug development projects involving collaborations with other NIH institutes, centers and offices; academic scientists; and industry and nonprofit organizations. The scientists within DPI come from a broad range of scientific disciplines — including therapeutic discovery, medicinal chemistry, pharmacology and preclinical development — and work to reduce, remove or bypass significant bottlenecks across the entire continuum of translation and to train the future translational science workforce. This position will require a strong understanding of all aspects of medicinal chemistry and related disciplines to be able to advance projects from lead identification to the development of candidate selection. The senior medicinal chemist will work with project teams to define project goals and go/no-go criteria and manage timelines and chemistry resources to drive projects toward key decision criteria. Core Responsibilities The selected candidate will lead projects at various stages, from lead generation through clinical candidate nomination, and will be responsible for designing, implementing and executing synthetic and medicinal chemistry strategies; developing new technologies to accelerate drug discovery; presenting results in internal and external meetings; and writing reports and manuscripts. Research will be conducted in the TDB medicinal chemistry group. Qualifications Applicants should possess a doctoral degree (M.D., Ph.D. or equivalent) in organic chemistry or medicinal chemistry, with at least 10 years of experience working in drug discovery or related fields. A strong background in synthetic organic chemistry is required. Experience in synthesis of complex small molecules, including natural products and designer molecules, is highly desirable. Candidates with experience in developing new methods or technologies highly relevant to the broad field of drug development will be considered favorably. Applicants should be able to lead medicinal chemistry projects and have a strong track record of scientific innovation and success in delivering clinical candidates. The ideal applicant should be self-motivated, possess a strong work ethic, have a keen attention to detail, and be able to work on multiple projects simultaneously. The applicant should possess strong oral and written communication skills, with a proven publication record in peer-reviewed journals. Salary/Benefits Salary is commensurate with experience and accomplishments; a full civil service package of benefits — including retirement; health, life and long-term care insurance; and Thrift Savings Plan (401[k] equivalent) participation — is available. How to Apply Please submit a cover letter describing your interest in the position, including a career synopsis (one to three pages); a current curriculum vitae and complete bibliography; and the names of and contact information for three references to Wenwei Huang, Ph.D., via ncatsssrecruit@mail.nih.gov. The position will remain open for 30 days beginning April 7, 2023. To learn more about the Therapeutics for Rare and Neglected Diseases (TRND) program, visit https://ncats.nih.gov/trnd. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Director, Office of Program Evaluation, Analysis and Reporting (OPEAR), Division of Clinical Innovation National Institutes of Health National Center for Advancing Translational Sciences Division of Clinical Innovation Office of Program Evaluation, Analysis and Reporting Bethesda, Maryland Description NCATS, a major research component of NIH, is seeking applications from exceptional candidates for a director position in the Office of Program Evaluation, Analysis and Reporting (OPEAR) within the center’s Division of Clinical Innovation (DCI). Candidates should have recognized leadership abilities and demonstrated expertise in program evaluation, analysis and reporting. This office will serve the Clinical and Translational Science Award (CTSA) Program, an innovative national network of more than 50 medical research institutions that aims to improve human health by transforming the research and training environment to enhance the efficiency and quality of clinical and translational research. The OPEAR is responsible for (1) planning, conducting and supporting evaluation, analysis and reporting for DCI; (2) coordinating, providing and supporting communications for DCI; and (3) liaising with the offices within NCATS and across NIH to accomplish synergistic goals. Core Responsibilities The director is responsible for providing authoritative, technical and scientific leadership and guidance in the areas of program evaluation, analysis and reporting for the CTSA Program. The director will serve as a senior leader, representing DCI and NCATS in program evaluation, analysis and reporting across NIH and with other government agencies, industry, academia and patient-support organizations, as well as advising the DCI director on related matters. The director will provide leadership and oversight in data collection, data analysis, reporting and evaluation, including coordinating and support communications for DCI. He or she also will serve as the DCI liaison to other offices within NCATS and across NIH to assist the DCI director in accomplishing synergistic goals. Qualifications Each applicant should possess an advanced degree (M.D. and/or Ph.D.) or an advanced health science degree and have extensive knowledge and experience in program evaluation, analysis and reporting used to demonstrate and communicate the impact of research and other activities. Candidates must have extensive expertise in (1) leveraging innovative approaches to assess, quantify and communicate impact for large research networks; (2) successfully applying methods and approaches for evaluating, analyzing and reporting on large complex programs; (3) providing expert advice to senior leaders on evaluating, analyzing and reporting on large complex programs; (4) developing innovative evaluation approaches to monitor progress and assess impact; (5) managing competing priorities and projects; and (6) leading teams. The candidate must appreciate the challenges of working with diverse stakeholders and communicating impact clearly to various audiences, and he or she must be aware of new trends in clinical and translational science research and be able to communicate and collaborate well with others. The ideal candidate will have contracting experience as a contracting officer representative (COR) with level COR II certification or above. Candidates should demonstrate (1) a clear pattern of success in setting, planning, implementing and analyzing research project or program objectives and priorities; (2) the ability to communicate effectively with diverse scientific and lay audiences; and (3) the ability to form collaborations with national and international organizations, as well as with individuals who represent wide-ranging disciplines and competing priorities. Salary/Benefits Salary is commensurate with experience and accomplishments; a full civil service package of benefits — including retirement; health, life and long-term care insurance; and Thrift Savings Plan (401[k] equivalent) participation — is available. How to Apply Interested individuals should submit applications via USAJobs.gov through the Health Science Administrator (601 series) or the Social Behavioral Scientist (101 series) at the supervisory GS-15 level or be considered for a transfer within NIH if currently in this type of position. Please email a cover letter describing your interest in the position, current curriculum vitae and complete bibliography to Erica K. Rosemond, Ph.D., acting deputy director, Division of Clinical Innovation, via rosemonde@mail.nih.gov. The review of applications will begin immediately and will continue until the position is filled. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Program Officer (Program Director), CTSA Program Branch, Education and Training Section, Division of Clinical Innovation National Institutes of Health National Center for Advancing Translational Sciences Division of Clinical Innovation CTSA Program Branch, Education and Training Section Bethesda, Maryland Description NCATS, a major research component of NIH, is seeking applications from exceptional candidates for a program officer (program director) position in the Education and Training Section of the Clinical and Translational Science Award (CTSA) Program Branch within the center’s Division of Clinical Innovation (DCI). Candidates should have recognized leadership abilities and demonstrated innovation and expertise in clinical research. The CTSA Program is an innovative national network of more than 50 medical research institutions that aims to improve human health by transforming the research and training environment to enhance the efficiency and quality of clinical and translational research. The Education and Training Section plans, conducts and supports the CTSA Education and Training Program in training and cultivating the translational science workforce and fostering the development of the field of translational science. Core Responsibilities The program officer in the Education and Training Section will support extramural grants through the CTSA Program, with a focus on institutional training, institutional career development, research education, small research grants and supplement awards (including research supplements to promote diversity, re-entry and reintegration into health-related research careers). Program officers in this section serve as DCI representatives to the CTSA Program groups focused on supporting the clinical and translational science workforce, including the Workforce Enterprise Committee, KL2 principal investigator (PI)/program director (PD) Group, and TL1 PI/PD Group. Qualifications Each applicant should possess an advanced scientific health degree (M.D. and/or Ph.D.) and have extensive knowledge and experience in a relevant scientific discipline. Candidates must have (1) recognizable accomplishments and career progression in a research activity related to health or biomedical/behavioral sciences, as well as competence in management; (2) the ability to communicate effectively to plan, initiate, administer and evaluate a scientific program successfully; (3) familiarity with the dynamics of health-related research; (4) the ability to understand the internal relationships of partner and grantee organizations conducting research, as well as the practices and policies affecting national health research efforts; (5) the ability to work effectively and cooperatively with others; (6) experience developing and maintaining good working relationships with Initial Review Groups, members of National Advisory Councils and Boards, representatives of academic institutions, the scientific community, public and private organizations and agencies, and the general public, as well as supervisors, colleagues and subordinates. The selected candidate must appreciate the challenges of working with diverse stakeholders and communicating impact clearly to various audiences. He or she should be aware of new and emerging trends in clinical and translational science research and be able to communicate and collaborate well with others. Salary/Benefits The current salary range is commensurate with experience and accomplishments for a Health Science Administrator (601 series), Physician (Research) — 602 series — or Social Behavioral Scientist (101 series) at the GS 12/13/14 levels; a full civil service package of benefits — including retirement; health, life and long-term care insurance; and Thrift Savings Plan (401[k] equivalent) participation — is available. How to Apply Interested individuals should submit applications via USAJobs.gov through the Health Science Administrator (601 series), the Physician (Research) — 602 series — or the Social Behavioral Scientist (101 series) at the GS 12/13/14 levels or be considered for a transfer within NIH if currently in these types of positions. Please email a cover letter describing your interest in the position, current curriculum vitae and complete bibliography to Patrick H. Brown, Ph.D., section chief, CTSA Program Branch, Education and Training Section, Division of Clinical Innovation, via patrick.brown@nih.gov. The review of applications will begin immediately and will continue until the position is filled. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Staff Scientist (Informatics Algorithms Engineer), Division of Preclinical Innovation, Informatics Core National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Informatics Core Rockville, Maryland Description NCATS, a major research component of NIH, seeks applications from exceptional candidates to fill a staff scientist (informatics algorithms engineer) position in the Informatics Core (IFX) within the Division of Preclinical Innovation (DPI). The mission of IFX is to produce data-driven decisions and accelerate translation through innovative informatics methods and software and deep domain expertise in informatics and various translational research data types. This mission is achieved through our team science culture and collaborations that span DPI, extramural NCATS programs, other federal institutions, industry/biotech, and academic institutions nationally and internationally. IFX efforts and contributions are broadly organized into 1) Building Standards, Knowledge Sources, and Software; 2) Translational Data Analytics; 3) Scientific Computing Services and Research. These efforts are highly synergistic where outcomes from one category inform and are expanded into others. Core Responsibilities The successful candidate will develop novel informatics and statistical methods/workflows and proof-of-concept tools to support the integration, analysis and interpretation of translational research data and make these outcomes publicly available to the broader research community. These data result from efforts in basic research, patient-oriented research and population-based research. The selected candidate will interact closely with the IFX director, computational and noncomputational (e.g., biologists, chemists, clinicians) IFX and NCATS scientists and our academic collaborators. He or she will contribute to the strategic vision and to the mentoring of trainees. The selected candidate will be encouraged to seek NCATS, NIH or external collaborations to further amplify and improve the center’s IFX informatics methods and software. He or she will elaborate on machine and deep learning and architectures from aggregation and cleaning of in-house translational research data (e.g., high-throughput screens, multi-omic, knowledge sources on chemical, biological, or disease annotations, etc.). To augment translational research efforts, the selected candidate will promote the use of and/or contribute to the development of chemical, biological and disease standards that help piece together complementary lines of information. The selected candidate will be expected to create and maintain documentation for methods/workflows to enable their reuse by IFX members or other researchers. Furthermore, he or she will contribute to the establishment of software development and deployment best practices for IFX, including acting as an owner/point of contact for repositories, data systems and servers. The selected candidate will contribute to building a consolidated scientific computing environment through integration and interoperability of libraries and software and will apply or develop appropriate, state-of-the art methods to support large-scale data-acquisition efforts within the DPI. Active participation in IFX and NCATS committees and meetings, as appropriate, will be encouraged to showcase and obtain feedback (e.g., user feedback) on methods and software developed. He or she will be expected to draft manuscripts and publish results in high-impact, peer-reviewed scientific journals and to present results at internal and external scientific meetings. Qualifications The ideal candidate should possess a doctoral degree (M.D., Ph.D. or equivalent) in a relevant field and be a recognized expert in the field. Applicants should possess a broad range of informatics experience that includes at least some of the following: Machine learning and/or deep learning (Bayesian inference, Probabilistic programming, NLP, TensorFlow, etc.); experience in graph, NoSQL and/or RDBMS databases and semantic data standards (e.g., OWL, RDF); scripting programming for high-throughput data processing and visualization (e.g., R, Python); Linux environments, high-computing servers, cloud computing; versioning systems (GitHub), full-stack software development. A strong preference will be given to applicants with knowledge in biology and/or chemistry and an understanding of data provenance (e.g., cell biology, methods for measuring multi-omic data, high throughput screens, biochemistry, genetics). Candidates should have proven experience in analyzing a broad range of data types across different diseases and exploit these data for therapeutic development. The selected candidate should have excellent interpersonal, verbal and written communication skills and should possess excellent analytical, organizational and time management skills. The desire and drive to seek out and master novel technologies and to develop new ones is expected. Salary/Benefits Salary is commensurate with experience and accomplishments; a full civil service package of benefits — including retirement; health, life and long-term care insurance; and Thrift Savings Plan (401[k] equivalent) participation — is available. How to Apply Please submit (via email) a cover letter describing your career goals and interest in the position, including a research summary (one to two pages), a current curriculum vitae with a complete bibliography, and the names of and contact information for at least three references to Ewy A. Mathé, Ph.D., at ewy.mathe@nih.gov. The review of applications will begin immediately and will continue until the position is filled. Learn more about informatics research at NCATS. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Research Associate (Biology), Division of Preclinical Innovation, Chemical Technologies Group National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Chemical Technologies Group Rockville, Maryland Description NCATS, a major research component of NIH, seeks applications from qualified candidates to fill a research associate (biology) position in the Chemical Technology group within its Division of Preclinical Innovation (DPI). The DPI is home to approximately 230 biologists, medicinal and process chemists, and computational scientists who work on a broad portfolio of preclinical drug discovery projects, as well as programs that involve the development of innovative new technologies to enable the acceleration of biomedical research. The Chemical Technology group operates at the interface between chemistry and biology. A major focus of the team involves conducting large-scale chemogenomic screenings to identify novel targets and to develop novel strategies for therapeutic intervention, mostly focusing on oncologic indications. A second major focus of the team involves the discovery, optimization and advancement of novel biologically active small molecules. Core Responsibilities The selected candidate will maintain mammalian cell-line cultures and expand them to scale in preparation of high-throughput drug screening; prepare various media, stock supplies and other reagents for use in the laboratory; perform in vitro cell-based assays to support the molecular characterization of drugs’ mechanism of action. These include DNA/RNA extraction, PCR and western-blot. The selected applicant also will maintain accurate daily records of experiments and results and interpret, evaluate and discuss the result of each experiment as part of the experimental-planning process. The selected candidate will perform computer analysis of data and use various software to prepare data figures for both internal discussion and publication. Qualifications Applicants to this research associate (biology) position should possess a bachelor's degree in biology, biochemistry or other related life science discipline. A master’s in cell biology, immunology, biochemistry or other related life science discipline is preferred. The selected candidate should possess a conceptual understanding of cancer biology and knowledge of major oncogenic signaling pathways in human cancers, a strong background in cell biology, have at least two years of previous experience with standard molecular biology techniques (e.g., tissue culture, RNA and DNA extraction, PCR and western-blot) and be proficient at the bench. He or she should demonstrate attention to detail and possess strong organizational and interpersonal skills. Applicants also should possess excellent verbal and written communication skills, the ability to interpret, summarize and present scientific results in a clear, concise and accurate manner; and be able to work productively as a member of a diverse and dynamic multidisciplinary team. The ideal candidate will have previous experience with high-throughput drug screening, Illumina next-generation sequencing platforms and related library preparation procedures (especially RNA-Seq and single-cell analysis), as well as documented knowledge of the hippo signaling pathway. Previous experience in microscopy, immunocytochemistry and flow cytometry, as well as strong computer literacy and Microsoft Excel proficiency — particularly with respect to graph/plots generation and analysis of large data sets — will be considered a plus. Salary/Benefits Salary is commensurate with experience and accomplishments; a full civil service package of benefits — including retirement; health, life and long-term care insurance; and Thrift Savings Plan (401[k] equivalent) participation — is available. How to Apply Please submit a cover letter describing your interest in the position, a current curriculum vitae with a complete bibliography, and the names of and contact information for three references to ncatspt3hiring@mail.nih.gov. The review of applications will begin immediately and will continue until the position is filled. Learn more about intramural research at NCATS. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Research Scientist (Virology) Position, Division of Preclinical Innovation, 3-D Tissue Bioprinting Laboratory National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation 3-D Tissue Bioprinting Laboratory Rockville, Maryland Description NCATS, a major research component of NIH, seeks applications from qualified candidates to fill a research scientist (virology) position in the 3-D Tissue Bioprinting Laboratory within its Division of Preclinical Innovation. Core Responsibilities The selected candidate will work as part of a multidisciplinary team of innovative scientists, using cutting-edge technologies — including tissue biofabrication, tissue chips, quantitative cell imaging, histology, assay development, drug screening, data science and other -omics technologies (e.g., scRNAseq) — to develop advanced 3-D cellular models to study viral infections and drug screening. The selected candidate should be a self-motivated, driven, thorough and careful experimentalist with the ability to multitask, think independently and work in a highly creative, interactive and fast-paced environment. The selected candidate also will be expected to work independently as a well-trained problem solver in virology. Effective communication and presentation skills are required. The selected applicant will keep accurate and complete records of all scientific experiments according to established procedures and ensure that these records and raw data are properly retained. The selected candidate will draft technical reports, manuscripts and patent applications, and present work to internal and external collaborators as needed. The selected candidate also should be eligible to work in the U.S. with whomever NCATS collaborates worldwide. Qualifications Applicants to this research scientist position should possess a Ph.D. in virology, cell or molecular biology or pharmacology, and at least three years of postdoctoral experience. The selected candidate should have expertise in virology to help establish a portfolio of complex physiologically relevant 3-D tissue models as predictive screening platforms to study viral infections and drug testing. Applicants should have additional expertise in histology, fluorescence microscopy, flow cytometry, single-cell RNA sequencing (scRNAseq), and production of induced pluripotent stem cell-derived cells. Candidates with previous experience working in a BSL3 lab and in areas such as organoids, tissue chip, cell imaging, histology and engineering of cells with biosensors will be considered favorably. How to Apply Please submit, in PDF format, a cover letter that includes a research summary and describes your interest in the position, a current curriculum vitae with a complete bibliography, and the names of and contact information for 3 references, including your current supervisor, to NCATSbioprinting@mail.nih.gov. Selected applicants will be required to submit letters of reference to complete the hiring process. The review of applications will begin immediately and will continue until the position is filled. Learn more about intramural research at NCATS. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Bioinformatician, Division of Preclinical Innovation, Chemical Genomics Branch, Stem Cell Translation Laboratory National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Chemical Genomics Branch Stem Cell Translation Laboratory Rockville, Maryland Description NCATS, a major research component of NIH, seeks applications from qualified candidates to fill a bioinformatician position in the Stem Cell Translation Laboratory (SCTL) within the Chemical Genomics Branch of the center’s Division of Preclinical Innovation. The SCTL focuses on translating human pluripotent stem cells, such as induced pluripotent stem cells, into clinical applications and drug discovery by developing innovative technologies, methods and comprehensive multi-omics data sets through differentiation into relevant cell types in 2-D and 3-D cell culture systems. The successful candidate will have a chance to develop their skills in a highly dynamic environment, embedded in a team of passionate scientists working on a wide range of projects related to translational stem cell biology. They will have a chance to interact with experienced bioinformaticians at NCATS and collaborators at top academic institutions. Core Responsibilities Computational analysis is integral to the laboratory’s efforts in the deep characterization of stem cell states and functional cell types from different developmental lineages. The bioinformatician will be required to promptly turn around analysis results to respond to biologists’ ongoing projects, work on multiple projects in parallel, and coordinate and oversee data analysis with external service providers. Qualifications Applicants should have a master’s degree or higher in bioinformatics, computational biology or biomedical data science. The ideal candidate should have strong science communication skills; clear and effective data visualization skills; the ability to work well independently and in a team environment; creative problem-solving skills; and a proven ability to apply the cutting-edge, rigorous standards of the bioinformatics fields. Applicants should possess a solid knowledge of R statistical programming language; familiarity with the handling, management and storage of large-scale sequencing data; and experience querying public databases, including the SRA, GEO and dbGaP. Preferred qualifications include experience with next-generation sequencing methods on Illumina and 10x Genomics platforms (e.g., bulk and single-cell RNA-Seq; ChIP-seq methods, such as MeDIP-seq; bulk and single-cell ATAC-seq; and miRNA-seq). Experience with other ‑omics — such as WES, WGS and targeted sequencing methods — are a plus. The ideal candidate will have experience with preprocessing tools for alignment, counting or sequence analysis (e.g., Cell Ranger, STAR, HTSeq, featureCounts, salmon, GATK) and R packages designed for the above-mentioned methods (e.g., DESeq2, limma, Seurat). A solid understanding of clustering and dimensionality reduction techniques for big genomic datasets, experience with Python programming, and familiarity with Linux BASH scripting, which is necessary for proper utilization of NIH’s high-performance computing capabilities, are preferred. Salary/Benefits Salary is commensurate with experience and accomplishments; a full civil service package of benefits — including retirement; health, life and long-term care insurance; and Thrift Savings Plan (401[k] equivalent) participation — is available. How to Apply Please submit a cover letter describing your interest in the position, a current curriculum vitae with a complete bibliography, and the names of and contact information for three references to NCATSstemcellhiring@mail.nih.gov. The review of applications will begin immediately and will continue until the position is filled. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Postdoctoral Positions in the Division of Preclinical Innovation The Division of Preclinical Innovation (DPI) is the intramural (i.e., on-site) research program of NCATS and is located in Rockville, Maryland, a few miles from the main NIH campus in Bethesda, Maryland. DPI focuses on early stages of the translational process, from target validation to first-in-human studies. More than 200 scientists from a variety of disciplines and across the spectrum from early-career scientists to senior leaders are responsible for advancing the diverse research portfolio of DPI. In addition to conducting cutting-edge laboratory research, DPI scientists collaborate with more than 250 research organizations worldwide. DPI scientists work in a collaborative, team-based environment. The postdoctoral candidate will be recruited to work on the specific projects described below and will have ample opportunities to collaborate with scientists both within and outside of NCATS on additional projects. Candidates are expected to present results of ongoing work at meetings (such as internal group meetings and national conferences) and submit their work for publication in scientific journals. Postdoctoral fellows also gain additional professional skills and exposure to a variety of career paths through participation in the DPI training program. Postdoctoral Fellow (Synthetic Chemist), Division of Preclinical Innovation, Therapeutic Development Branch, Medicinal Chemistry Group National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Therapeutic Development Branch Medicinal Chemistry Group Rockville, Maryland Description NCATS, a major research component of NIH, seeks a highly motivated synthetic chemist to serve as a postdoctoral fellow in the Therapeutic Development Branch (TDB) within its Division of Preclinical Innovation (DPI) in Rockville, Maryland. The selected candidate will work on drug discovery projects as part of a multidisciplinary team to identify clinical candidates to address unmet medical needs. Core Responsibilities The postdoctoral fellow will be responsible for designing and synthesizing compounds for structure–activity relationship and structure–property relationship studies, developing new technologies to accelerate drug discovery, presenting results in internal and external meetings, and writing reports and manuscripts. Research will be conducted in the TDB medicinal chemistry group. Qualifications Applicants should have (or expect to receive) a Ph.D. in organic or medicinal chemistry at the time of joining the laboratory. The ideal candidate should be self-motivated, possess a strong work ethic, have a keen attention to detail and be able to work on multiple projects simultaneously. The candidate should possess strong oral and written communication skills with a proven publication record in peer-reviewed journals. Applicants should be eligible to work in the United States for any employer. Stipends/Benefits Annual stipends are provided commensurate with experience based on the NIH Postdoctoral Intramural Research Training Award scale; medical insurance coverage will be provided. The fellow also may take part in Foundation for Advanced Education in the Sciences courses at NIH. The position is renewable for up to five years. How to Apply Please email a cover letter that includes a research summary and describes your interest in the position, a current curriculum vitae with a complete bibliography, and the names of and contact information for three references to Wenwei Huang, Ph.D., via huangwe@mail.nih.gov.The review of applications will begin immediately and will continue until the position is filled. Learn more about intramural research at NCATS. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Systems Toxicology Postdoctoral Fellow, Division of Preclinical Innovation, Toxicology in the 21st Century (Tox21) Program National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Toxicology in the 21st Century (Tox21) Program Rockville, Maryland Description NCATS, a major research component of NIH, is seeking applications from exceptional candidates to fill a postdoctoral fellow position in the Toxicology in the 21st Century (Tox21) program within its Division of Preclinical Innovation. To meet the challenges of toxicology research in the 21st century, NCATS has partnered with the National Toxicology Program, the U.S. Food and Drug Administration and the U.S. Environmental Protection Agency to form the Tox21 program. Since 2010, this program has utilized a quantitative high-throughput screening approach to assess a 10,000-compound (10K) library using a group of biologically and toxicologically relevant in vitro assays. The data generated from the screening will be used to prioritize chemicals for further in-depth toxicological evaluation, identify mechanisms of chemical toxicity and develop predictive models for in vivo biological response in humans. The selected postdoctoral fellow should be self-motivated and prepared to work on Tox21 research projects to develop physiologically relevant assays for assessment of environmental chemicals. NCATS provides a unique and exciting environment that employs state-of-art technologies enabling assay development, chemical screening and profiling for toxicology research. Core Responsibilities The postdoctoral candidate will develop in vitro cell-based assays using physiologically relevant cell models (primary cells, stem cell/ induced pluripotent stem cell-derived cells, and 3-D cell/organoid models) with biotransformation-capability for screening chemicals. The fellow will apply new technologies including 3-D cell/organoid models and high-content phenotypic profiling using cell-based imaging assays for evaluating chemical toxicity. The fellow will perform follow-up studies (e.g., mechanisms of compound action) after the primary screening. The fellow also will interact regularly with informatics scientists to aid data analysis and interpretation. Qualifications Applicants should hold a doctoral degree (M.D., Ph.D. or equivalent) in the life sciences (e.g., toxicology, pharmacology, biology, cell biology, biochemistry or a related field is preferred) with solid understanding of toxicology, cell biology or general aspects of signal transduction. A strong preference will be given to applicants with prior experience in in assay development, including biotransformation-capable assays, imaging technology or compound screening. He or she should possess data analysis skills and familiarity with Excel spreadsheets. The applicant must possess strong oral and written communication skills, with a proven publication record in peer-reviewed journals. The selected candidate should be an independent thinker and a team player who is able to work in an interactive, fast-paced environment. Applicants must be eligible to work in the United States for any employer. Stipends/Benefits Annual stipends are provided commensurate with experience based on the NIH Postdoctoral Intramural Research Training Award scale; medical insurance coverage will be provided. The fellow also may take part in Foundation for Advanced Education in the Sciences courses at NIH. The position is renewable for up to five years. How to Apply Please email a cover letter describing your research and career goals, a current curriculum vitae with a complete bibliography, and the names of and contact information for three references to Menghang Xia, Ph.D. at mxia@mail.nih.gov. Applicants also should indicate when they are available to start. The review of applications review will begin immediately and will continue until the position is filled. Learn more about intramural research at NCATS. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Biology Postdoctoral Position, Division of Preclinical Innovation, Early Translation Branch National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Early Translation Branch Rockville, Maryland Description NCATS, a major research component of NIH, is seeking applications from exceptional candidates to fill a postdoctoral position in the Early Translation Branch (ETB) of its Division of Preclinical Innovation. Part of the ETB’s mission is to develop new therapeutic approaches in areas of medical need. The branch partners with external collaborators who specialize in specific disorders, creating a multidisciplinary team of innovative scientists with expertise in assay development, high-throughput and high-content screening, automation engineering, bioinformatics and various -omics technologies. The selected postdoctoral fellow will work under the mentorship of a biology team leader in an interactive laboratory environment within the ETB. He or she will use cutting-edge cell biology and bioassay technologies to develop disease-relevant screening assays and will be involved in all aspects of implementing small molecule screening programs, including assay design, assay development and optimization, high-throughput screening, data analysis, and mechanism-of-action studies to develop assay technologies and novel pharmacological probes. Core Responsibilities The postdoctoral candidate will need to have training in drug screening. This project includes the study of a new platinum agent for clinical development, along with an ambitious goal of screening and discovering new uses for platinum chemotherapeutic agents. The trainee will bring experience in cell biology or bioinorganic chemistry and learn to work in a team-based world-class drug discovery environment. He or she will keep accurate and complete records of all scientific experiments according to established procedures and ensure that these records and raw data are properly retained. He or she also will draft technical reports and manuscripts and will present their work internally and to external collaborators as needed. Qualifications Applicants should have (or expect to receive) a Ph.D. and have less than three years of postdoctoral experience in cell biology, bioinorganic chemistry, pharmacology, or a related discipline. Applicants interested in furthering their knowledge and exposure to translational science are encouraged to apply; prior high-throughput screening experience is not a prerequisite. The selected candidate should be an independent thinker and a team player who is able to work in an interactive, fast-paced environment. Applicants must be eligible to work in the United States for any employer. Stipends/Benefits Annual stipends are provided commensurate with experience based on the NIH Postdoctoral Intramural Research Training Award scale; medical insurance coverage will be provided. The fellow also may take part in Foundation for Advanced Education in the Sciences courses at NIH. The position is renewable for up to five years. How to Apply Please email a cover letter describing your research and career goals, a current curriculum vitae with a complete bibliography, and the names of and contact information for three references to NCATS ETB Careers at ncatsetbcareers@mail.nih.gov. Applicants also should indicate when they are available to start. Please note that the starting date of the fellowship is flexible, preferably within 2023. The review of applications review will begin immediately and will continue until the position is filled. Learn more about intramural research at NCATS. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Biology Postdoctoral Position, Division of Preclinical Innovation, Early Translation Branch National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Early Translation Branch Rockville, Maryland Description NCATS, a major research component of NIH, is seeking applications from exceptional candidates to fill a postdoctoral position in the Early Translation Branch (ETB) of its Division of Preclinical Innovation. Part of the ETB’s mission is to develop new therapeutic approaches in areas of medical need. The branch partners with external collaborators who specialize in specific disorders, creating a multidisciplinary team of innovative scientists with expertise in assay development, high-throughput and high-content screening, automation engineering, bioinformatics and various -omics technologies. The selected postdoctoral fellow will work under the mentorship of a biology team leader in an interactive laboratory environment within the ETB. He or she will use cutting-edge cell biology and bioassay technologies to develop disease-relevant screening assays and will be involved in all aspects of implementing small molecule screening programs, including assay design, assay development and optimization, high-throughput screening, data analysis, and mechanism-of-action studies to develop assay technologies and novel pharmacological probes. Core Responsibilities The postdoctoral candidate will work on a project that includes the study of an understudied target class of enzymes, with the goal of SAR profiling the target class to promote probe development. Successful candidates will have a background in biochemistry, molecular biology, or cellular biology. Enzymology experience is preferred. Experience with drug screening and informatics are useful, but not required. The trainee will learn to work in a team-based world-class drug discovery environment. He or she will keep accurate and complete records of all scientific experiments according to established procedures and ensure that these records and raw data are properly retained. He or she also will draft technical reports and manuscripts and will present their work internally and to external collaborators as needed. Qualifications Applicants should have (or expect to receive) a Ph.D. and have less than three years of postdoctoral experience in cell biology, molecular biology, biochemistry, or a related discipline. Applicants interested in furthering their knowledge and exposure to translational science are encouraged to apply; prior high-throughput screening experience is not a prerequisite. The selected candidate should be an independent thinker and a team player who is able to work in an interactive, fast-paced environment. Applicants must be eligible to work in the United States for any employer. Stipends/Benefits Annual stipends are provided commensurate with experience based on the NIH Postdoctoral Intramural Research Training Award scale; medical insurance coverage will be provided. The fellow also may take part in Foundation for Advanced Education in the Sciences courses at NIH. The position is renewable for up to five years. How to Apply Please email a cover letter describing your research and career goals, a current curriculum vitae with a complete bibliography, and the names of and contact information for three references to NCATS ETB Careers at ncatsetbcareers@mail.nih.gov. Applicants also should indicate when they are available to start. Please note that the starting date of the fellowship is flexible, preferably within 2023. The review of applications review will begin immediately and will continue until the position is filled. Learn more about intramural research at NCATS. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Bioanalytical Chemistry Postdoctoral Fellow, Division of Preclinical Innovation, Drug Metabolism and Pharmacokinetics National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Drug Metabolism and Pharmacokinetics Rockville, Maryland Description NCATS, a major research component of NIH, seeks applications from exceptional scientists to serve as a postdoctoral fellow in bioanalytic assay development for therapeutical biologics — for preclinical development projects involving drug metabolism and pharmacokinetics (DMPK) — within the center’s Division of Preclinical Innovation. The DMPK Core partners with collaborators (academic institutions, foundations and private industry) to conduct preclinical discovery and development studies leading to Investigational New Drug (IND) applications for new therapeutics. These projects play a leading role in NCATS’ mission to develop new ways to reduce, remove or bypass bottlenecks across the entire continuum of translational science and to address rare and neglected diseases. Core Responsibilities The selected candidate will collaborate with team members to evaluate, develop and implement bioanalytical assays to quantify therapeutical biologics and its carriers in blood and tissues for assigned projects. Specific duties include providing bioanalytical strategies for novel therapeutical biologics, such as peptides, conjugated peptides, monoclonal antibodies, engineered human proteins, antibody-drug conjugates, oligonucleotides, mRNAs, gene therapies and other novel modalities. The selected candidate also will be responsible for generating specific reagents for the assay development and will collaborate with biologists and researchers across different teams within NCATS to address project-specific needs. Additional duties include quantitatively analyzing biological samples collected from preclinical pharmacokinetic and biodistribution studies, preparing documents for the regulatory filing purpose, and disseminating research via peer-reviewed publications and participating in scientific conferences and meetings. The selected candidate should possess strong oral and written communication skills and excellent interpersonal skills, including the ability to communicate clearly and succinctly in a timely manner. The selected candidate will be expected to demonstrate a proven ability to collaborate with colleagues to achieve project, team and organizational goals. Qualifications Applicants to this postdoctoral fellow position should hold a Ph.D. in biology, immunology, biochemistry, analytical chemistry, proteomics, pharmaceutical science or a related field and have a proven track record of quantitative bioanalytical method development (e.g., ligand binding assays); excellent skills to quantify active biologics in serum/plasma or tissues; and a solid knowledge in method validation and data interpretation. Candidates with advanced knowledge and skills in high-performance liquid chromatography, mass spectrometers, electrochemiluminescence ligand binding device or related instruments will receive preferential consideration. Applicants with experience working on qPCR, TR-PCR, proteomics sample preparation and immunogenicity assessment will be considered favorably. Candidates also should have strong oral and written English communication skills and be able to work in a highly collaborative team setting. Stipends/Benefits Annual;stipends will be commensurate with experience based on the NIH Postdoctoral Intramural Research Training Award and Visiting Fellow scale; medical insurance coverage will be provided. The position is renewable for up to five years. How to Apply Please email a cover letter describing your interest in the position, including a career synopsis (one to two pages), a current curriculum vitae with a complete bibliography, and the names of and contact information for at least three references to Xin Xu, Ph.D., at xin.xu3@nih.gov. The review of applications will begin on July 1, 2022, and will continue until the position is filled. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Computational Toxicology/Informatics Postdoctoral Fellow Position, Division of Preclinical Innovation, Computational Toxicology Laboratory National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Computational Toxicology Laboratory Rockville, Maryland Description NCATS, a major research component of NIH, seeks applications from qualified candidates to fill a computational toxicology/informatics postdoctoral position in the Computational Toxicology Laboratory within the center’s Division of Preclinical Innovation (DPI). To meet the challenges of toxicology research in the 21st century, NCATS has formed a partnership with the National Toxicology Program, the U.S. Food and Drug Administration, and the U.S. Environmental Protection Agency to develop a high-throughput screening (HTS) program. The goals of the Toxicology in the 21st Century (Tox21) program are to prioritize chemicals for further in-depth toxicological evaluation, identify mechanisms of chemical toxicity and develop predictive models for in vivo biological response in humans. NCATS has a unique and exciting environment that employs state-of-art technologies for assay development, chemical screening and profiling for toxicology research. Core Responsibilities The selected candidate will engage in several activities, including analyzing large data sets generated from HTS assays; developing novel methods to identify and prioritize toxicity response pathways for assay development and compound testing; building predictive models for different in vivo toxicity endpoints using chemical structural data, genomic data and in vitro assay data; and generating testable hypotheses on compound mechanisms of toxicity. The candidate should be familiar with public genomic and genetic databases and be capable of data mining using complex data sets. The successful candidate also should have experience building and integrating genomic databases and working at the interface of genomic and chemoinformatic information. The fellow will work closely with informatics scientists and biologists in the DPI to aid in data interpretation and project development. Qualifications Applicants to this position should possess a Ph.D. in the biomedical sciences, extensive experience with one or more programming languages, and knowledge in database queries and data retrieval. A background in cheminformatics or bioinformatics, biology, chemistry or toxicology is preferred. Experience in 2-D or 3-D modeling, large data set manipulation or data mining is a plus. The ideal candidate should possess strong oral and written communication skills with a proven publication record in peer-reviewed journals. Applicants should be eligible to work in the United States for any employer. Stipends/Benefits Annual stipends commensurate with experience are provided and are based on the NIH Postdoctoral Intramural Research Training Award and Visiting Fellow scale; medical insurance coverage will be provided. The fellow also may take part in Foundation for Advanced Education in the Sciences courses at NIH. The position is renewable for up to five years. How to Apply Please submit (via email) a cover letter that includes a research summary and describes your interest in the position, a current curriculum vitae with a complete bibliography, and the names of and contact information for at least three references to Ruili Huang, Ph.D., at huangru@mail.nih.gov. The review of applications will begin immediately and will continue until the position is filled. Learn more about intramural research at NCATS. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Neuroscientist Postdoctoral Fellow Positions, Division of Preclinical Innovation, 3-D Tissue Bioprinting Laboratory National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation 3-D Tissue Bioprinting Laboratory Rockville, Maryland Description NCATS’ Division of Preclinical Innovation seeks applications from qualified candidates to fill neuroscientist postdoctoral fellow positions in the Division’s 3-D Tissue Bioprinting Laboratory. The selected candidates will develop human functional neural 3-D tissue models as assay platforms for the discovery and development of new therapeutics for pain, addiction or overdose. Applicants with a background in neurosciences, in vitro neural organotypic models and neural stem cells will receive preferential consideration. Core Responsibilities The selected candidates will work as part of a multidisciplinary team of innovative scientists with expertise in bioengineering, 3-D bioprinting, quantitative cell imaging, electrophysiology, histology, assay development, drug screening, data science and other cutting-edge “omics” technologies. The selected candidates will develop and characterize functional 3-D neural organotypic assays for drug discovery and development. Qualifications Applicants to these postdoctoral fellow positions should possess a Ph.D. in neuroscience, cell biology, molecular biology, pharmacology, pathology or a related discipline with relevant experience in neuroscience, physiology and pathology of the nervous system to help establish a portfolio of assays to model neural circuitry of pain, addiction and overdose. The ideal candidates will be expected to work independently as well-trained problem solvers in the production of 3-D neural organotypic models, including architectural and physiological validation, and develop functional assay readouts for drug screening. They will keep accurate and complete records of all scientific experiments according to established procedures and ensure that these records and raw data are properly retained. They also will draft technical reports, manuscripts and patent applications and present work internally and externally to consultants and collaborators as needed. Experience in techniques necessary to develop CNS and PNS assays for drug testing using tissues, including extracellular electrophysiological recording (field potential or multi-unit), calcium imaging, neural stem cell and primary cell culture and associated analysis is required. Experience with techniques such as histology, quantitative analysis of microscopy images, time-lapse microscopy is highly desired. Candidates with additional experience in physiology and pathology of pain, addiction or overdose, optogenetics microscopy, or tissue engineering or bioprinting techniques will receive preferential consideration. Each candidate should be an independent thinker and team player able to work and multitask in a highly interactive, fast-paced environment. The ideal candidate should possess strong oral and written communication skills with a proven publication record in peer-reviewed journals. Applicants should be eligible to work in the United States for any employer. Stipends/Benefits Annual stipends commensurate with experience are provided and are based on the NIH Postdoctoral Intramural Research Training Award and Visiting Fellow scale; medical insurance coverage will be provided. The fellow also may take part in Foundation for Advanced Education in the Sciences courses at NIH. The position is renewable for up to five years. How to Apply Please submit (via email) a cover letter that includes a research summary and describes your interest in the position, a current curriculum vitae with a complete bibliography, and the names of and contact information of at least three references to NCATSbioprinting@mail.nih.gov. The review of applications will begin immediately and will continue until these positions are filled. Learn more about intramural research at NCATS. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Postdoctoral Bioinformatics Position, Division of Preclinical Innovation, Informatics Core National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Informatics Core Rockville, Maryland Description NCATS, a major research component of NIH, seeks applications from exceptional candidates to fill a postdoctoral bioinformatics position in the Informatics Core (IFX) within the Division of Preclinical Innovation. The IFX is an interdisciplinary team of bioinformaticians, clinical informaticians, cheminformaticians and software engineers who collaborate closely with molecular biologists to augment the use of metabolomics and multi-omics analysis approaches to identify dysregulated pathways and putative therapeutic targets. Core Responsibilities The selected candidate — a postdoctoral fellow in bioinformatics — will have a solid foundation in bioinformatics and biostatistics, including machine learning, and experience in cleaning, processing, and integrating metabolomic and other -omic datasets. He or she will develop novel bioinformatics methods to optimize the predictive capacity of metabolomics and -omic (e.g., proteomic, transcriptomic) profiles in differentiating groups (e.g., cell characteristics, individuals). These novel approaches will augment the bioinformatics field by addressing issues not addressed by standard approaches. The selected candidate will interact closely with computational and noncomputational (e.g., biologists, chemists, clinicians) IFX and NCATS scientists and our academic collaborators. In addition to working independently on collaborative translational research projects, the fellow also would be involved in building a computational infrastructure for the QC, analysis and interpretation of metabolomic and multi-omic profiles. He or she will be expected to draft manuscripts and publish results in high-impact, peer-reviewed scientific journals and to present results at internal and external scientific meetings. Qualifications The ideal candidate should possess a doctoral degree or equivalent in bioinformatics, biomedical informatics, or a related field and have demonstrated hands-on experience in leading the large-scale analysis of multi-omic data. Experience with metabolomics data is strongly preferred. He or she should have demonstrated experience leveraging publicly available datasets, including their organization, cleaning and preprocessing. Applicants also should have demonstrated experience in multivariable analyses and machine/deep learning. Basic knowledge and understanding of biology and chemistry is a plus. Knowledge of R and/or Python and working within a high-performance computing/cloud environment is required. The selected candidate should have excellent interpersonal, verbal and written communication skills in English and should possess strong collaborative, organizational and recordkeeping skills; the ability to work productively as a member of a diverse and dynamic multidisciplinary team, managing multiple research studies simultaneously; and the desire to acquire new skills as required for research studies. While the team is highly collaborative in nature, the pursuit of original computational research directions by the candidate is encouraged. Applicants should be eligible to work in the United States for any employer. Stipends/Benefits Annual stipends are provided and are based on the NIH Postdoctoral Intramural Research Training Award and Visiting Fellow scale; health insurance benefits are available. The fellow also may take part in Foundation for Advanced Education in the Sciences courses at NIH. The position is renewable for up to five years. How to Apply Please submit (via email) a cover letter describing your career goals and interest in the position, including a research summary (one to two pages), a current curriculum vitae with a complete bibliography, and the names of and contact information for at least three references to Ewy A. Mathé, Ph.D., at ewy.mathe@nih.gov. The review of applications will begin immediately and will continue until the position is filled. Learn more about informatics research at NCATS. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Postdoctoral Biomedical Engineer Position, Division of Preclinical Innovation, 3-D Tissue Bioprinting Laboratory National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation 3-D Tissue Bioprinting Laboratory Rockville, Maryland Description NCATS, a major research component of NIH, seeks applications from qualified candidates to fill a postdoctoral biomedical engineering position in the 3-D Tissue Bioprinting Laboratory within its Division of Preclinical Innovation. The selected candidate should have expertise in tissue biofabrication to help establish a portfolio of complex physiologically relevant 3-D tissue models as predictive screening platforms to study viral infections and conduct drug testing. Applicants should have additional expertise in histology, fluorescence microscopy and experience working with primary cells or induced pluripotent stem cell-derived cells. Core Responsibilities The selected candidate will work as part of a multidisciplinary team of innovative scientists, using cutting-edge biofabrication methodologies — including 3-D bioprinting, quantitative cell imaging, histology, assay development, drug screening, data science and other -omics technologies including scRNAseq — to develop advanced cellular models for drug discovery and development. The selected candidate should be a self-motivated, driven, thorough and careful experimentalist with the ability to multitask, think independently and work in a highly creative, interactive and fast-paced team environment. They also will be expected to work independently as well-trained problem solvers in tissue biofabrication, including architectural and physiological validation of the tissues. Effective communication and presentation skills are required. The selected applicants will keep accurate and complete records of all scientific experiments according to established procedures and ensure that these records and raw data are properly retained. They will draft technical reports, manuscripts and patent applications and present work to internal and external collaborators as needed. The selected candidates also should be eligible to work in the U.S. with whomever NCATS collaborates worldwide. Qualifications Each applicant to this postdoctoral position should possess a Ph.D. in bioengineering or biomedical engineering. Candidates with previous experience developing and characterizing complex 3-D cell-based functional assays — including work in areas such as organoids, tissue chip or biofabricated tissues, biomaterials, cell imaging, histology and engineering of cells with biosensors — will be considered favorably. Stipends/Benefits Annual stipends are provided and are based on the NIH Postdoctoral Intramural Research Training Award and Visiting Fellow scale; health insurance benefits are available. The fellow also may take part in Foundation for Advanced Education in the Sciences courses at NIH. How to Apply Please submit, in PDF format, a cover letter that includes a research summary and describes your interest in the position, a current curriculum vitae with a complete bibliography, and the names of and contact information for two to three references, including your current supervisor, to NCATSbioprinting@mail.nih.gov. The review of applications will begin immediately and will continue until the position is filled. Learn more about intramural research at NCATS. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Postdoctoral Antibody Discovery and Characterization Position, Division of Preclinical Innovation, Early Translation Branch National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Early Translation Branch Rockville, Maryland Description NCATS, a major research component of NIH, is seeking applications from exceptional candidates to hold a postdoctoral position in antibody discovery and characterization in the Early Translation Branch (ETB) of its Division of Preclinical Innovation. Part of the ETB’s mission is to develop new therapeutic approaches in areas of medical need. The branch partners with external collaborators who specialize in specific disorders, creating a multidisciplinary team of innovative scientists with expertise in assay development, high-throughput and high-content screening, automation engineering, bioinformatics and various -omics technologies. The selected postdoctoral fellow will work under the mentorship of a biology team leader in an interactive laboratory environment and be exposed to cutting-edge high-throughput screening, assay biology, bioinformatics, medicinal chemistry and disease-relevant biological models. They will implement antibody discovery technologies (including phage display), directed evolution, and related technologies to produce and characterize antibodies relevant to diseases and conditions related to pain, addiction and overdose, and other public health emergencies, such as the SARS-CoV-2 pandemic. The selected applicant will apply cutting-edge cell biology and bioassay technologies for the development of disease-relevant antibody selection and screening assays and will be involved in all aspects of the implementation, including assay design, assay development and optimization, antibody screening, protein engineering, data analysis and mechanism-of-action studies. Core Responsibilities The selected candidate should be able to work independently under team supervision. The selected applicant will keep accurate and complete records of all scientific experiments according to established procedures and ensure that these records and raw data are properly retained. They will draft technical reports and manuscripts and will present work internally and to external collaborators as needed. Qualifications Applicants should have (or expect to receive) a Ph.D. and have less than three years of postdoctoral experience in cell biology, molecular biology, pharmacology or a related discipline. Experience with antibody phage display technologies — including panning, ELISA, and protein purification — and an understanding of antibody domain architecture are highly desirable. The candidate should be an independent thinker, a team player, and able to work in a very interactive, fast-paced environment. Applicants should be eligible to work in the United States for any employer. Stipends/Benefits Annual stipends are provided and are based on the NIH Postdoctoral Intramural Research Training Award and Visiting Fellow scale; health insurance benefits are available. The fellow also may take part in Foundation for Advanced Education in the Sciences courses at NIH. How to Apply Please submit, in PDF format, a cover letter that includes a research summary and describes your interest in the position, a current curriculum vitae with a complete bibliography, and the names of and contact information for three references to NCATSantibody_hiring@nih.gov. Selected applicants will be required to submit letters of reference to complete the hiring process. The review of applications will begin immediately and will continue until the position is filled. Learn more about intramural research at NCATS. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Postdoctoral Medicinal Chemistry Position, Division of Preclinical Innovation, Therapeutic Development Branch National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Therapeutic Development Branch Rockville, Maryland Description NCATS, a major research component of NIH, is seeking a highly motivated synthetic chemist to serve as a postdoctoral fellow for drug discovery projects within the Therapeutic Development Branch (TDB) of its Division of Preclinical Innovation. The selected candidate will work on a multidisciplinary team to identify clinical candidates to address unmet medical needs. Core Responsibilities The postdoctoral fellow will be responsible for designing and synthesizing compounds for structure-activity relationship and structure-property relationship studies, developing new technologies to accelerate drug discovery, presenting results in internal and external meetings, and writing reports and manuscripts. The research will be conducted in the TDB medicinal chemistry group. Qualifications Applicants should have (or expect to receive) a Ph.D. in organic chemistry or medicinal chemistry at the time of joining the laboratory. The ideal candidate should be self-motivated, possess a strong work ethic, have keen attention to detail, and be able to work on multiple projects simultaneously. The candidate should possess strong oral and written communication skills with a proven publication record in peer-reviewed journals. Applicants should be eligible to work in the United States for any employer. Stipends/Benefits Annual stipends are provided and are based on the NIH Postdoctoral Intramural Research Training Award and Visiting Fellow scale; health insurance benefits are available. The fellow can take part in Foundation for Advanced Education in the Sciences courses at NIH, as well. How to Apply Please submit a cover letter describing your interest in the position, including a research summary, a current curriculum vitae, and the names of and contact information for three references to Wenwei Huang, Ph.D., at huangwe@mail.nih.gov. The review of applications will begin immediately and will continue until the position is filled. Learn more about intramural research at NCATS. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Postdoctoral Genomic Toxicology Position, Division of Preclinical Innovation, Genomic Toxicology Laboratory National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Genomic Toxicology Laboratory Rockville, Maryland Description NCATS, a major research component of NIH, seeks applications from qualified candidates to fill a postdoctoral position and apply genomic tools to toxicology and pharmacology in the Genomic Toxicology Laboratory within the center’s Division of Preclinical Innovation (DPI). The Genomic Toxicology Laboratory, led by David L. Gerhold, Ph.D., participates in the Toxicology in the 21st Century (Tox21) program by developing methods to assess the effects of chemicals on human health, focusing on early stages of the translational process from target validation to first-in-human studies. This laboratory also develops novel human cellular 3-D and co-culture models to study cardiovascular disease, as well as neurological and renal diseases. DPI researchers collaborate closely with scientists in the 3-D Tissue Bioprinting Program, the Stem Cell Translational Laboratory, and the Therapeutics for Rare and Neglected Diseases program, as well as with other NIH institutes, centers and offices; and academic scientists. In addition to conducting cutting-edge laboratory research, DPI scientists work in a team-based environment and collaborate with more than 250 research organizations worldwide. Core Responsibilities The selected candidate — a self-motivated, collaborative postdoctoral fellow — will complete the development and implementation of a novel high-throughput screening method that quantifies the expression of selected genes in cultured mammalian cells. The unprecedented throughput of this method will enable the screening of large chemical libraries of environmental toxicants or drug candidates. Because quantitative high-throughput screening of large chemical libraries is NCATS’ core expertise, the collaborative opportunities to apply this method to identify drug candidates and to screen Tox21 toxicant libraries are abundant. The successful applicant will work with collaborators who have developed induced Pluripotent Stem Cell (iPSC)–derived endothelial cells, as well as 3-D endothelial cell models that incorporate shear flow and co-culture with vascular smooth muscle cells. The postdoctoral candidate also will have opportunities to collaborate with scientists both within and outside of NCATS on additional projects. The selected candidate is expected to present results of ongoing work at meetings (such as internal group meetings and national conferences) and submit their work for publication in scientific journals. Qualifications The ideal candidate will possess a doctoral degree (i.e., a Ph.D.) with a background in a relevant field of molecular or medical biology and have a strong record of high-impact publications. Applicants should possess molecular biology expertise and mammalian cell culture skills. Applicants also should possess strong oral and written English communication skills. Applicants with additional expertise in vascular biology or high-throughput screening will receive preferential consideration. Applicants should be U.S. citizens or legal residents or should hold a valid work permit to be considered for the position. How to Apply Please submit a cover letter describing your interest in the position, a current curriculum vitae with a complete bibliography, and the names of and contact information for three references to David L. Gerhold, Ph.D., at NCATSGenomicTox@mail.nih.gov. The review of applications will begin immediately and will continue until the position is filled. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Postdoctoral Mass Spectrometry Position, Division of Preclinical Innovation, Analytical Chemistry Core Facility National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Analytical Chemistry Core Facility Rockville, Maryland Description NCATS, a major research component of NIH, seeks applications from qualified candidates to fill a postdoctoral mass spectrometry position in the Analytical Chemistry Core Facility within NCATS’ Division of Preclinical Innovation. The selected candidate should have expertise in mass spectrometry, high-performance liquid chromatography (HPLC) and proteomics fields. Applicants with additional expertise in protein biochemistry, automation systems and high-throughput screening will receive preferential consideration. The Analytical Chemistry Core Facility maintains a state-of-the-art laboratory, the mission of which is to support chemistry research throughout the center. The laboratory has a variety of instrumentation utilizing various analytical techniques, including liquid chromatography-mass spectrometry, gas chromatography-mass spectrometry, high-resolution mass spectrometry and nuclear magnetic resonance to facilitate early-stage chemical development. Initially focused on small-molecule purification and analysis, the laboratory’s capabilities have expanded to other therapeutic modalities, such as peptides, proteins, antibody-drug conjugates and lipids. The laboratory manages several cutting-edge mass spectrometers with the capability to perform high-throughput sample analysis, peptide and protein analysis (top-down and bottom-up), post-translational modification analysis, multiple reaction monitoring (MRM), proteomics, metabolomics, and ultra-high-resolution analysis of small molecules. NCATS’ goal is to increase the productivity, efficiency and integrity of chemistry efforts by optimizing workflows and integrating automated processes. Core Responsibilities The postdoctoral fellow will work as part of a multidisciplinary team of innovative scientists using the available resources to develop novel methods and assays for high-throughput proteomics analysis and mass spectrometry-based compound screening. The postdoctoral fellow will be expected to work independently as a well-trained problem solver in the areas of mass spectrometry and HPLC. He or she will manage, troubleshoot and regularly maintain the instrumentation. The fellow will be expected to prepare samples of various modalities prior to analysis. The fellow also will be required to keep accurate and complete records of all scientific experiments according to established procedures and ensure that these records and raw data are properly retained. He or she will draft technical reports, manuscripts and patent applications, as well as present work at internal and external meetings. Qualifications The successful applicant should possess a Ph.D. in analytical chemistry, biochemistry or a related discipline, with a focus in mass spectrometry and have relevant research experience. Candidates should possess extensive proteomics experience, including sample preparation, post-translational modification analysis and data analysis, using Proteome Discoverer, MaxQuant, Mascot and/or Skyline. Direct experience with ultra-HPLC/nano-HPLC instrumentation is a preferred. Familiarity with the RapidFire high-throughput sampling system and protein biochemistry is necessary. Training in the areas of metabolomics, lipids analysis, MRM, intact protein and protein top-down analysis is desirable. The ideal candidate should be self-motivated, possess a strong work ethic, have a keen attention to detail, and be able to work on multiple projects simultaneously. Excellent analytical, organizational and time-management skills are required. The candidate should possess strong oral and written communication skills with a proven publication record in peer-reviewed journals. Applicants should be eligible to work in the United States for any employer. How to Apply Please submit a cover letter describing your interest in the position, including a research summary (one to two pages); a current curriculum vitae with a complete bibliography; and the names of and contact information for at least three references to Christopher A. LeClair, Ph.D., at ncats_info@mail.nih.gov. The review of applications will begin immediately and will continue until the position is filled. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Postdoctoral Bioengineering Positions, Division of Preclinical Innovation, 3-D Tissue Bioprinting Laboratory National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation 3-D Tissue Bioprinting Laboratory Rockville, Maryland Description NCATS’ Division of Preclinical Innovation seeks applications from qualified candidates to fill postdoctoral bioengineering positions in the Division’s 3-D Tissue Bioprinting Laboratory. The selected candidates should have expertise in biofabrication, biomaterials or microfluidics to help establish a portfolio of functional, physiologically complex 3-D tissue models as predictive screening platforms for toxicity and efficacy drug testing. Applicants with additional expertise in microphysiological systems, immunology, neuroscience and production of induced pluripotent stem cell-derived cells will receive preferential consideration. Core Responsibilities The candidates will work as part of a multidisciplinary team of innovative scientists, using cutting-edge biofabrication methodologies—including 3-D bioprinting, quantitative cell imaging, histology, assay development, drug screening, data science and other cutting-edge -omics technologies — to develop advanced cellular models for drug discovery and development. Candidates should be self-motivated, driven, thorough and careful experimentalists with the ability to multitask, think independently and work in a highly creative, interactive and fast-paced environment. They also will be expected to work independently as well-trained problem solvers in biofabrication and microfluidics, including on architectural and physiological validation of the tissues. Effective communication and presentation skills are required. The successful candidates will keep accurate and complete records of all scientific experiments according to established procedures and ensure that these records and raw data are properly retained. They will draft technical reports, manuscripts and patent applications and will present work to internal and external collaborators as needed. Qualifications Each applicant for this postdoctoral position should possess a Ph.D. in bioengineering, biomedical engineering, immunology, neuroscience, cell/molecular biology, pharmacology, pathology or a related discipline relevant to 3-D tissue models. Candidates with previous experience developing and characterizing complex 3-D cell-based functional assays—including work in such areas as organoids or biofabricated tissues, biomaterials, microfluidic systems, cell imaging, histology and engineering of cells with biosensors—as well as experience using bioprinting techniques, will be considered favorably. Candidates with a strong background in immunology and tissue engineering with induced pluripotent stem cell-derived cells are encouraged to apply. Applicants should be eligible to work in the United States for any employer. How to Apply Please submit a cover letter, a curriculum vitae with a complete bibliography, a one-page research proposal/plan for a physiologically complex 3-D tissues for disease modeling and compound testing, and the contact information for at least three references to NCATSbioprinting@mail.nih.gov. The review of applications will begin immediately and will continue until these positions are filled. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Postdoctoral Computational Biologist/Bioinformatician, Division of Preclinical Innovation, Therapeutic Development Branch National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Therapeutic Development Branch Rockville, Maryland Description NCATS, a major research component of NIH, seeks applications from exceptional candidates to fill a postdoctoral computational biologist/bioinformatician position in NCATS' Therapeutic Development Branch (TDB) within the Division of Preclinical Innovation. TDB develops new systems, novel approaches and methodologies to achieve conceptual breakthroughs in preclinical therapeutics. The branch also provides collaborative access to technology and expertise in the scientific disciplines of early-discovery biology and medicinal chemistry; drug metabolism and pharmacokinetics; toxicology; and chemistry, manufacturing and controls synthesis and formulation. Core Responsibilities The selected candidate — a self-motivated, collaborative postdoctoral fellow — will join an interdisciplinary team with a focus on profiling different cell types and responses in the context of rare genetic diseases, infectious diseases and drug treatments. He or she will be a bioinformatician/computational biologist with experience in bioinformatic analysis of NexGen sequencing datasets, with a strong emphasis in RNA-Seq analysis (bulk and single-cell). The fellow will collaborate with researchers in other universities and institutes and will learn preclinical drug development from colleagues in multidisciplinary project teams. The fellow should obtain extensive experience and skills in this training program that can be applied toward translational research for therapeutics development. Qualifications The ideal candidate should possess a doctoral degree or equivalent in biology, computer sciences, bioinformatics or a related discipline, with one to three years of relevant research experience. Candidates should possess strong computer programming skills in R and other required languages (e.g., Python/Perl, Java, C/C++). Experience analyzing bulk and single-cell RNA-Seq data sets is essential. The candidate also should possess strong self-motivational and problem-solving skills, as well as outstanding interpersonal and teamwork skills. Excellent analytical, organizational and time management skills are required. Experience with proteomics data sets also is preferred, but not necessary. Applicants should be eligible to work in the United States for any employer. How to Apply Please submit a cover letter describing your interest in the position; a current curriculum vitae with a complete bibliography; and the names of and contact information for three references to Wei Zheng, Ph.D., at NCATSTDBBioHiring@mail.nih.gov. The review of applications will begin immediately and will continue until the position is filled. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Postdoctoral Informatics Scientist, Division of Preclinical Innovation, NCATS Chemical Genomics Center (NCGC), Adenine Informatics Group National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation NCATS Chemical Genomics Center (NCGC), Adenine Informatics Group Rockville, Maryland Description NCATS is one of the 27 institutes and centers at NIH. The Informatics group collaborates closely with biologists and chemists to develop robust assay designs, analyze experimental outcomes and validate new hypothesis. NCATS’ informatics personnel perform a variety of ligand- and protein structure-related modeling tasks, support the drug discovery process and accelerate translational sciences. The team members also are developing infrastructure and software for the meta-analysis of high-content screens and for integration of the existing biomedical data to discover new hypothesis. NCATS’ Informatics group is seeking a creative, self-motivated postdoctoral informatics scientist to develop new algorithms for prediction of i) protein-ligand interactions; ii) chemical reactions and comprehensive support of drug discovery projects. Core Responsibilities The postdoctoral fellow will be responsible for uploading and analyzing pilot and quantitative high-throughput screening runs; analyzing assay reproducibility; analyzing confirmation and secondary screening assays; developing and applying QSAR models and molecular modeling for virtual screening of compounds; supporting medicinal chemistry efforts; and developing new algorithms for prediction of protein-ligand interactions and chemical reactions. Research will be conducted by NCATS' Informatics group. Qualifications The ideal candidate will possess a minimum of a Ph.D. in computational science/bioinformatics with specialization in machine learning. He or she will have published at least three research articles as first author. The successful candidate should have experience with common cheminformatics libraries and data formats (e.g., RDKit, OpenBabel, SMILES, InChi, etc.), modern software packages (e.g., MOE/CCG, OpenEye tools) and scientific programming (e.g., Python, JAVA) and data analytics (e.g., KNIME, Spotfire). He or she should be able to script work flows and implement new algorithms, have experience working with multi-disciplinary teams, and possess strong oral and written English communication skills. He or she should have experience using modern machine learning and deep learning frameworks (e.g., TensorFlow, Keras), as well as experience in developing algorithms for prediction of protein-ligand interactions and/or chemical reactions. Applicants should be U.S. citizens or legal residents or should hold a valid work permit to be considered for the position. How to Apply Please submit a cover letter describing your interest in this position, a current curriculum vitae with a complete bibliography to Alexey V. Zakharov, Ph.D., at alexey.zakharov@nih.gov. The review of applications will begin immediately and will continue until the position is filled. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Postdoctoral Informatics Scientist Position, Division of Preclinical Innovation, Informatics Group National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Informatics Group Rockville, Maryland Description NCATS’ Informatics group seeks a creative, self-motivated, collaborative research scientist to develop new algorithms for predicting chemical reactions and to provide comprehensive support of the center’s A Specialized Platform for Innovative Research Exploration (ASPIRE) initiative. NCATS proposes to transform chemistry from an individualized craft to a modern, information-based science through ASPIRE. By addressing long-standing challenges in the field of chemistry — including lack of standardization, low reproducibility and an inability to predict how new chemicals will behave — ASPIRE is designed to bring novel, safe and effective treatments to more patients more quickly at lower cost. The Informatics group collaborates closely with biologists, chemists, engineers and information technology professionals to develop robust assay designs, analyze experimental outcomes and to validate new hypothesis. NCATS' Informatics group performs a variety of ligand- and protein structure-related modeling tasks, supports the drug discovery process and accelerates translational sciences. The team members also are developing infrastructure and software for the meta-analysis of high-content screens and for integration of the existing biomedical data to discover new hypothesis. Core Responsibilities The successful candidate will be an integral team member for the creation and maintenance of a chemical reaction database, the development of new methods for reaction normalization and standardization, the analysis of reaction screens, and the development and application of AI/Machine learning approaches for prediction of synthetic routes and chemical reactions. He or she also should have experience working with multi-disciplinary teams. Qualifications Applicants should possess a minimum of a Ph.D. in computational chemistry or a related field with one to three years of industry or academic experience. He or she should have experience using modern machine learning and deep learning frameworks (e.g., TensorFlow, Keras, sklearn, PyTorch, etc.) Applicants also should have experience with common cheminformatics libraries and data formats (e.g., RDKit, Indigo, CDK, SMIRKS, SMARTS, SMILES, InChi, etc.), as well as experience in scientific programming (e.g., Python, JAVA), data analytics (e.g., KNIME, Spotfire) and relational databases (e.g., Oracle, SQL). Additionally, applicants should be able to script work flows and implement new algorithms. Applicants also should possess strong oral and written English communication skills. How to Apply Please submit a cover letter describing your interest in this position, a current curriculum vitae with a complete bibliography (all in PDF format), and three letters of reference to Alexey V. Zakharov, Ph.D., at NCATSAspire-Hires@nih.gov. The review of applications will begin immediately and will continue until the position is filled. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. Stem Cell Scientist and Postdoctoral Positions, Division of Preclinical Innovation, Chemical Genomics Branch, Stem Cell Translation Laboratory National Institutes of Health National Center for Advancing Translational Sciences Division of Preclinical Innovation Chemical Genomics Branch Stem Cell Translation Laboratory Rockville, Maryland Description NCATS, a major research component of the NIH, seeks applications from qualified candidates with expertise in developmental biology and human induced pluripotent stem cells (iPSCs) to fill stem cell scientist and postdoctoral positions in the Stem Cell Translation Laboratory (SCTL) within the Chemical Genomics Branch of the center’s Division of Preclinical Innovation. The SCTL focuses on translating human pluripotent stem cells, such as iPSCs, into clinical applications and drug discovery by developing innovative technologies, methods and comprehensive multi-omics data sets through differentiation into relevant cell types in 2-D and 3-D cell culture systems. Successful candidates will have a chance to develop their skills in a highly dynamic environment, embedded in a team of passionate scientists working on a wide range of projects related to translational stem cell biology. They will have a chance to interact with experienced bioinformaticians at NCATS, external service providers and collaborators at top academic institutions. Core Responsibilities The selected candidates will join a multidisciplinary team of innovative scientists with expertise in assay development, high-throughput and high-content screening, compound management, automation engineering, bioinformatics, medicinal chemistry and various -omics technologies. They will work in a highly creative environment, focusing on important aspects of human pluripotency and cellular differentiation using cutting-edge technologies (e.g., single-cell analysis, deep sequencing, robotic cell culture, high-throughput electrophysiology, genome editing). They will keep accurate and complete records of all scientific experiments according to established procedures and ensure that these records and raw data are properly retained. They also will draft technical reports, manuscripts and patent applications and present work internally and externally to consultants and collaborators as needed. Qualifications Each applicant should possess an advanced degree (M.D. and/or Ph.D.) in a relevant field. Exceptional candidates with master’s degrees and strong backgrounds in stem cell biology will be considered. Candidates with experience in drug discovery, cell and tissue engineering, cell signaling, or quantitative biology are encouraged to apply. The ideal candidates should be team players with high scientific standards and have the ability to work in an interactive, fast-paced environment. They should be self-motivated to learn new technologies and be familiar with the methods and concepts of stem cell biology and regenerative medicine. Stipends/Benefits Annual stipends are provided and are based on the NIH Postdoctoral Intramural Research Training Award and Visiting Fellow scale; health insurance benefits are available. Fellows also are able to take part in Foundation for Advanced Education in the Sciences courses at NIH. How to Apply Please submit a cover letter describing your interest in the position, a current curriculum vitae with a complete bibliography, and the names of and contact information for three references to NCATSstemcellhiring@mail.nih.gov. The review of applications will begin immediately and will continue until the position is filled. Additional Information Employment is subject to the successful completion of the preappointment process (e.g., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents). At the discretion of the supervisor and NIH policy, you may be eligible for workplace flexibilities, which may include remote work or telework options and/or flexible work scheduling. These flexibilities may be requested in accordance with the NIH Workplace Flexibilities policy. | Job Opportunities | Job Opportunities | ||||||
| 24356 | 2020 NCATS ASPIRE Reduction-to-Practice Challenge Winners, Stage 2, Milestone 1* | NCATS is happy to announce the winners of the 2020 NCATS ASPIRE Reduction-to-Practice Challenge, Stage 2, Milestone 1: Prototype Development and Milestones Delivery. *According to the rules for these ASPIRE Design Challenges, non-U.S. citizens and non-permanent residents were not eligible to win a monetary prize (in whole or in part). Iterative Learning and Automated Modular Platform for Optimum Nonaddictive Analgesic Discovery Closed Loop Bio-Assay-Chemputer for Next Generation Analgesics (BioChemputer) Development of a Comprehensive Integrated Platform for Translational Innovation in Pain, Opioid Abuse Disorder and Overdose Accelerating Molecular Innovation in Pain through an AI-Driven, Human-Guided and Automated Open Drug Discovery Platform Iterative Learning and Automated Modular Platform for Optimum Nonaddictive Analgesic Discovery Gaurav Chopra Ram Samudrala R. Graham Cooks Connor W. Coley Panayotis K. Thanos Jun-Xu Li Purdue University State University of New York (SUNY) Purdue University Massachusetts Institute of Technology University at Buffalo University at Buffalo Closed Loop Bio-Assay-Chemputer for Next Generation Analgesics (BioChemputer) Babak Esmaeli-Azad Leroy Cronin Sara I. Walker Philip J. Kitson S. Hessam M. Mehr James Zapf Evan Snyder Larry H. Ellisman Shaochen Chen CiBots, Inc. University of Glasgow Arizona State University University of Glasgow University of Glasgow Visionary Pharmaceuticals Inc. Sanford Consortium for Regenerative Medicine University of California, San Diego University of California, San Diego Development of a Comprehensive Integrated Platform for Translational Innovation in Pain, Opioid Abuse Disorder and Overdose Jeffrey Skolnick Andre Ghetti Nicole Jung Hongyi Zhou Georgia Institute of Technology ANABIOS Corporation Karlsruhe Institute of Technology Georgia Institute of Technology Accelerating Molecular Innovation in Pain through an AI-Driven, Human-Guided and Automated Open Drug Discovery Platform Daniel H. Robertson Timothy I. Richardson Gaurav Chopra Richard M. van Rijn Indiana Biosciences Research Institute Indiana University School of Medicine Purdue University Indiana University School of Medicine Back to top Contact Dobrila D. Rudnicki, Ph.D. | NCATS announced the winners of the ASPIRE Reduction-to-Practice Challenge, Stage 2, Milestone 1. | ASPIRE Reduction-to-Practice Challenge Winners, Stage 2, Milestone 1 | NCATS announced the winners of the ASPIRE Reduction-to-Practice Challenge, Stage 2, Milestone 1.. | ASPIRE Reduction-to-Practice Challenge Winners, Stage 2, Milestone 1 | ||||
| 24215 | Researchers Create 3-D Model for Rare Neuromuscular Disorders, Setting Stage for Clinical Trial | Scientists have created a 3-D bioengineered model that mimics the biology of two rare neuromuscular diseases. In both disorders, the brain’s messages to muscles are disrupted by the body’s immune system. The model consists of motoneurons, which are cells that transmit messages from the brain to muscles, and Schwann cells, which help the signals move more quickly. In section A, arrows point to immune system antibodies (red and green) that bind to Schwann cells, interfering with their activity. In section B, the arrows show antibodies binding to motoneurons. (Reproduced with permission. Copyright 2022, The Authors, published by Wiley-VCH)April 19, 2022Tissue chip platform shows potential uses for developing treatments for rare diseasesA scientific team supported by the National Institutes of Health has created a tiny, bioengineered 3-D model that mimics the biology of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, a pair of rare, devastating neuromuscular diseases. The researchers used the organ-on-a-chip, or “tissue chip,” model to show how a drug could potentially treat the diseases. They provided key preclinical data for a drug company to submit to the U.S. Food and Drug Administration to get authorization for testing in a clinical trial.This work provides one of the first examples of scientists using primarily tissue chip data for an FDA Investigational New Drug application to test the efficacy of a candidate drug in people with rare diseases. The drug company Sanofi started recruiting participants into a Phase 2 clinical trial in April 2021. The drug was tested for safety previously and approved by the FDA for a different indication.The tissue chip research was led by Hesperos, Inc., an Orlando-based company partially funded by a Small Business Innovation Research grant from NCATS. This study could open the door to studying and developing new therapies for other rare diseases by establishing a new avenue for repurposing existing drugs for rare diseases. Most of the known 7,000 rare diseases do not have effective treatments. Researchers often lack animal models for studying rare disease biology and testing potential drugs.“This marks an important milestone in the evolution of the use of tissue chips,” said Lucie Low, Ph.D., scientific program manager for the NCATS Tissue Chip for Drug Screening initiative. “We know that pharmaceutical companies are using tissue chips internally. Submitting data to regulatory agencies generated from tissue chip platforms is a powerful indicator of their growing promise.”James Hickman, Ph.D., chief scientist at Hesperos, and his colleagues described the development of the model and their research results in Advanced Therapeutics. In these diseases, the immune system makes proteins called antibodies that damage nerve cells and slow down messages moving from the brain to the muscles. This can make it hard for people to move their arms, hands and legs. Current treatments can help, but often are inconsistent.The researchers developed a tissue chip model consisting of two cell types: motoneurons and Schwann cells. Motoneurons transmit messages from the brain to muscles. Schwann cells help the signals move more quickly. The model could mimic functional characteristics of the diseases, allowing the scientists to see how a drug was working by determining whether the brain’s messages to muscles were slowing down or not.The researchers showed that exposing the cells to blood serum from people with these rare diseases caused a shower of immune system antibodies against the cells. This made the motoneuron signals move more slowly. After treatment with TNT005, a drug that blocks the immune system reaction, the cells and the message speed returned to normal.“We’re confident that our system can reproduce what happens to a patient, including the disease symptoms and disease progression,” said Hickman. “It’s important to create functionally relevant patient models that will mimic what is seen in clinical trials.”Approximately 90% of promising therapies fail in clinical trials because animal models used in preclinical testing are not good at predicting how people will respond. To improve that success rate and help get more treatments to people who have few options, scientists are exploring the uses of tissue chips. Designed to support living human tissues and cells, tissue chips mimic the structure and function of human organs and systems, such as the lungs, heart and liver. Researchers are studying their uses in many areas, including for testing the safety and effectiveness of candidate drugs and modeling diseases.The potential clinical uses of tissue chip data are growing. Recently, an NIH-supported research team at Harvard University’s Wyss Institute reported using a tissue chip model to generate data on the effectiveness of a repurposed drug for treating lung damage from COVID-19 infection. In the NCATS-funded Clinical Trials on a Chip program, several projects examine how tissue chip data can help researchers design more useful clinical trials. This might include using such data to predict which patients in a trial are most likely to respond to a therapy.“Creating a platform that can predict human responses to a drug in a rare disease could lead to exciting new opportunities in research,” said Low. “If tissue chip data can be generated that inform the decisions made before early human trials, this could reduce the risks to vulnerable populations.”Funding for this research was provided by True North Therapeutics (now Sanofi), NCATS (SBIR 2R44TR001326-03) and internal Hesperos development funds.Media Contact: NCATS Information Officer, ncatsinfo@mail.nih.gov.About the National Center for Advancing Translational Sciences (NCATS): NCATS conducts and supports research on the science and operation of translation — the process by which interventions to improve health are developed and implemented — to allow more treatments to get to more patients more quickly. For more information about how NCATS helps shorten the journey from scientific observation to clinical intervention, visit https://ncats.nih.gov.About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov.NIH…Turning Discovery Into Health® | Hesperos, Inc., researchers, partly funded by NCATS, created a tissue chip model for rare neuromuscular disorders. | /sites/default/files/tissue-chip_rare-diseases_1_0.jpeg | Tissue Chip Model of Rare Disorders Sets Stage for Clinical Trial | Hesperos, Inc., researchers, partly funded by NCATS, created a tissue chip model for rare neuromuscular disorders. | /sites/default/files/tissue-chip_rare-diseases_1_1.jpeg | Tissue Chip Model of Rare Disorders Sets Stage for Clinical Trial | ||
| 24146 | Winners Announced for NLP Challenge to Harness the Power of Biomedical Data | Image Credit: National Center for Advancing Translational Sciences The number of scientific studies is constantly increasing, but a large amount of biomedical information from these studies is not easily accessible to the researchers and data scientists who can use it to improve health. Simply placing biomedical data in open data repositories is not enough to deliver public health solutions. Many of these repositories are either incomplete or too large to be fully explored. The LitCoin Natural Language Processing (NLP) Challenge aimed to address this accessibility issue and increase the power and value of data to identify new treatments. Through the challenge, NCATS rewarded the most creative and effective uses of free text from biomedical publications to create knowledge graphs that relate concepts within existing research. By engaging technologists, the scientific and medical community and the public, we can help researchers find connections that otherwise may have been difficult to discover, drastically increasing the data’s value in solving public health issues. The LitCoin challenge is part of a broader initiative at NCATS to change the “currency” of biomedical research. NCATS partnered with the NASA Tournament Lab to find the ideal challenge platform, selecting CrowdPlat and the artificial intelligence competition platform bitgrit. Participants used information from published abstracts to create NLP systems that could recognize biomedical concepts and relationships between them. Using a custom evaluator program, the output of each NLP system was compared to a set of hand-annotated assertions created by researchers at the National Center for Biotechnology Information. Judges used the scores from the evaluator program to determine the winning submissions, subject to the final decision by the Award Approving Official. The software packages built for this challenge will be used to further NCATS’ goal of creating a new type of biomedical publication. This will encourage the sharing of computationally accessible data from the time of publication with the goal of changing the way research results are compiled for use when developing public health policies and new treatments and cures. The results of the challenge showcase what is possible when scientists and computational researchers come together to change the research landscape. Winners: 1st place: JZhangLab@FSU (Florida State University, Tallahassee, Florida) 2nd place: UTHealth SBMI (University of Texas Health Science Center, Houston, Texas) 3rd place: UIUCBioNLP (University of Illinois at Urbana-Champaign, Champaign, Illinois) Runners Up: OsborneLabUAB (University of Alabama at Birmingham, Birmingham, Alabama) RMIT-READBio (RMIT University, Melbourne, Australia) UMaas (Maastricht University, Maastricht, Netherlands) LasigeUnicage (University of Lisbon, Lisbon, Portugal) Honorable Mention: Hao Liu (Columbia University Irving Medical Center, New York, New York) | Winners of the NLP Challenge developed solutions to find biomedical concepts in free text and connect them into accurate knowledge statements. | Winners Announced for NLP Challenge to Harness the Power of Biomedical | Winners of the NLP Challenge developed solutions to find biomedical concepts in free text and connect them into accurate knowledge statements. | Winners Announced for NLP Challenge to Harness the Power of Biomedical | ||||
| 23887 | Application Information for PAR-22-058: Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed) | Please note: The primary source of all information regarding PAR-22-058: Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed) is the funding opportunity itself and any notices linked therein.OverviewSee LessWhat is translational science?Translational science is the field of investigation focused on understanding the scientific and operational principles underlying each step of the translational process.What is a translational scientist?NCATS has defined seven characteristics that distinguish translational scientists — being a systems thinker, a skilled communicator, a rigorous researcher, a domain expert, a process innovator, a team player and a boundary crosser× Translation is the process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and the public—from diagnostics and therapeutics to medical procedures and behavioral changes. The professionals involved in this process, either developing interventions or improving the process itself, are TRANSLATIONAL SCIENTISTS. Conducts research at the highest level of rigor and transparency, possesses strong statistical analysis skills, and designs research projects to maximize reproducibility. Practices a team science approach by leveraging the strengths and expertise and valuating the contributions of all players on the translational science team. Breaks down disciplinary skills and collaborates with others across research areas and professions to collectively advance the development of a medical intervention. Seeks to better understand the scientific and operational principles underlying the translational process and innovates to overcome bottlenecks and accelerate that process. Possesses deep disciplinary knowledge and expertise within one or more of the domains of the translational science spectrum ranging from basic to clinical to public health research and domains in between. Communicates with understanding with all stakeholders in the translational process across diverse social, cultural, economic and scientific backgrounds, including patients and community members. Evaluates the complex external forces, interactions and relationship impacting the development of medical interventions, including patient needs and preferences, regulatory requirements current standards of care, and market and business demands.Close !function () {"use strict"; function a() { function a() { function a(a) { function c(a) { return a * b[1 === (d = 1 - d) ? "width" : "height"] } var d = 0; return a.split(",").map(Number).map(c).map(Math.floor).join(",") } for (var b = { width: i.width / j.width, height: i.height / j.height }, c = 0; g > c; c++) f[c].coords = a(h[c]) } function b() { j.onload = function () { (i.width !== j.width || i.height !== j.height) && a() }, j.src = i.src } function c() { function b() { clearTimeout(k), k = setTimeout(a, 250) } window.addEventListener ? window.addEventListener("resize", b, !1) : window.attachEvent && window.attachEvent("onresize", b) } function d(a) { return a.coords.replace(/ *, */g, ",").replace(/ +/g, ",") } var e = this, f = e.getElementsByTagName("area"), g = f.length, h = Array.prototype.map.call(f, d), i = document.querySelector('img[usemap="#' + e.name + '"]'), j = new Image, k = null; b(), c() } function b() { function b(b) { if (!b.tagName) throw new TypeError("Object is not a valid DOM element"); if ("MAP" !== b.tagName.toUpperCase()) throw new TypeError("Expected <MAP> tag, found <" + b.tagName + ">."); a.call(b) } return function (a) { switch (typeof a) { case "undefined": case "string": Array.prototype.forEach.call(document.querySelectorAll(a || "map"), b); break; case "object": b(a); break; default: throw new TypeError("Unexpected data type (" + typeof a + ").") } } } "function" == typeof define && define.amd ? define([], b) : "object" == typeof exports ? module.exports = b() : window.imageMapResize = b(), "jQuery" in window && (jQuery.fn.imageMapResize = function () { return this.filter("map").each(a).end() }) }(); //# sourceMappingURL=imageMapResizer.map $('map').imageMapResize(); Credit: Translation TogetherWhat is an example of a translational science career-enhancement experience?A potential translational science career-enhancement experience would provide the awardee with varied translational research opportunities over the course of the grant period. The areas of requisite capabilities and expertise are described in the funding opportunity announcement (FOA). The entire translational process for a single project or program may be difficult to see because translation can be a rather lengthy process. Thus, the awardee may participate in several projects and programs at various stages of the translation process to gain the full breadth of the experience.Does the proposed project need to have a pain and/or opioid use disorder (OUD) focus?Yes. These funding opportunities were issued in response to the declared public health emergency issued by the Secretary of Health and Human Services. This public health emergency exists nationwide as the result of the opioid crisis; therefore, projects must focus on addressing pain and/or OUD.AdministrativeSee MoreWhat is the purpose of a K18 funding opportunity?The K18 grant supports a research career development program for early- to mid-career investigators. This funding mechanism provides support to experienced scientists who wish to broaden their scientific capabilities or make changes in their research careers by acquiring new research skills or knowledge.Is a specific project plan required for this opportunity?A sound research project that is consistent with the candidate’s level of research development and objectives of their career development plan must be provided. A detailed description of required content for the research is described in the FOA. It is important to note that the application should provide a detailed description of environments that will ensure a broad translational research experience.Does a host institution need to be identified prior to application to the FOA?Responsive applicants will have identified a host institution prior to application to the funding opportunity. The candidate must name a primary mentor who, together with the candidate, is responsible for planning, directing, monitoring and executing the proposed program at the translational science site. The application must include a statement from the mentor providing the following: (1) information on their research qualifications and previous experience as a research supervisor and (2) a plan that describes the nature of the supervision and mentoring that will occur during the proposed award period.What is meant by “short term”?A short-term period is considered to be up to 12 months.Is an institutional review board (IRB) required for responsive applications?Responsive applications to this funding opportunity do not require an IRB. These applications will have identified a host institution that provides an opportunity to view many aspects of the translational process. Any requirement for an IRB should be addressed by the translational science center.Is there a clinical trial component to this opportunity?No. No clinical trial component to this opportunity is required. Applications proposing an independent clinical trial, a clinical trial feasibility study or an ancillary study to a clinical trial will be considered nonresponsive to this funding opportunity. However, if the applicant is proposing to gain experience in a clinical trial, an ancillary study to a clinical trial, or a clinical trial feasibility study on which the mentor or co-mentor is the Principal Investigator as part of his or her research career development, he or she must describe the relationship of the proposed research project to the clinical trial.What is considered nonresponsive to the funding opportunity?The following will be considered nonresponsive and will not be reviewed:Applications that propose that the K scholar lead an independent clinical trial, a trial feasibility study or an ancillary study to a clinical trialApplications that propose experiences that are not associated with the development of therapies for pain, addiction or overdoseBudget/FundingSee MoreWhat are the budget requirements for this funding opportunity?NIH will provide salary and fringe benefits for the award recipient. The guidance on budgeting for career development salaries is provided in the SF424 (R&R) Application Guide. See also NOT-OD-17-094. The total NIH contribution to salary, however, may not exceed the legislatively mandated salary cap.MilestonesSee MoreDoes this FOA require specific milestones?No. This funding opportunity does not require specific milestones. This FOA is a short-term career-enhancement opportunity aimed at providing the applicant with a broad educational experience in the translational research environment. Project milestones are not expected for career-enhancement experiences.PersonnelSee MoreWho can apply to this opportunity?This funding opportunity is designed for early- and mid-career scientists with pain or opioid abuse expertise who are interested in receiving hands-on experience in translation at an industry laboratory or an academic or government research center performing therapeutic development activities.For the purposes of this FOA, the following definitions apply:An early-career investigator is a new investigator or an individual at the level of an assistant professor who has completed the terminal research degree or medical residency — whichever date is later — within the past 10 years and has not yet competed successfully for a substantial, competing NIH research grant.A mid-career investigator is at the level of an associate professor or functioning at that rank in an academic setting or an equivalent nonacademic setting with an established record of independent, peer-reviewed, patient-oriented research grant funding and a record of publications at the time of application. function toggleText(pn) { var elem = document.querySelector(pn); if (elem.textContent === 'See More') { elem.textContent = 'See Less'; } else { elem.textContent = 'See More'; } } | NCATS K18 funding opportunity for projects focusing on addressing pain and/or OUD. | Answers to Questions on HEAL Initiative: Translational Science Career | NCATS K18 funding opportunity for projects focusing on addressing pain and/or OUD. | Answers to Questions on HEAL Initiative: Translational Science Career | ||||
| 23680 | NCATS, Duke Scientists Show Compound’s Novel Effects on Key Brain Chemical in Drug Addiction | March 3, 2022Scientists at NCATS and Duke University have discovered a novel compound that rapidly enters the brain and restores abnormal dopamine levels back to normal. The compound works by modulating the activity of the receptor, an entry point on a cell, for ghrelin, a hormone that affects the brain and other areas in the body. Here, a computer-generated model shows the compound, N8279 (green), sitting on the hormone (ghrelin, purple) and docked in the ghrelin receptor GHSR1a. (Joshua Gross, Ph.D., and Yang Zhou, Ph.D., Duke University)Compound helps restore the brain’s normal dopamine levels, offering a potential approach to help treat addiction, Parkinson’s and age-related brain diseases.Scientists at NCATS and Duke University have discovered a compound that can restore the brain’s normal amount of dopamine, a key chemical that fuels addictive behavior. Their studies in both cells and mice suggest a possible new treatment approach for drug addiction. This work eventually could have implications for treating and preventing other dopamine-related conditions, including such disorders as Parkinson’s disease and Alzheimer’s disease.A collaborative team led by NCATS translational scientist Juan Marugan, Ph.D., and Duke University’s Lawrence Barak, M.D., Ph.D., and Marc Caron, Ph.D., reported these findings March 3 in the Proceedings of the National Academy of Sciences.Activities that can produce pleasure or reward raise dopamine levels in the brain. The release of dopamine from brain cells is controlled in part by ghrelin, a stomach hormone that also has broad effects in the brain and other areas of the body. Scientists have looked for a way to harness ghrelin activity to control dopamine and possibly reduce the addictive effects of drugs. But ghrelin also is involved in releasing growth hormone, increasing hunger and controlling blood sugar. As a result, blocking its activity can bring unwanted side effects.One possible way to regulate dopamine levels is through the ghrelin receptor. Many drugs work by either blocking or turning on a cell’s receptor, which is a chemical entry point on the cell.“This ghrelin receptor can control the levels of dopamine in the brain and plays an important role in addiction,” said Marugan. “The receptor is considered one of the best targets for drug intervention.”When the ghrelin receptor is turned on, it sends a chemical signal to brain cells by interacting with a pair of proteins, beta-arrestin and G protein. Beta-arrestin promotes the release of dopamine. When beta-arrestin is too active, the brain eventually produces too much dopamine. NCATS researchers used their expertise in drug screening to search through roughly 40,000 compounds to test their ability to interfere with beta-arrestin activity. They identified compounds that blocked beta-arrestin but also turned on the G protein’s activity.This ghrelin receptor can control the levels of dopamine in the brain and plays an important role in addiction. The receptor is considered one of the best targets for drug intervention.“We found compounds that activate the receptor in a selective manner,” Marugan said. “Until now, it wasn’t clear how to do it. It’s a new compound that works in a fundamentally different way than all previously studied compounds. It’s able to reach the brain and is considered a good potential candidate for development.”He noted that the compound, N8279, was not one of the compounds originally tested; it resulted from a chemical reaction that happened when testing a different compound that did not work.“This type of receptor can send chemical signals that produce broadly different physiological and behavioral effects,” said Duke postdoctoral fellow Joshua Gross, Ph.D., a co-author. “We thought if a drug could either turn on or halt these signals through a specific pathway, we might be able to more selectively develop drugs. This strategy could lead to a more effective drug with fewer side effects.”The Duke team showed that the compound could reduce dopamine-related behaviors in two different mouse models. In one experiment, the researchers found that the compound reduced the effects of cocaine on dopamine levels and calmed the animals’ hyperactive behavior. In a separate model, scientists shut down a key dopamine-related mouse gene, and again, the compound helped return normal behavior.The scientists suggest that this treatment approach also can be applied to other disorders and conditions. The Duke group is planning to use their understanding of how the compound works to study its potential use in Parkinson’s and Alzheimer’s diseases, which are related to abnormal amounts of dopamine. In Parkinson’s disease, for example, the death of dopamine-producing brain cells leads to movement difficulties.“We started on this narrow problem of drug addiction, and now we think this compound could be a key to understanding how to protect brain cells,” Barak said, adding that the compound might lead to a drug that could eventually help delay symptoms of neurodegenerative diseases or perhaps aging.The researchers consider N8279 just a start. Marugan and his NCATS colleagues continue to modify the compound. They are creating newer versions that could be more selective in their effects on beta-arrestin and dopamine function while also attempting to improve how the body and brain use them. Duke scientists also are using different models to test the effects of these compounds, including their effects on behavior. | Scientists at NCATS and Duke University discovered a compound that can restore the brain’s dopamine levels to normal. | Scientists Show Compound’s Effects on Key Brain Chemical in Addiction | Scientists at NCATS and Duke University discovered a compound that can restore the brain’s dopamine levels to normal. | Scientists Show Compound’s Effects on Key Brain Chemical in Addiction |
Last updated on